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ABSTRACT
Urinary tract sensory symptoms provide an additional symptomatic burden
for women with fibromyalgia. The urogenital symptoms of both fibromyalgia and
interstitial cystitis have been described as non-infective sensory disorders, suggesting
the existence of substantial clinical overlap between the two conditions. Research
suggests that although interstitial cystitis has been treated as a specific bladder
condition, it may be part of the disorder of central processing of sensory information
as seen in fibromyalgia.
The interstitial cystitis symptom index and problem index (ICSI/ICPI) have
been used to measure lower urinary tract symptoms and to examine the impact of
these symptoms in patients with interstitial cystitis. This current two phase study was
designed to test the ICSI/ICPI for use within a population of women diagnosed with
fibromyalgia known to be experiencing sensory bladder symptoms.
Phase I involved focus group interviews and discussions with women who
reported fibromyalgia and bladder irritability (N=lO). This phase was designed to
identify whether the key indicators and the way in which women experienced
bladder irritability were indexed by the ICSI/ICPI instrument. The second phase of
the study tested the ICSI/ICPI within the fibromyalgia population for reliability and
validity.
Phase II data was derived via a self-administered questionnaire issued to
women (N=90) who had been diagnosed with fibromyalgia by a rheumatologist and
who were experiencing lower urinary tract sensory symptoms. Data analysis revealed
two separate components in urinary symptom/problem combinations within the
fibromyalgia population. These components were distinct from those described in the
ICSI/ICPI. Subsequently, two separate subscales were developed to form the
Fibromyalgia Bladder Index (FBI). The development and testing of the FBI within
the fibromyalgia population has provided an accurate measure for assessing the
symptoms and symptom impact of urinary symptoms for women with this condition.
The FBI has been developed as an adjunct to clinical assessment and as an outcome
measure for intervention therapies for patients with fibromyalgia and bladder
irritability.
Outcomes of this study form the basis to the following recommendations:
further refinement of the FBI; utilisation of the index in fibromyalgia assessments;
development of fibromyalgia educational, support and self help programs; pelvic
fitness awareness and intervention studies.
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CHAPT ER l

INTRODUCTION
Issues and challenges in relation to the measurement of genitourinary
symptoms in women with Fibromyalgia (FM) are the primary themes of this thesis.
The research was initiated because of my association with and clinical knowledge of
symptomatology of patients who had disabling urological symptoms in conjunction
with their FM. Many of these patients had not been looked at critically in a clinical
setting. There has been little recognition of or intervention for the management of
these urological symptoms in the population of Fibromyalgia women who already
experience multiple non-bladder symptoms. This study will provide important
information for women experiencing the disabling urogenital symptomatology of
FM.
The research activity in bladder and urological conditions has been expanded
by the establishment of various foundations supported by health care workers,
researchers and patients through out the world. The USA Coalition for Urological
Research and Education (CURE) (Interstitial Cystitis Association, 2003), the USA
Coalition for Improved Bladder Health (National Association for Continence, 2003),
the Fishbein Foundation and the Interstitial Cystitis Association (Interstitial Cystitis
Association, 2004) all attest to the bother of urological symptoms in afflicted
patients. The lack of progress in some areas has evoked new strategies such as the
initiative by the National Institute of Diabetes and Digestive and Kidney Disease
(Urology Times, 2004) where a new paradigm for Interstitial Cystitis (IC) looks at it
as a chronic pain syndrome.
There are interesting new developments within the urological area, especially
the increase of knowledge in the biology of up-regulation of sensory processing,
central sensitisation and the possibility of some bladder conditions being visceral
pain syndromes rather than end organ diseases. This is an area that needs to be
- 13 -

revisited to facilitate further knowledge as it has the potential to change the way
clinicians consider the condition of FM and its associated bladder symptomatology.
The women in this study are a group of disenfranchised people who have a
challenging condition, whose non-bladder FM symptoms cohabitate with bladder
symptomatology that impacts on their quality of life. Their needs need to be
addressed.
FM with its debilitating musculoskeletal pain has come under renewed
evaluation by rheumatologists and health specialists. However, evaluation of
urogenital symptoms and their impact in this debilitating chronic condition has not
been undertaken. For a comprehensive evaluation in quality of life issues with
multiple systems disease, specific and directive measurement tools are required.
This study explores these issues of lower urinary tract sensory symptoms in
Australian women who have been diagnosed with the condition of FM. Although
irritable bladder symptoms are listed as an associated symptom of the condition of
FM, there is little in the literature on these symptoms of urinary urgency, urinary
frequency, nocturia and bladder pain and their resultant impact on the quality of life
of these women. One of the aims of this study is to quantify the impact of these
bladder symptoms on the quality oflife of Australian women with FM.
Interstitial cystitis (IC) is a condition of uncertain etiology that results in
chronic bladder pain, urinary frequency, nocturia and urgency. O'Leary, Sant,
Fowler, Whitmore and Spolarich-Kroll ( 1 997) have designed and validated the
Interstitial Cystitis Symptom Index and Problem Index (ICSVICPI) to capture the
most significant voiding and pain symptoms and assess how problematic these
urinary symptoms are for patients with interstitial cystitis. Research by Clauw,
Schmidt, Radulovic, Singer, Katz and Bresette ( 1 997a) suggests that the conditions
of interstitial cystitis and FM have a significant overlap in symptomatology.
This study was undertaken to validate this Interstitial Cystitis Symptom Index
and Problem Index (Appendix A) for use within a population of women diagnosed
with FM who exhibit lower urinary tract sensory symptoms.

- 14 -

Background to the Study
FM is recognised as a distinct rheumatic disorder.

It is a chronic non

degenerative, non-inflammatory, non-progressive systemic pain condition of
unknown etiology. It is a complex syndrome characterised by pain amplification,
diffuse musculoskeletal pain and systemic symptoms. The American College of
Rheumatology (ACR) classification criteria was outlined for the diagnosis of FM in
1990 (Wolfe, Symthe, & Yunus, 1990). The diagnostic criteria for FM require
patients to have wide spread pain of at least three months duration in combination
with at least 1 1 of 18 specified tender points. Patients diagnosed with FM also
present with a variety of other symptoms.
A group of international FM experts issued the Copenhagen Declaration in
1992 that was adopted by the World Health Organisation in 1993 (Wallace &
Wallace, 1999). They recognised the use of the criteria of the American College of
Rheumatology for research purposes, but at the same time recognised and defined
FM as part of a wider spectrum. This spectrum included headache, irritable bladder,
irritable bowel syndrome, painful menstrual periods, temperature sensitivities,
atypical patterns of numbness and tingling, exercise intolerance, complaints of
weakness, persistent fatigue, stiffness and non-restorative sleep (Wallace & Wallace,
1999). Other associated symptoms included gastrointestinal complaints, chest pain,
skin problems, restless leg syndrome, dizziness, cognitive disorders, environmental
sensitivity and depression. These multifactorial symptoms of FM contribute to the
delay in the diagnosis of FM and increase the dilemma of its unknown etiology.
Current research is attempting to unearth a more sophisticated diagnostic marker than
the above criteria for the diagnosis of this syndrome.
Wolfe, Ross, Anderson, Russel and Herbert ( 1995) determined that FM
affects between 3% and 5% of the population (according to the American College of
Rheumatology classification criteria), that females outnumber males by a ratio of
about 6 to 1 and that the prevalence of the syndrome increased with age. The median
age for the onset of FM is from 29 years to 3 7 years although formal diagnosis is
more often from 35 years to 53 years (Boissevain & McCain, 199 1). Buskila and
Neumann ( 1997) noted a striking familial prevalence of FM with the prevalence in

- 15 -

female relatives being much higher. The mechanism of FM is thought to involve a
complex interaction between neuroendocrine factors and central pain mechanisms
with increased sensitivity in pain pathways. Symptoms of FM can be grouped
according to their organ system (Clauw et al., 1997a). These organ groups include
genitourinary, musculoskeletal, neurological, gastrointestinal, cardiopulmonary and
others.

Urological Symptoms
From the genitourinary group, irritable bladder symptoms similar to the
irritative bladder symptoms of interstitial cystitis (IC) are listed as one of the
associated disorders of FM (Littlejohn, 1996). These symptoms include urinary
frequency, urinary urgency, nocturia and pelvic pain in the absence of infection.
Paira (1994) found that 38 of 212 patients (18%) with FM met the criteria for the
definition of female urethral syndrome with symptoms of urinary frequency, dysuria,
supra pubic pain and urethral discomfort. Wolfe and colleagues (1990), in their study
on signs and symptoms of FM reported that 26.3% of his sample experienced urinary
urgency.

In a study by Wassem, McDonald and Racine (2002) on FM patient

perspectives on symptoms, irritable bladder symptoms were reported in greater than
70% of the 54 respondents.
Clauw and colleagues (1997a) considered the relationship between FM and
IC. Interstitial cystitis is a complex inflammatory condition of the bladder. Although
the pathophysiology of the condition is not fully understood, it is known that there is
altered epithelial permeability, mast cell activation and sensory afferent nerve
upregulation within the bladder (G. R. Sant & Theoharides, 1999b). Z. S.
Wisniewski (personal communication, September 3, 2004) describes the typical
history of a woman with IC as one who presents with pain on a full bladder with
ensuing frequency. As a consequence of this, some fibrosis of the bladder can occur
with the bladder shrinking down to a smaller contracted form that encourages
increased urinary frequency and urgency. Bladder and/or pelvic pain on bladder
filling are a major part of the urological profile of these women.
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The study on IC and FM (Clauw et al., 1 997a) showed the prevalence of
genitourinary symptoms within three groups, patients with FM (n = 60), patients with
IC (n = 30) and a control group (n = 30). These results show the prevalence of a
bladder fullness sensation at 38%, 80%, and 7%, urinary urgency at 45%, 80% and
1 3%, pelvic pain at 45%, 77% and 7%, dyspareunia at 1 8%, 50% and 7%, burning
with urination at 6%, 40% and 0% and vaginal pain with insertion or removal of a
tampon at 1 5%, 23% and 3% respectively.
In a randomised community survey of 3395 non institutionalised adults,
White, Speechley, Harth and Ostbye (1 999a) identified clinical features that
distinguished FM from other chronic widespread pain. They included in the study
1 00 FM cases, 76 widespread pain controls (PC) and 1 3 5 general controls (GC).
From a list of 4 1 presented symptom items, the prevalence of urinary frequency (>
5x/day) was recorded at 32% (FM), 23.7% (PC) and 7.5% (GC). Pain with urination
was recorded for 6% of those with FM, 2. 7% of those with widespread pain and none
for those in the general control group.
Clauw and colleagues (1 997a) speculated that central neurological
mechanisms that have been suspected to contribute to the pathogenesis of FM may
be the same type of mechanisms operative in IC, which until now has been primarily
considered to be a bladder disorder. Clauw and colleagues found that patients they
studied with interstitial cystitis displayed diffusely increased peripheral nociception
as seen in FM, nociception being the electrochemical process through which humans
perceive pain. Erickson, Morgan, Ordille, Keay and Xie (2001 ) extended the inquiry
into non-bladder symptoms related to interstitial cystitis. Their findings were very
similar to those of Clauw and colleagues (1 997), but it is not known whether any of
the non-bladder symptoms found associated with interstitial cystitis were directly
related to the pathophysiology. Research on neurological etiological factors rather
than bacteriological etiology in the area of bladder and pelvic pain is becoming more
evident.
IC like FM is a condition of unknown etiology that is treatable but not
curable. For patients with IC, the most common symptoms include the irritative
symptoms of urinary frequency, urinary urgency and pelvic pain. Pain can be
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experienced within the pelvis, bladder, urethral and vaginal areas. IC is a complex
inflammatory condition of the bladder and is seen as a major portion of the "painful
bladder" disease complex that includes a large group of urologic patients with
bladder and/or pelvic pain and irritative voiding symptoms with negative urine
cultures (Hanno, 1 992). Hanno also lists FM as an associated disease with IC
because of the over representation of FM in the IC population.

Current Definition ofInterstitial Cystitis
In Japan in 2003, international experts met at the inaugural International
Consultation on Interstitial Cystitis (Ueda, 2003) to define areas of agreement and
differences in their approach to IC and to determine a uniform IC definition. The
original definition of the Division of Kidney, Urologic, and Hematologic diseases of
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for
IC was developed in 1989 and was intended mainly for research purposes to ensure
that a homogenous group of patients with IC were available for IC studies. The
original diagnostic criteria have been found to be too restrictive for clinical purposes
with the resultant potential for misdiagnosis and under diagnosis of many patients
with IC (Diokno, Homma, Sekiguchi, & Yasuyuki, 2003 ). Hanno ( 1 994b) found that
90% of patients meeting the original NIDDK criteria were considered by IC experts
to have the disease, but 60% who did not meet these criteria were also thought to
have IC. Many IC patients were therefore excluded from research studies with only
the most severely affected patients included. These original criteria have been
described as a de facto defi n ition (Hanno, 1994b).
The main objectives of this International Consultation on Interstitial Cystitis
in 2003 were to define the basic symptoms that encompass the condition of IC and to
develop a more appropriate terminology that represents this symptom complex.
Discussion from the workshops indicated that chronic pelvic pain may not always be
recognised as an essential component of the symptom complex. The final consensus
from the 2003 International Consultation on Interstitial Cystitis adopted the term
IC/CPPS to signify the symptom complex of chronic pelvic pain (CPPS), with
urinary urgency and / or urinary frequency (Diokno et al., 2003). A draft algorithm
for the treatment of painful bladder syndrome (including IC) was developed at the
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International Consultation on Interstitial Cystitis in Monaco in August 2004
(Appendix 8). This Consultation group also worked on a definition and review of the
painful bladder. This latest version will be published in December 2004 (A.
Rosamilia, personal communication, September 8, 2004).

Commonalities between FM and IC
As with FM, the majority of IC patients are female. The demographic
features, associated features and response to tricyclic compounds are very similar in
both conditions. One epidemiological study (Koziol, 1 994) showed that the main
symptoms in women with IC were frequency (92%), urgency (92%) and pelvic pain
(70%). Physical assessment found vaginal and suprapubic tenderness. Bladder charts
revealed an average number of 2 1 voids per 24 hours with an average interval of 2.6
hours between voids over night. Some authors refer to the FM associated disorder of
irritable bladder syndrome as "interstitial cystitis" (Littlejohn, 1 996).
Alagiri and colleagues ( 1 997) undertook a study to determine the prevalence
of concomitant disease in individuals with IC and compared these results with the
general population. They concluded that IC has an unexplained association with
certain other chronic diseases and pain syndromes including FM. Within this survey
of 2682 patients with IC, 25% reported having comorbid FM. Another study (Aaron,
Burke, & Buchwald, 2000) investigated the frequency of ten clinical conditions
among three groups of patients with chronic fatigue syndrome (CFS),

FM and

temporomandibular disorder (TMD). The patients with FM had a significantly
greater number of symptoms characteristic of IC compared with the patients with
CFS and TMD or control subjects.

Significance of the Study
Despite the emerging evidence on commonalities between FM and IC and the
listing of bladder irritability as a symptom of FM, there appears to be little discussion
between the medical specialities on the issue of bladder symptomatology in FM.
Rosamilia and Dwyer (2000) suggest that many women with lower urinary tract
sensory disorders present after having unsuccessfully trailed antibiotics for their
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urinary symptoms. This unsuccessful treatment and a failure to cultivate
uropathogens will often lead the clinician to consider an alternative diagnosis in the
realm of non-infective sensory disorders of the lower urinary tract. Rosamilia and
Dwyer (2000) suggest that women presenting with irritative urinary symptoms
should be assessed both gynaecologically and generally. A short rheumatological list
of questions on FM symptoms could assist in the urological identification of possible
FM sufferers within this group of women.
Perhaps the lack of a general assessment of women with FM for these non
infective sensory disorders of the lower urinary tract is because bladder irritability is
one of the less common symptoms of the FM condition. Ang and Wilke ( 1999)
describe two types of non-specific symptoms groups of FM. They describe the first
group of symptoms as fatigue, non-restorative sleep, distress and morning stiffness
occurring in 75% of patients. They describe the less common symptoms occurring
between 25% and 50% of patients as irritable bowel syndrome, urinary frequency,
headache, subjective swelling, diffuse paraesthesia, psychological distress and
functional disability.
Research on issues related to these less common symptoms of FM such as
lower urinary tract symptoms is needed to increase the awareness and knowledge
development of the health professional regarding the disability and frustration that
these less distinguishing symptoms may cause to patients. Hunt (1995) poses the
question as to whether there is a void in the research in relation to bladder irritability.
Hunt (1995: 440) refers to the importance of psychological factors and stress in
bladder functioning and cites Smith in the Chinese proverbial description of the
bladder as 'the mirror of the soul' .

Current Bladder Research Emphasis
The Division of Kidney, Urologic, and Hematologic diseases of The National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) within the United
States of America recognises that IC represents only one of a number of symptom
complexes of chronic pain of bladder origin. In July 2000 the NIDDK invited
applications for investigators to use ongoing prospective cohort studies, clinical
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trials, and large patient databases to design epidemiological, quality of life, and
health resource utilisation studies for chronic pelvic pain of bladder origin and IC
(Kusek & Nyberg, 2000).
This research is providing information on the broader, more inclusive
disorder of the symptom complex of chronic pelvic pain, and associated symptoms of
urinary frequency and urgency. This research proj ect on the epidemiology of chronic
pelvic pain of the bladder and IC has attracted significant funds as the magnitude and
the impact of the burden of chronic pelvic pain of the bladder symptom complex on
the health of the US population is not known. In January 2004 the NIDDK
announced a request for applications for a study entitled Interstitial Cystitis / Painful
Bladder Syndrome: Epidemiology (Interstitial Cystitis Association, 2004a). The
funding is a $ 1 ,000,000 per year grant for a period of 5 years. These on going
research grants and international consultations on IC demonstrate the clinical need to
assess bladder symptomatology in these disabling conditions.

Social and Economic Impact
The increased consultation and research funding within the area of bladder
pain and irritability reflects the need within both professional and community groups
to view bladder health as a priority area of health research. This focus on bladder
health increases the si gnificance and relevance of all current research in this specific
area. A recent survey by the John Hopkins Bloomberg School of Public Health in the
United States (G. Anderson, 2003 ) found that chronic health conditions in that
country were a major concern. The survey found that the majority of physicians,
policy makers and the public were concerned that the nation's health care system was
not appropriately meeting the needs of people with chronic disease. This was a
significant survey where the attitudes of 1 ,74 1 physicians, 1 ,663 adults from the
general public and 1 55 health policy makers were sampled.
A study on the service utilization costs for FM patients has shown that the
annual cost per FM patient in the United States of America is $2,274 US (Wolfe et
al., 1 997a). Rates of hospitalization occurred at approximately once a year and
outpatient medical visits at 9.8 times per year. When alternative treatments were
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added, the total outpatient service was once per month. This report confirms that
patients with FM report more symptoms and comorbid and/or associated conditions
that other patients with rheumatological conditions. The resultant impact on medical
budgets and personal costs to patients for the treatment of FM is substantial.

Health Related Quality of Life

Health-related quality of life (HRQOL) is a multidimensional construct
referring to an individual's perceptions of the effect of a health condition or disease
and its resultant treatment (Lose et al., 1 998). Kelleher, Cardozo, and Toozs-Hobson
( 1 995) describe quality of life as an abstract concept that encompasses a person's
perception of their physical, psychological and social well being and further describe
quality of life as a subjective phenomenon influenced by culture, beliefs, self concepts and life's goals and expectations. Currently there is an increasing interest in
the development of health scales and indices for measuring subject's assessment of
their symptoms and for their measuring quality of life. Health related quality of life
(HRQOL) is one of several elements being studied in the field of medical outcome
research according to Penson and Litwin ( 1 997). They describe HRQOL as
encompassing a wide range of human experience but emphasise the involvement of
the patient's perception of their own health and ability to function in life.
The impact of lower urinary tract symptoms on the quality of life on women
has been well documented over recent years. Pinnock and Marshall ( 1 997) have
shown that the impact and bothersomeness of lower urinary tract symptoms on
quality of life in an Australian community is a major reason for people seeking
medical help. It is important to determine the increased impact and bother that these
urinary symptoms could have, not only on the financial impact to the sufferer but
also on the quality of life of a person already coping with the many other symptoms
of FM.
Bernard, Prince and Edsall (2000) reported a significant reduction in the
quality of life in FM patients. In their study of 270 subjects with FM, most rated their
present quality of life as 4.8 on a O to 1 0 scale compared to a score of 8.6 prior to
having FM. They estimated their future quality of life as 9.6 in the absence of FM. A
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recent study on health related quality of life in multiple musculoskeletal diseases
(Picavet & Hoeymans, 2004) has shown that subjects with musculoskeletal diseases
had significantly lower scores on all SF-36 health status dimensions than subj ects
without musculoskeletal disease. In this study, the worst health related quality of life
patterns were found for FM, osteoarthritis of the hip, osteoporosis and rheumatoid
arthritis.
Asbring (2001 ) in her study on the affects of chronic illness such as FM on
women found that the illness can cause a radical disruption in a woman' s biography
and that the illness has profound consequences for her identity, especially in relation
to her work and social life. A study by Schaefer (1995) of women living with FM
reveals how women attempted to gain control of their illness, their symptoms, as they
struggled to maintain a balance in their life. Validating the Interstitial Cystitis
Symptom and Problem Index (ICSVICPI) within the FM population will enable
accurate assessment of the impact of one group of these symptoms, the urinary
symptoms of FM.

Health Outcome Measures
Dunkl, Taylor, McConnell, Alfano and Conaway (2000) assessed the
responsiveness of FM clinical trial outcome measures, and found the Fibromyalgia
Impact Questionnaire to be the most responsive measure to perceived clinical status.
Bennett (2001 ) commented on this study and wrote of the need to develop outcome
measures. Bennett remarked on the need for accurate quantification of relevant
symptoms and physical findings in FM for defining improvement in clinical trials.
The measurement approaches used to assess HRQOL are generic or specific
(condition-specific or patient-specific). Generic scales allow for comparisons
between different demographic and cultural groups as well as across different
disorders, severities of disease and interventions (Patrick & Deyo, 1989). McHorney,
Ware, Lu and Sherbourne (1994) comment that these scales can also be used to
measure the burden of illness of populations with chronic medical conditions as
compared with normals. The use of the generic scale also enables meta-analysis to
produce the combined results of different studies. Condition-specific or patient-
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specific questionnaires do not have to cover a large range of disorders that may be
inappropriate or irrelevant for one specific problem. There are therefore more
specific and relevant questions to detect changes in the patient's condition (Streiner
& Norman, 1 996).
The Interstitial Cystitis Symptom Index and Problem Index (ICSI/ICPI) is a
condition-specific instrument designed to measure the impact of the symptoms of
urinary frequency, urinary urgency, nocturia and bladder pain in patients with IC.
Condition-specific instruments should include the measurement of the presence of a
symptom and the bothersomeness of the symptom. O' Leary and colleagues ( 1 997)
have developed such an outcome measure for IC where the different items of urinary
pain, nocturia, urgency and frequency symptoms and their bothersomeness are
combined in a symptom and problem index.
This ICSI/ICPI was developed to measure lower urinary tract symptoms and
their impact in patients with IC. Because there is not a precise consensus definition
of what constitutes the disease of IC, it is important to have a scientifically validated
instrument to evaluate symptoms. O'Leary and colleagues ( 1 997) commented on the
plethora of new therapies for the treatment of IC and the need for reliable and valid
outcome measures. Their development of the ICSI/ICPI was the result of the critical
need to have a uniform and reliable method to evaluate these symptoms. The authors
of the index comment that apart from its adjunct role in clinical decision making, the
ICSI/ICPI will be valuable to future researchers in this area. This instrument has only
been validated within the IC population.
Currently there is no validated instrument available for the assessment of
significant bladder irritability and bladder pain or for the assessment of how
problematic these symptoms are within the FM population. Such an instrument
would enable rheumatologists, urologists and medical practitioners to quickly detect
specify and assess the bothersomeness of the urinary symptoms for the FM patients
and enhance referral to appropriate health professionals for management. A validated
instrument for measuring these lower urinary tract symptoms and their impact will
also be a valuable research tool, an objective quantifiable measure, especially where
intervention is directed at improving the management of this problem.
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Purpose of the Study
The purpose of this study is to investigate the impact and measurement of
bladder irritability symptoms in Australian women who have been diagnosed with
the condition of FM. This study will test the ICSI/ICPI within the female FM
population for reliability and validity.

Research Questions
To validate the ICSI/ICPI instrument within a population of women
diagnosed with the condition of FM who exhibit sensory urinary symptoms.
To establish the measured impact of lower urinary tract sensory symptoms on
the quality of life of women with FM.

Summary
This is the first Australian study to seek quantification of lower urinary tract
sensory symptoms and their impact on women diagnosed with FM and to validate an
outcome measure for the symptoms and symptom impact. The investigation plans to
increase awareness and discourse within the health professions about the disability
and frustration that these less distinguishing features of FM can present. The
validation of a condition specific outcome measure for documenting a patient's
assessment of her symptoms and for measuring her health related quality of life is a
step to provide accurate quantification of symptoms for bladder bother in patients
with FM.
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CHAPTER 2

LITERATURE REVIEW

Introduction

Current literature on the condition, symptoms, diagnosis, associated disorders
and demographics of Fibromyalgia syndrome (FM) are examined in this chapter. The
key FM symptoms of pain, stiffness, fatigue, insomnia and cognitive dysfunction, as
well as the psychosocial implications of FM, are discussed. Current theories and
models on the etiology of FM and possible etiological theories of bladder
symptomatology in FM will be considered.
Treatment options and recommendations for the management of FM will be
considered, with a focus on the role of patient education, exercise, pharmacological
treatment and cognitive behavioural therapy. Specific attention is given to the
urogenital symptoms associated with FM and their connection with interstitial
cystitis (IC), chronic pelvic pain, and vulvod ynia. Current literature on measures of
health status and their development in regard to FM are also included in this
literature review. The issues and challenges in relation to the measurement of
genitourinary symptoms in women with FM are the primary themes of this thesis.
This research was initiated because of the lack of such measurement tools for these
genitourinary symptoms. This research will provide important information to women
with these disabling symptoms.
This review will be an extensive review on the available areas of literature
covering the wide range of symptoms, etiological possibilities and treatment
management strategies of FM because all of these areas may be associated with, or
impact on, the urogenital influence of FM on women.
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In January 2002, the World Health Organisation launched the Bone and Joint
Decade. The naming of this decade was initiated in response to the identification of a
world epidemic of musculoskeletal disease (Hazes & Woolf, 2000). The World
Health Organisation World Global Burden of Disease Proj ect reported that the
musculoskeletal conditions represented more than half of all chronic conditions
(Dieppe, 1998). The Australian Coordinator of the Bone and Joint Decade (Brooks &
Hart, 2000) recognised that many musculoskeletal conditions produce chronic pain,
disability and a decrease in the quality of life. They commented that the Bone and
Joint Decade will attempt to bring together research, education and service to
improve the life of millions of Australians who suffer each week from these
conditions. Littlej ohn and Morand (2002) concluded that, with the impetus that this
Bone and Joint Decade will bring to research in rheumatic disease, the medical
profession can expect greater understanding of disease mechanisms with a
subsequent increase in treatment options.
More specific to FM is the development of one of the largest international
FM research centres at the University of Michigan Centre for Chronic Pain and
Fatigue Research. The report of the Senate Appropriations Committee of the USA
has urged the National Institute of Health (NIH) to increase the emphasis on the
neurological aspects of FM and to encourage new partnerships in FM research
between the two NIH institutes. The report also encourages studies for drugs and
biologicals which are Fibromyalgia-specific (Liller, 2002).
The USA Coalition for Urological Research and Education (CURE)
encourages and funds research that will improve the care of patients with urological
conditions. The Coalition emphasises not only the individual suffering and the
financial burdens involved with urological conditions, but also the fact that
urological research is the most under-funded research area in their nation (Interstitial
Cystitis Association, 2003). The Coalition for Improved Bladder Health is another
partnership that was formed with the aim of increasing awareness of bladder and
pelvic health issues and includes a diverse collaborative group of health professional
organisations.
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The Fishbein Foundation and the Interstitial Cystitis Association (ICA), also
piloting research programs in the United States, are providing large financial grants
for research areas such as the epidemiology of IC and abnormalities in sensory
nerves in the bladder of IC patients (Interstitial Cystitis Association, 2004). The
National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)
announced in 2004 applications for a large scale five-million-dollar study entitled
' Interstitial Cystitis/Painful Bladder Syndrome: Epidemiology' (Urology Times,
2004). It is against this backdrop of advances in rheumatic and urological disease
research and increasing awareness that the current study on Fibromyalgia and
bladder irritability has evolved.
Fibromyalgia (FM) has mainly been the domain of the rheumatologist until
now, with the primary focus on pain management. This horizon is expanding with
multiple health specialities now having input into the research and intervention
strategies for the many facets of this multi-dimensioned disorder (Busch, Schachter,
Peloso, & Bombardier, 2002b). This literature review will include the primary and
associated symptoms of this condition with particular focus on one of the associated
symptoms, the urogenital symptoms. The lack of research specifically in the area of
the genitourinary symptoms of FM, and the measurement and impact of these
symptoms, is apparent. Recent research into the etiological factors contributing to
FM and consideration of studies in the area of effective treatment and management
will act as background to further discussion of these urogenital symptoms.

Fibromyalgia
Fibromyalgia is a chronic musculoskeletal pain syndrome characterised by
widespread pain and predictable tenderness at numerous anatomical sites, together
with other characteristic clinical manifestations (Wolfe et al., 1990). The World
Health Organisation has classified FM in the International Classification of Diseases
as non-articular rheumatism. It is thought to be a pain amplification syndrome related
to increased sensitivity of dynamic components of the pain system (Littlejohn, 1996).
Fibro refers to the fibrous tissue of ligaments and tendons, myo refers to muscle and

algia refers to pain (Jain et al., 2004).
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Bennett (2002d) describes the current paradigm of FM as a complex pain
syndrome in which abnormalities of central sensory processing interact with some
peripheral pain generators and psychoneuroendocrine dysfunction, generating a wide
spectrum of symptoms and distress. The classic primary symptoms of FM are the
diffuse pain, fatigue, stiffness and non-restorative sleep. Associated symptoms
include morning stiffness, gastrointestinal symptoms, genitourinary problems,
paraesthesia, temperature sensitivity, thoracic pain and dysfunction, cognitive
disorder, vestibular problems, oesophageal dysmotility, headaches, restless leg
syndrome, dizziness and anxiety.
Littlejohn (200 I ) distinguishes between two different types of chronic
musculoskeletal pain syndromes, one involving pain generation and the other being
pain amplification. The pain generation syndromes include the myofascial pain
syndrome and segmental spinal dysfunction. The pain amplification syndromes
include FM, regional pain syndrome and complex regional pain syndrome.
The International Association for the Study of Pain, in its classification of
chronic pain, defines FM as diffuse musculoskeletal aching and pain with multiple
tender points (Merskey & Bogduk, 1994). They describe the syndrome as chronic
with remissions being uncommon. Jain and colleagues (2004) in the Canadian
Consensus Document on FM classify FM as one of the large group of soft tissue pain
syndromes. They describe the soft tissue pain syndromes as characterised by pain
from the periarticular structures located outside of joint capsule and periosteum,
namely ligaments, tendons, fascia, bursae and muscles.
FM associates with significant disability. Kaplan, Schmidt and Cronan (2000)
have demonstrated that patients with FM obtain lower scores on a validated measure,
the Quality of Well Being Scale, than patients diagnosed with chronic obstructive
airways disease, rheumatoid arthritis, atrial fibrillation, advanced cancer and some
other chronic diseases. This is indicative of the quality of well being and the
significant disability experienced by people with FM.
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Diagnosis
In 1990, the American College of Rheumatology published criteria (Wolfe et
al., 1990) for classification of patients as having FM. These criteria are also often
used for clinical diagnosis. The criteria comprise widespread pain defined as pain on
the left and right sides of the body, as well as above and below the waist, for three
months duration, together with the presence of abnormal tenderness on digital
palpation, at 1 1 or more out of 18 specifically designated sites. These sites are
deemed 'tender points' when 4 kilograms of palpation pressure induces pain. For a
'tender point' to be positive, the subj ect must experience the palpation as painful and
not just tender. These classification criteria are research based and are validated and
rigid. The tender points of the classification criteria are as follows:
•

Bilateral occiput at the suboccipital muscle insertion.

•

Bilateral low cervical at the anterior aspects of the intertransverse spaces at
C5-C7.

•

Bilateral trapezius at the mid point of the upper border.

•

Bilateral supraspinatus at origins above the scapula spine near the medial
border.

•

Bilateral second rib at the second costochondral junctions just lateral to the
junctions on the upper surfaces.

•

Bilateral lateral epicondyle 2cm distal to the epicondyles.

•

Bilateral gluteals in the upper outer quadrants of buttocks in anterior fold of
the muscle.

•

Bilateral greater trochanter posterior to the trochanteric prominence.

•

Bilateral knee at the medial fat pad proximal to the j oint line.

•

Axial skeletal pain in the cervical spine, anterior chest, thoracic spine or
lower back must also be present.
These classification criteria were designed as a tool to standardise research

into FM. The ACR classification criteria have pain at the centre of their definition.
They do not encompass the other symptoms of sleep disturbance, fatigue, cognitive
dysfunction, psychological distress, irritable bowel, irritable bladder and other
concurrent symptoms. Crofford and Clauw (2002a) suggest that by excluding
symptoms other than pain, the ACR criteria fail to encapsulate the essence of the FM
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syndrome. These authors recognise that one of the strengths of these criteria, from a
research point of view, is that FM patients who meet the ACR criteria are at the
extreme end of the pain and tenderness spectrum.
A diagnosis is fundamental to managing any medical condition, but it can be
particularly problematical when dealing with patients who suffer with chronic and
musculoskeletal pain (King, 2004). King describes a diagnosis as a process whereby
data provided by or gained from the patient are integrated with scientific knowledge
to identify the nature and cause of a medical condition. King offers four distinct
diagnostic strategies each with a distinct rationale. These include: the Gestalt or
'heuristic' method that is a product of a rapid process of pattern recognition that is
based on the clinician's previous experience; the hyp othetico-deductive strategy
where a short list of possible diagnostic alternatives is considered; the exhaustive
diagnostic strategy involving a comprehensive assessment of all aspects of the
patient and his/her symptomatology; and the algorithm strategy providing an
evidence-based algorithm with rational alternatives.
Many clinicians see a need to develop better criteria for clinical diagnosis in
the community, recognising that the ACR classification criteria address only two
domains of this multi-faceted disorder, namely pain and tenderness. Because of the
growing recognition of the need for better information about all of the objective
abnormalities in people with FM, and the need for an integrated approach to the
diagnosis, a Canadian consensus document on FM has been developed (Jain et al.,
2004). An expert subcommittee from Health Canada established the terms of
reference and selected the Expert Medical Consensus Panel representing treating
physicians, teaching faculty and researchers (Jain et al., 2004). This consensus
document includes a clinical case definition, diagnosis and management of FM.
Russell (2004) sees the development of this document as the next step in a
longer term plan. He comments that, since the development of the ACR 1990
Classification Criteria for the Fibromyalgia Syndrome, it has been apparent that it is
necessary to determine what to include in a clinical case definition for use in
community medicine. This clinical case definition from Health Canada will be
refined and validated by the international scientific community and it will be of
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interest to the FM community of both health care professionals and patients to follow
its influence within Canada and within other international medical communities.

Demographics

FM is a disease of various age groups, affecting more women than men. It is
the third most common diagnosed rheumatic disorder after osteoarthritis and
rheumatoid arthritis. FM affects between 2% and 6% of the population. A
community prevalence study by Wolfe, Ross, Anderson, Russel and Herbert ( 1 995)
has shown the overall prevalence at 3.4% in women and 0.05% in men. This study
showed an even higher prevalence 7% in older women between the ages of 65 and 79
years. Prevalence shown in the London Fibromyalgia Epidemiology Study (White et
al., 1 999a) was 4. 9% for women and 1 .6% for men.
Male patients have been shown to have fewer symptoms, fewer tender points,
less common 'pain all over' symptoms, fati gue, morning fati gue and irritable bowel
symptoms than women (Yunus, Inanici, Aldag, & Mangold, 2000). The reasons for
this variation are unclear but seem multifactorial. Yunus (2002b) describes these
gender differences as a composite of biology, psychology and sociocultural factors.
Gijsbers ( 1 997) suggests that although women may be constitutionally more prone to
pain than men, their attitudes to pain allow women to report on their pain in a way
less likely to be biased by psychosocial issues. Gijsbers also suggests that the
essential difference between the sexes is that women are more discriminating than
men in their perceptions of pain-related sensations and that they develop a repertoire
of strategies that help them cope with pain more efficiently.
The usual age range at diagnosis of FM is 34 to 53 years although the age at
onset is usually between 29 to 3 7 years (Boissevain & McCain, 1 99 1 ). It has been
diagnosed in children and older people. The prevalence of FM increases with age and
is commonly associated with comorbid disorders (Wolfe et al., 1 995). Patients can
endure many years of pain and associated dysfunction before a correct diagnosis is
made.
Although the majority of FM patients experience pain and fati gue, there is no
obvious tissue damage identified on clinical evaluation. Kramis ( 1 998) describes FM
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as ' pain without tissue pathology', which undermines the individuals' credibility and
interferes with all aspects of their life. Wagner ( 1997) describes chronic pain as
having no function and being destructive both physically and psychologically. The
definition for pain set out by the International Association for the Study of Pain
(Merskey & Bogduk, 1994) defines pain as an unpleasant sensory and emotional
experience associated with actual or potential tissue damage, or described in terms of
such damage. This definition fits the pain of FM very well. Wolfe and colleagues
(1997a) concluded that patients with established FM, who were followed in a tertiary
hospital setting for seven years, showed markedly abnormal scores for pain,
functional disability, fatigue, sleep disturbance and psychological status.
Littlej ohn ( 1996) has stated that the commonness of the problem of FM,
together with its potential for serious disability, makes it a major cause of loss of
health quality for the individual and a significant economic loss to the community. A
six-year prospective study of a cohort of FM patients by Baumgartner and colleagues
(2002b) examined the long term prognosis in patients with FM. Their results showed
that most of the symptoms remained stable. Although pain had increased, some
aspects of the patients' quality of life had improved. An Australian two-year outcome
study from a rheumatology community practice showed a remission in
approximately 25% of the patients (Granges, Zilko, & Littlej ohn, 1994). Wolfe and
colleagues (1997a) followed up 538 FM tertiary hospital referred patients over a .
seven-year period to find that their markedly abnormal scores for pain, functional
disability, sleep disturbance, fatigue and psychological status did not change
significantly over that time. Fifty-nine percent of the study participants rated their
health as fair or poor. Possibly, community-managed FM patients may have a better
prognosis than those patients severe enough to attend tertiary institutions.
A recent research study (Giesecke et al., 2003) supports the clinical
impression that there are distinct sub groupings of FM patients. Giesecke and
colleagues noted that although the ACR criteria for FM were used to identify people
with pain and tenderness, these individuals were not a homogeneous group. The
researchers recognised that, as well as patients experiencing different clinical
symptoms, there was the influence of the biologic, psychological and cognitive
factors on their symptom expression. One group of FM patients exhibited extreme
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tenderness, but no associated psychological and cognitive factors. Another group
exhibited moderate tenderness with normal mood levels. A third group exhibited
significant mood and cognitive factor influences on their symptomatology (Giesecke
et al., 2003).

Key Symptoms of Fibromyalgia
Yunus (Baldry, 200 1) divides and describes the symptoms of FM as
musculoskeletal

symptoms,

non-musculoskeletal

symptoms

and

associated

symptoms. The musculoskeletal symptoms are listed as pain at multiple sites,
stiffness, hurting all over and swollen feelings in soft tissue. The non
musculoskeletal symptoms include fatigue at most times of the day, morning fatigue,
poor sleep, and paraesthesia. Associated symptoms as listed by Yunus (Baldry, 200 1 )
include self-assessed anxiety, headaches, dysmenorrhoea, irritable bowel symptoms,
restless leg syndrome, self-assessed depression, sicca symptoms, Raynaud' s
syndrome and female urethral syndrome.
Littlej ohn (2001) comments that most patients with FM experience a
fluctuating set of symptoms occurring over months or years. He also includes the
symptoms of cognitive dysfunction, dizziness, irritable bladder syndrome, multiple
chemical sensitivities and neurally mediated hypotension. The main symptoms
reported on in this literature review include the key symptoms of FM and include
pain, non-restorative sleep and insomnia, cognitive dysfunction, autonomic nervous
system and neuroendocrine dysfunction.

Pain
Until the 1 960s, pain was thought only to be a response to tissue damage. The
medical community understood only the Cartesian view of pain at this time. Melzack
( 1996) describes this Descartes' concept of pain as that produced by a direct
transmission system from injured tissue in the body to a pain centre in the brain. He
comments that this concept of pain has dominated pain therapy until recent times.
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In 1965, the Melzack-Wall Gate Control Theory (Melzack, 1 996) suggested
that a mechanism in the dorsal horns of the spinal cord acted as a gate that facilitated
or inhibited the transmission of pain from the body to the brain. Melzack's Gate
Control Theory encompassed the dynamic action of brain processes. The Gate
Control Theory did not include the long term changes in the central nervous system
resulting from the noxious input or other external influencing factors (Loeser &
Melzack, 1 999). Melzack ( 1 996) commented that this theory does not explain some
of the chronic pain conditions.
Govind, (2004) in discussing pain management, states that "for treatment to
be logical, rational and biologically plausible, an understanding of the mechanisms
and an appreciation of the pathophysiology remains paramount - as exemplified by
the successful treatment of hypertension, gastric ulcer and asthma. Devoid of this
basic understanding, treatment may be empirical or at best a 'guesstimate "' (p. 1 ). At
the recent International Association for the Study of Pain (IASP) Neuropathetic Pain
Meeting, there was debate on the current IASP definition for neuropathic pain
(Siddal, 2004). Some delegates took a broad approach of nervous system dysfunction
to neuropathetic pain and included conditions such as FM and irritable bowel
syndrome while others preferred a narrower definition such as evidence of a nervous
system lesion (Siddal, 2004). There is still non-consensus on the definition of
neuropathic pain within the confines of the International Association for the Study of
Pain.
The Pain ofFibromyalgia
Bennett (2002e) identifies four major sites of pain m FM patients as
peripheral tissues, the spinal cord, the brain and the descending modulation. These
sites reflect the input of the peripheral pain generators, dorsal horn sensitisation,
psychological influences and the modulating influence of the descending pathways.
Pain therefore can be modified or influenced by various physiological and
psychological factors.
Pain is the primary symptom of FM and is often described as 'pain all over
the body' . The International Association for the Study of Pain, in their classification
of chronic pain (Merskey & Bogduk, 1 994), describe the pain of FM as widespread
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aching of more than three months duration, perceived as deep pain and usually
referred to muscle or bony prominences. The common areas are cervical, thoracic
and lumbar spines. Pain in the trunk and proximal girdle is described as aching while
distal limb pain is perceived as associated with swelling, numbness and stiffness.
Pain intensity fluctuates daily, and although the pain can move from one area of the
body to the other, it is usually continuous (Merskey & Bogduk, 1994). In the ACR
1990 criteria report, 97% of patients had widespread pain. Over 75% of patients had
pain in the cervical area, posterior thorax or lower lumbosacral area and 56% had
pain in at least 15 of the zones when the body was divided into 30 regions (Wolfe et
al., 1990).
Jain and colleagues (2004), in the Canadian Consensus Document on FM,
describe the pain of FM as any combination of burning, searing, tingling, shooting,
deep aching, stabbing, sharp and/or feeling bruised all over. They list the
characteristics of FM pain as allodynia, hyperalgesia, persistent pain, pronounced
summation effects and after-reaction to repetitive stimuli and tenderness on
examination. Other listed features of FM pain include widespread pain, non
anatomical distribution, delay in onset following injury, pain felt in areas of
perceived sensory deficit, diffuse arthralgia, shortness of breath and chest pain, low
back pain, leg cramps, generalised stiffness and chronic headache (Jain et al., 2004).
The core components of FM are chronic musculoskeletal pain and abnormal
soft tissue tenderness, without tissue damage. Although muscle exhibits signs of
tightness, examination does not reveal inflammation, degenerative changes or
abnormal neurological signs. Maquet, Croisier, Renard and Crielaard (2002)
compared muscle performance in women with FM and healthy women free of
muscle and joint disease. The variables reflecting muscle strength, muscle fatigue,
resistance and static muscle endurance were diminished in the FM group.
Overview of the Pain of Fibromyalgia
Zimmerman (199 1) describes the pain of FM as a complex interaction of
nociceptive, neuropathic and other dysregulatory central nervous system and
psychosomatic mechanisms. Nociceptor pain results from the excitation of
specialised nervous sensors that signal potentially harmful stimuli. Zimmerman
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( 1 99 1 ) commented on metabolic deficiencies and neurogenic inflammation resulting
from the release of Substance P and other neuropeptides from peripheral nerve
endings, as possibly resulting in the chemical sensitisation of nociceptors and
hyperalgesia. The neuropathic pain as described by Zimmerman is due to
pathological mechanisms within the nerve cells and fibres in the peripheral and
central nervous system. He suggests that the possible resultant neuronal
hyperexcitability encouraged by 'a disturbed axonal transport system' may be
causative factors of pain in FM.
Cook, Lange, Ciccone, Liu, Steffener and Natelson (2004) discuss the
emergence of brain imaging as an investigative tool, which has resulted in an
increased understanding of the complexities of the nociceptive system in humans.
The function of the nociceptive system in patients with FM was examined using
functional magnetic resonance imaging (Cook et al., 2004). These studies concluded
that subjects with FM were significantly more sensitive to experimental heat pain,
and exhibited greater activity than controls, over multiple brain regions, in response
to painful and non-painful stimuli. The authors conclude that these results provide
support for a physiological explanation for FM pain, and comment that FM
symptoms may be being maintained by amplified neural responses to afferent
sensory stimuli. Their results indicate that brain responses to sensory stimuli in
regions of the brain responsible for sensory, cognitive, and emotional aspects of the
pain experience are increased in FM.
Borg-Stein (2002) describes peripheral pain generators within local
musculoskeletal, neurological and other sources as increasing in FM patients. Borg
Stein divides peripheral pain generators into five major categories: joint and
cartilage, enthesopathies, soft tissue pain, neuropathic pain, and visceral pain. She
recommends a methodical search for these nociceptive peripheral pain generators, to
decrease the total pain burden by decreasing the perpetuation of central sensitisation
and decreasing the stimulus. She comments that FM sufferers are more able to
participate in exercise programs if these peripheral musculoskeletal and neurologic
pain generators are found and appropriately treated. These pain generators have
features that distinguish them from the widespread pain of FM.
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Chronic Pain and Its Impact
As scientific inquiry into the neurobiology of chronic pain increases, the
multiplicity of symptoms in FM becomes more understandable. The concept is
emerging that FM is positioned toward the more painful end of a continuous
spectrum of chronic pain (Bennett, 2000).
In this area of chronic pain, Staud (2002) comments on the neuroplasticity of
the brain where the central nervous system can learn and change, where the central
nervous system adjusts and remodels itself if there is a need for different
modifications or different expressions. FM sufferers fall into the category of chronic
pain. The American Pain Society has created the phrase "Pain: The Fifth Vital Sign"
to increase the awareness of pain treatment among health professionals (Clark 2004).
They are encouraging health professionals to consider pain as the fifth vital sign and
to assess patients for pain every time they check for pulse, blood pressure, core
temperature and respiration. Jackson (2002) also refers to pain as the fifth vital sign.
She describes chronic pain as the type of pain that does not serve any known purpose
and that has outlived its usefulness, and describes chronic pain as a signalling system
stuck on the ' on' position.
Blyth (2003) believes that chronic pain such as musculoskeletal conditions
and injury should be a recognised health priority in the public health arena in
Australia. He describes chronic pain as waiting on the sidelines to be recognised.
Though there is evidence on the efficacy of treatments for chronic pain, the health
care policy on chronic pain is minimal in Australia (Blyth, 2003).
Chronic pain can affect people's identity, interrupt behaviour, interfere with
functioning and affect their sense of who they are (Harris, Morley, & Barton, 2003).
Harris and colleagues (2003) have shown that depression and adjustment problems,
in chronic pain patients, can result from extended interference with social roles and
personal identity rather than momentary frustrations. McCracken and Eccleston
(2003) recommend the acceptance-based approach to chronic pain rather than the
coping strategies that have been dominant in clinical and research areas. Their
research results from a chronic pain study have shown that the 'coping with chronic
pain' variables were weakly related to acceptance of pain and unreliably related to
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pain adjustment, while the 'acceptance of chronic pain' was associated with less
pain, disability, depression and pain-related anxiety (McCracken & Eccleston, 2003).
Two independent cross-sectional studies on the acceptance of pain (Viane et
al., 2003) have confirmed the value of acceptance of pain in predicting well-being in
patients suffering from chronic pain. The researchers found that the acceptance of
chronic pain was strongly related to engagement in normal life activities and the
recognition that pain may not change. They conclude that the acceptance of chronic
pain is best envisaged as the shift away from pain to non-pain aspects of life,
together with a shift away from the search for a cure and acknowledging that their
pain may not change (Viane et al., 2003).
Staud (2002) refers to pain as not just a biological phenomenon, but as a
psychological and social phenomenon. Sator-Katzenschlager, Schiesser and Kazek
Langenecker (2003) studied the effects of effective pain reduction on mood,
behavioural and cognitive outcome measures in chronic pain patients. Significant
reductions in pain intensity were accompanied by improvement in behavioural and
cognitive dimensions, while mood and psychological well-being did not improve
(Sator-Katzenschlager et al., 2003).
Gender-related Differences in the Experience of Pain
In the United States of America and other Western cultures, more women
than men seek medical advice for symptoms of functional pain disorders (Chang &
Heitkemper, 2002). The authors of a study on gender differences in irritable bowel
syndrome suggest that influencing factors may be gender-related differences in
visceral sensitivity, central nervous system pain processing, neuroendocrine, and
autonomic nervous system and stress reactivity. Research in this area (Naliboff et al.,
2003b) has shown that different areas of the brain are stimulated in reaction to pain
depending on the gender. In response to the same painful stimulus, the female brain
showed greater activity in the emotion-based limbic system, while in men, the
analytical-based centres of the cognitive regions resulted in greater activity (Naliboff
et al., 2003b ). This issue of gender-related pain differences might be relevant to FM
sufferers, because the maj ority of sufferers are female.
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Hoffinan and Tarzian (2001) have commented that even though women more
readily seek treatment for pain than men, they are less likely to receive it. The
authors comment on several important questions around the biological origins of
pain, gender differences related to pain and possible gender bias in the treatment of
pain. They note the differences in the psychological factors influencing pain in how
men and women attribute different meaning to their experience of pain.
Pain of Urogenital Origin
Pain of urogenital origin is a specific field in the area of chronic pam
conditions. There are many specialities and multi-disciplinary centres for the
management of pain involved with research into pain from the urinary tract. These
include urologists, urogynaecologists, gynaecologists, surgeons, anesthesiologists,
neuroscientists,

psychologists

and

physiotherapists

amongst

many

health

professionals. It is recognised that many patients who experience pain of urogenital
origin often suffer immensely and without the benefit of specific pain relief strategies
(International Association for the Study of Pain, 2000). Researchers (Wesselmann,
Burnett, & Heinberg, 1997) explain pain syndromes of the urogenital and rectal areas
as well described but poorly understood and under-recognised focal pain syndromes.
They list vulvodynia, orchialgia, urethral syndrome, penile pain, coccygodynia,
prostatodynia, perineal pain, proctalgia fugax and proctodynia in this list of pain
syndromes. The etiology of these pain syndromes often remains unknown.
Pain Outcomes
Bennett (2000) describes some of the possible end results of chronic pain as
depression, marital relationship issues, vocational problems, medication dependency,
sleep disorders, physical fatigue, personality changes, functional disability,
emotional fatigue, painful movements, muscle deconditioning and stress increases.
A recent Australian study (Oldroyd et al., 2003) explored the views of
general medical practitioners on the care of the patient with a chronic disease. This
qualitative study revealed consistent themes regarding the complexity of chronic
disease management. Tension from the differences between the patients and their
general practitioners' goals for care, time-consuming aspects of care and the lack of
structure

preventing

the

practitioner

from
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being involved in

structured

multidisciplinary care of their patients were all included in the emerging themes.
Recommendations from the study included changes to assist the medical general
practitioners in moving from acute care to providing longer term care as part of a
multi-disciplinary team (Oldroyd et al., 2003).

Fatigue
The International Association for the Study of Pain describes fatigue as
affecting 80% of people with FM and describes its severity as severe enough to
interfere with daily activities (Merskey & Bogduk, 1994). Wolfe, Hawley and
Wilson (1996) describe fatigue as a poorly understood symptom that is prevalent in
several rheumatic conditions. Fatigue for FM patients is often worse in the morning
with many of them experiencing unrefreshed sleep. Jain and colleagues (2004) note
that the type of mechanism that generates fatigue can classify fatigue and assist in its
assessment. They refer to the following classification in assessing fatigue: structural
fatigue, muscular fatigue, arousal fatigue, motivational fatigue, oxygenation fatigue
and metabolic fatigue.
Nicassio, Moxham, Schuman, and Gevirtz (2002) evaluated the three
predictors of fatigue in patients with FM as depression, sleep quality and pain. Their
findings indicate a dysfunctional, cyclical pattern of heightened pain and non-restful
sleep underlying the experience of patients' fatigue. In a study to determine diurnal
rhythm characteristics of pain, stiffness and fatigue in patients with FM, the ratings
of pain, stiffness and fatigue were found to be significantly correlated and revealed
diurnal and possible weekly rhythmicity (Bellamy, Sothern, & Campbell, 2004). A
structured, evidence-based review of all available literature on the coexistence of
fatigue and pain has been completed (Fishbain et al., 2003). Of the 1 7 reports that
met the quality criteria, 94. 1 % indicated there was an association between fatigue
and pain. Additionally, 100% of a subgroup of 13 reports indicated there may be an
etiological relationship between fatigue and pain (Fishbain et al., 2003). The
researchers recommend that future research directions consider these possible
mechanisms for the relationship between fatigue and pain.
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Soderberg, Lundman and Norberg (2002) clarified the meaning of fatigue and
tiredness as narrated by women with FM and healthy women. These results inform
us that tiredness and fatigue are experienced differently by women with FM
compared to healthy women who experience fatigue. For women with FM, the
findings revealed four maj or themes: the body as a burden, an interfering obstacle, an
absent presence and being in hope of alleviation. For healthy women, the main theme
was of needing natural recovery. This study has shown that fatigue experienced and
narrated by women with FM is quite different from the experience of tiredness as
explained by healthy women.
The maj ority of patients with FM and all patients with chronic fatigue
syndrome experience fatigue (Clauw & Chrousos, 1997b ). These two conditions
share overlapping clinical features. These authors suggest that current studies have
not shown that poor sleep is the primary cause of these illnesses. However, the
authors attribute some of the symptoms and physiological abnormalities to poor sleep
such as the disruption of the circadian secretion of hormones released during sleep.
Guymer and Clauw (2002) describe fatigu e as one of the most prevalent
features of FM, affecting between 76% and 8 1 % of patients. For management of the
fatigu e, they suggest a multi-modal treatment model that incorporates both
pharmacological and non-pharmacological methods. The non-pharmacological
methods include patient education on sleep hygiene, exercise management, energy
expenditure and activity pacing. Pharmacological treatment includes the tricyclic
antidepressants and serotonin reuptake inhibitors. Arnold, Keck and Welge (2000)
undertook a meta-analysis and review of antidepressants for use in FM. Nine of
sixteen trials were suitable for meta analysis. When compared with placebo, the
tricyclic medications were associated with effect size larger than zero for all
measurements. The largest effect was apparent in sleep quality. The authors
recommend further randomised, double blind, placebo-controlled parallel designs
where the antidepressants are administered at therapeutic dose ranges (Arnold et al.,
2000).
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Non-restorative Sleep and Insomnia
The International Association for the Study of Pain describes sleep
disturbance as affecting 75% of people with FM and describe the feeling on waking
as unrefreshed and tired (Merskey & Bogduk, 1994). Patients are encouraged to
develop good sleep hygiene, to maintain low impact exercise, to pace their daytime
activities, to slowly wind down activity in the evening, to use a supportive mattress
and pillow, and to effectively manage any psychological problems. They are
encouraged to continue with low dose tricyclics antidepressants or other prescribed
medication where appropriate. Moldofsky (2002) suggests that tricyclic drugs may
provide long term benefit for improving sleep, but queries the continuing benefit of
these medications beyond one month in the reduction of pain. Growth hormone is
reported to improve symptoms, but the high economic cost and the need for an
injection restrict its use (Moldofsky, 2002).
Research to characterise the patterns of electroencephalographic sleep and its
association with sleep and pain in people with FM concluded that alpha intrusion
during sleep can be of different patterns (Roizenblatt, Moldofsky, Benedito-Silva, &
Tufik, 2001). Roizenblatt and colleagues (200 1) detected three distinct patterns of
alpha sleep activity in FM patients: phasic alpha that was simultaneous with delta
activity in 50% of patients, tonic alpha that was continuous through non-REM sleep
in 20% of patients and low alpha activity in 30% of patients. The authors report that
83 .7% of control subjects exhibited low alpha activity. The phasic alpha intrusion
pattern correlated better with clinical manifestations of FM (Roizenblatt et al., 200 1).
Electroencephalographic evidence of rapid alpha wave intrusion into slower
delta wave deep sleep periods in FM patients are shown to be significantly greater
than in controls (Boissevain & McCain, 1 991 ). Shaver, Lentz, Landis, Heitkemper,
Buchwald and Woods ( 1997) found on polysomnography, that FM patients had more
level I transitional sleep, more sleep-state changes and a higher sleep fragmentation.
Studies by Affleck, Urrows, Tennen, Higgins and Abeles (1996) showed that, with
FM patients, one night of poor sleep was followed by a significantly more painful
day and another poorer night's sleep. Tryptophan, an amino acid that is the precursor
of serotonin, is a significant neurotransmitter in the pathways related to level IV
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sleep. The reduced concentration of tryptophan in relation to other plasma amino
acids suggests an abnormality in serotonin metabolism (Bennett, 1 993).
Italian researchers (Sarzi-Puttini et al., 2002) evaluated daytime hypersomnia
m patients affected by FM (n=30) and found that the occurrence of daytime
hypersomnia in these patients is linked to a greater severity of FM symptoms and
evidence of greater polysomnographic alterations.

Patients with daytime

hypersomnia displayed a higher number of tender points (p < 0.0 1 ), a higher
subjective pain score (p

<

0.05) and more fatigue (p

<

0.05). These patients had

significantly less effective sleep than FM patients with no daytime hypersomnia (p <
0.05), with a lower proportion of level III sleep (p

<

0.00 1 ), level IV sleep (p

<

0.00 1 ) and twice as many arousals as per hour of sleep (p < 0.01 ) (Sarzi-Puttini et al.,
2002).
A common cause of sleep deprivation for FM patients is restless leg
syndrome, an unpleasant sensation in the lower limbs resulting in an urge to
frequently move the legs. Yunus and Aldag ( 1 996) investigated the prevalence of
restless leg syndrome and leg cramps in FM patients to find these symptoms were
significantly more prevalent in FM patients and in those with rheumatoid arthritis
than in normal controls.
It is now recognised that sleep deprivation is a very serious health and safety
risk factor within our communities and workplaces. The research focus on sleep is
reflected in the Woolcock Institute of Medical Research 2nd Annual Sleep Loss
Symposium held in Sydney, Australia in November 2004. Internationally there is
increased interest in the health issues resulting from chronic sleep loss. Lamberg
(2004) refers to the harm on health and quality of life of 70 million individuals in the
United States of America because of chronic sleep loss and sleep disorders. The
United States Surgeon General, R H Carmona, is cited in Lamberg (2004)
commenting on sleep problems costing their nation $ 1 5 billion in health care
expenses and $50 billion in lost productivity annually. The National Centre on Sleep
Disorders Research in the United States aims to increase recognition and treatment of
sleep disorders to cut health costs, treat sleep disorders and improve public health
and quality of life of sufferers (Lamberg, 2004 ).
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This deprivation of restorative sleep is also an area of continuing research
specifically in the FM area as non-restorative sleep is a major symptom for FM
sufferers that can contribute to fatigue and intensify pain.
Cognitive Dysfunction
Patients with FM frequently report a decline in cognitive functioning,
memory and mental alertness. This is also referred to as neurocognitive dysfunction.
Jain and colleagu es (2004) describe this as cognitive fatigue rather than a fixed
impairment. They list the symptoms of cognitive dysfunction as: cognitive fog;
problems with linguistic performance; dyslexia; difficulty with writing, reading
mathematics, word retrieval and speaking; and short term memory dysfunction.
Researchers (Park, Glass, Minear, & Crofford, 200 1 ) evaluated FM patients for the
presence of cognitive deficits and tested the hypotheses that these abnormalities
would fit into a model of cognitive ageing. They concluded that cognitive
impairment, especially memory and vocabulary deficits, were evident although they
found that the cognitive defects were not global. Their results show that there is
cognitive dysfunction in FM patients and that it is related to pain.
One study on sleep, daytime symptoms and cognitive performance in patients
with FM (Cote & Moldofsky, 1 997) concluded that, rather than an impairment in
accuracy, the cognitive performance of FM patients was affected by a slower speed
in information processing, possibly due to pain, non-restorative sleep and mental
fatigue. Sephton, Studts, Hoover, Weissbecker, Lynch, Ho, McGuffin and Salmon
(2003) investigated the biological and psychological factors associated with memory
function in FM. Although the authors suggest that their interpretation of results is
limited by the lack of contrasting data from an age-matched healthy sample, the
study suggests that hypocortisolism and depressive symptoms are factors underlying
the cognitive deficits in FM.

Associated Disorders and Other Symptoms of Fibromyalgia
Clauw ( 1 995a) comments on the significant overlap between FM and other
systemic illnesses/syndromes such as somatoform disorders, chronic fati gue
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syndrome and Persian Gulf Syndrome. He lists these overlapping conditions as
headaches, irritable bowel syndrome, temporomandibular dysfunction, non-cardiac
chest pain, myofascial pain syndrome and urogenital symptoms.

Clauw, when

interviewed by Meisler (2000), described a spectrum of regional syndromes that
involve different areas of the body in which there is a bidirectional relationship with
FM. These include migraines, interstitial cystitis, non-cardiac chest pain and mitral
valve prolapse. The ACR Criteria for the Classification of FM (Wolfe et al., 1 990)
includes the following as symptoms: sleep disturbance, ' pain all over' , fatigue,
morning stiffness > 1 5 minutes, anxiety, headache, prior depression, irritable bowel
syndrome, sicca symptoms, urinary urgency, dysmenorrhea history and Raynaud' s
disease. Some of these associated disorders and symptoms will now be considered.

Irritable Bowel Syndrome
Irritable bowel syndrome and FM share many similarities. Both conditions
are defined and diagnosed by symptom-based criteria. Both are defined as a
symptom complex. There is no biological marker for either condition and the
pathophysiologic basis for both is still unclear. In 1989, a group of investigators and
experts on functional gastrointestinal disorders proposed a set of criteria known as
the 'Rome' criteria. An updated set of criteria, the 'Rome II' was first published in
2000 (Fennerty, 2003). Fennerty describes the criteria as useful in ensuring similar
patients are enrolled in clinical research proj ects, but adds they are much less useful
as a diagnostic tool in clinical practice.

Similar to the criteria for FM, this

classification criterion is research-based and is validated and rigid. The other criteria
mentioned for the diagnosis of FM are the diagnostic criteria, which are clinically
based, non-validated and ' softer' . Fennerty (2003) adds that, because of the
limitations of the existing diagnostic criteria for IBS, the 'Rome III' criteria will soon
need to be developed.
The American Gastroenterology Association (AGA) medical position
statement list three interrelated factors that affect the symptoms of IBS (American
Gastroenterological Association, 2002). These include altered gut reactivity, a
hypersensitive gut with enhanced visceral perception and pain and dysregulation of
the brain-gut axis which may be associated with an increased stress reactivity and
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altered perception and modulation of visceral afferent signals. This medical position
statement also acknowledges that IBS adversely affects the health-related quality of
life of patients. This includes impairment of their physical, emotional and psycho
social roles to a degree that exceeds that found in patients with other medical
conditions (American Gastroenterological Association, 2002). Olden (2003)
comments on the progress in IBS research in finding enhanced visceral
hypersensitivity in the colon and rectum as well as altered processing of signals to
the brain and raises the question as to which neurotransmitters play a role in the
altered processing of neural sensation in IBS patients. The similarities between the
research paths of both FM and IBS are significant and noticeable.
One study (Sperber et al., 1 999) has shown that FM and IBS co-exist in many
patients. In their IBS study, 25 of the 79 IBS patients (3 1 .6%) and 3 of the 72
controls (4.2%) had FM. Irritable bowel syndrome is a functional disorder of the
gastrointestinal tract that presents as chronic abdominal pain and changed bowel
function without evidence of laboratory or structural abnormalities on routine testing
(Sperber et al., 1999). A further study by Sperber and colleagues (2000) evaluated
the use of the Functional Bowel Disorder Severity Index (FBDSI) as a measure of
the severity of disease among patients with IBS. This study included FM patients
with IBS. An association was found between the FBDSI and IBS patient status with
IBS non-patients, patients with IBS only and patients with both IBS and FM having
increasingly severe scores.
The Visceral Sensitivity Index (VSI) has been developed and validated as a
reliable, valid measure of gastrointestinal symptom-specific anxiety (Labus et al.,
2004). Labus and colleagues acknowledge that anxiety, related to gastrointestinal
sensations and symptoms, may play a significant role in the pathophysiology and
health outcomes of patients with IBS. This 15-item scale may be useful for clinical
assessment and treatment outcome studies. In the first prospective study of its kind,
researchers have indicated that familial aggregation of IBS may occur (Kalantar,
Loche, Zinsmeister, Beighley, & Talley, 2003). These findings need to be replicated
in larger studies. The authors state that further studies will need to carefully evaluate
the roles of intrafamilial, environmental and inherited factors in the etiology of these
conditions.
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Veale, Kavanagh, Fielding and Fitzgerald ( 199 1) suggest that primary FM
and IBS may be different expressions of a common pathogenic process. The authors
suggest that abnormalities of the central nociceptive processing may be present in
IBS. They describe visceral hypersensitivity or decreased pain thresholds to
distension of the gut as biological markers for IBS. Their studies suggest that patients
with IBS may have cutaneous hyperalgesia similar to that experienced by patients
with FM. In a prospective case-controlled study (n= 32), urinary frequency and
urgency and the urodynamic findings of detrusor instability were significantly more
common in women with irritable bowel syndrome (p < 0.05) (Monga, Marrero,
Stanton, Lemieux, & Maxwell, 1997). The authors comment that these findings are
indicative of an irritable bladder in the irritable bowel syndrome supporting the
concept that irritable bowel syndrome may be part of a more generalised disorder of
smooth muscle.

Temporomandibular Joint Dysfunction
A majority of FM patients suffer with temporomandibular joint dysfunction
syndrome (Silver & Wallace, 2002). The authors found that symptoms associated
with this dysfunction included teeth grinding, jaw clenching, and spasm in the
temporomandibular j oints with resultant localised pain and headaches. One study
(Rhodus, Fricton, Carlson, & Messner, 2003) on the prevalence and profile of oral
symptoms in an FM population has shown that there was a significant prevalence in
temporomandibular dysfunction in an FM population (67.6%) compared to controls
(20%) (p < 0.001).

Chest Wall Symptoms
Chest pain, palpitations and discomfort of the costochondral margins and
chest wall are common in people with FM (Silver & Wallace, 2002). Cetin and Sivri
(2001) have shown that dyspnea is a common symptom for patients with FM. The
authors note that it is not associated with pulmonary function, but rather chest wall
discomfort and pain. Studies suggest that FM patients have a significantly increased
incidence of mitral valve prolapse with a greater than 20% incidence compared to
2% recorded with healthy controls (Freed et al., 1 999). This may be due to the
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dysautonomia in FM causmg diffuse smooth muscle dysmotility that could be
responsible for some of the associated FM symptoms such as mitral valve prolapse
and non-allergic rhinitis (Clauw, 1995a).

Restless Leg Syndrome
Silver and Wallace (2002) describe restless leg syndrome as periodic limb
movement disorder or nocturnal myoclonus and associate it with the alpha anomaly
in non REM sleep in FM patients. This restless leg syndrome is found m
approximately 15% of people diagnosed with FM (Silver & Wallace, 2002).

Headaches
Silver and Wallace note that over half of patients with FM experience
headaches, and that many of these patients experience these headaches daily or many
times per week. Wassem, McDonald and Racine (2002) found that headaches were
one of the listed symptoms of FM, reported in greater than 70% of 54 study
respondents. Kim (2004) cites Bernstein' s study from the American Headache
Society Annual Meeting in 2004, where three quarters of FM patients were shown to
have chronic headaches (n= 100). The survey from the department of anaesthesiology
at the University of Pittsburgh has shown that 76% of FM patients had regular
headaches and, of those, 21 % had migraine with aura and 27% had migraine without
aura. Kim (2004) cites Bernstein in describing headaches as an integral part of FM
for these patients, a part of the pain dysregulation of FM syndrome.

Autonomic and/or Neuroendocrine Dysfunction
Petzke and Clauw (2000) present an overview of findings of studies that
assess aspects of the sympathetic nervous system function in FM. These reviewed
studies included the areas of muscle sympathetic activity, microcirculation, heart rate
variability, tilt table testing, endogenous pain modulation and biochemical markers
(Petzke & Clauw, 2000). Jain and colleagues (2004) list autonomic dysfunctions as
dizziness, neurally mediated hypotension and vertigo, loss of thermostatic and
vasomotor stability, neurogenic or trophic oedema, sicca syndrome, cardiac and
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respiratory irregularities, intestinal irregularities and bladder dysfunction. Also listed
are the neuroendocrine dysfunctions of loss of adaptability and stress tolerance,
weight gain, hypothyroidism, and dysmenorrhoea. Also listed are associated signs
such as musculoskeletal asymmetry and muscle dysfunction.

Other Findings
Cold intolerance is a common symptom of FM. Wolfe and colleagues ( 1990)
have shown that approximately 30% of FM patients experience this cold intolerance
and that some may develop Raynaud's disease. Multiple sensitivities can result from
the disordered sensory processing in people with FM with many sensations being
amplified (Slotkoff, Radulovic, & Clauw, 1997). Dizziness is also a common
symptom experienced by patients with FM.
Recent findings from a genetic linkage study (Weissman, Gross, Fyer, &
Heinman, 2004) indicate a possible syndrome in some families with panic disorder.
This syndrome includes bladder problems such as IC, thyroid disorders, chronic
headaches/migraines and mitral valve prolapse. Weissman and colleagues (2004)
suggest that the range of symptom disorders includes disorders associated with IC
such as FM, celiac disease and irritable bowel syndrome and further suggest that
many or all of these conditions may share underlying pathophysiologic features.
Swezey and Adams ( 1999) investigated the associations of bone mineral
density and osteoporosis in patients with FM and healthy controls. The researchers
concluded that in this study FM was frequently associated with osteoporosis and
recommended appropriate prophylactic strategies. Further studies are necessary to
consider the impact of the lack of exercise due to pain and fatigue on the decreased
bone mineral density.

Psychosocial Implications
Physical trauma or emotional stress can trigger and/or exacerbate the
symptoms of FM. Crofford and Clauw (2002a) state that as well as the
neurobiological mechanism, behavioural factors can have an effect in symptom
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expression in some FM patients. The effects of pain and other symptoms of FM can
result in changed behaviour patterns and coping skills. These non-biologic factors
play a maj or role in symptom expression in all rheumatic diseases, not just FM
(Crofford & Clauw, 2002a). Jain et al (2004) refer to the common assertion that FM
symptoms result from an underlying depression or other psychological issues, but
state that this is not supported by available data.
Psychosocial health is often used as an umbrella term under which diverse
research inquiries are carried out (Martikainen, Bartley, & Lahelma, 2002). The
Oxford English Dictionary defines ' psychosocial' as ' pertaining to the influence of
social factors on an individual's mind or behaviour, and to the interrelation of
behavioural and social factors' (Simpson & Weiner, 1 989). Schaefer (1 995) writes of
the psychosocial aspects of living with FM in describing acceptable ways of living
with the pain and discomfort of FM as a struggle to find balance.
Soderberg, Lundman and Norberg (1999), in their study on women's
experience of living with FM, showed women with FM lived lives significantly
influenced by their illness. This study of women's experiences of living with FM was
defined according to the themes of loss of freedom, threat to integrity and struggles
to achieve relief and understanding. This loss of freedom embraced a body in pain,
suffering from fatigue and from a loss of energy, living a changed life every day and
having economic restrictions. The theme of threat to integrity emerged from the loss
of credibility and the invisibility of the illness, together with the lack of knowledge
about FM and a negative societal attitude. Women's struggle to achieve
understanding and relief reflected the need to find an explanation for the condition,
to seek relief and to plan one's daily life in accordance with the illness (Soderberg et
al., 1 999).
Researchers Soderberg and Lundman (2001 ) further considered transitions
experienced by women with FM. These transitions are described as transitions in
patterns of daily living, family life, social life, working life and learning to live with
the changes caused by FM. The authors referred to FM as the "choreographer of
activities and relationships" (p.617). In this study by Soderberg and Lundman
(200 l ), women described these transitions as invisible to almost everyone except
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themselves, but felt that other people viewed them as healthy beings. "It is like
living in two different worlds simultaneously, the world of the sick and the world of
the healthy" (p. 6 1 7).
Mannerkorpi, Kroksmark and Ekdahl (1 999) have shown how patients with
FM experience their symptoms in everyday life and they illuminated qualitative
differences in FM patients' experiences and their management of symptoms. The
study findings reveal four different patterns of perceiving and managing symptoms:
Struggling, where patients perceived they managed their lives by mobilising their
psychological and physical strength to manage pain and fatigue; Adapting, where
patients perceived they managed their day by planning their activities on the basis of
their assumptions of limitations; In despair, where patients despaired because they
could no longer cope with their pain and life situations; Giving up, where patients
had given up many activities of daily life and felt that symptoms dominated their
lives (Mannerkorpi et al., 1 999).
Toombs (1 992) writes of the taken-for-grantedness of daily living being
interrupted by illness, as well as the experience of illness as a loss of wholeness.
Toombs describes this loss of wholeness as not just the recognition of specific
symptoms, but rather as a profound loss of total body integrity where the painful
body disrupts the fundamental unity between one' s body and one's self. For patients,
the contradiction between their perception of their illness and the lack of medical
objective findings, together with the long investigative periods, is very stressful
(Hendriksson, 1 995). Being given a diagnosis is a relief, but presents the new stress
of managing this chronic, incurable condition.
FM and chronic fatigue syndrome (CFS) have an elusive etiology. There are
no objective measures and both conditions are difficult to diagnose (Asbring &
Narvanen, 2002). Accordingly, the potential for stigmatisation of women with these
conditions needs evaluation. Asbring and Narvanen (2002) investigated whether
women experienced their illness as stigmatising and examined the strategies women
used in avoiding such compartmentalisation. Their findings have shown that the
women felt they were being challenged by others about the truthfulness of their
illness experience, and their moral character was being questioned. They also
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described the 'psychologising' of their symptoms as stigm atising (Asbring &
Narvanen, 2002). This is compounded by the lack of objective findings that can
verify a physical illness that can encourage health care professionals to consider
psychological factors as the precipitators of the illness.
Asbring and Narvanen (2004) interviewed 1 2 women with FM and 1 3 women
with CFS in a study defining the potential for the patients to gain control over their
situation during the health care process, and to have some influence on the outcome
of this process. The women described various strategies they utilised with health care
providers to influence this process. These strategies included gaining control through
knowledge, and using power strategies such as changing doctors, not following
advice, confrontation, persuasion and insistence in directing treatment wishes.
The stress of diagnosis and management of FM has a profound effect not only
on the women diagnosed, but also on their family members. A study from the
husband' s perspective of living with a woman with FM (Soderberg, Strand, Haapala,
& Lundman, 2003) identified several themes: increasing responsibility and work in
the home; being an advocate for and supporting the wife; learning to see the
woman's changing needs; changing relationship between spouses; changing
relationship with friends and relatives; deepening relationship with the children; and
lacking information and knowledge about FM.
A recent Australian study (Infante et al., 2004) explored the perceptions of
patients with chronic conditions about the nature and quality of their care in general
practice. Participants in the study included 76 consumers in 1 2 focus groups in two
Australian states. The results of the study described three emerging priorities. The
first centred on the quality of doctors, including their technical competence,
interpersonal skills, consultation time for patients and continuity of care. The second
priority was for the general practitioners to develop closer links with consumer
organisations and support groups and to pass the information to their patients. Many
participants felt that their general practitioners were ' good' at the management of the
condition, but were 'weak' in recognising the emotional impact of chronic illness.
There was also the expectation that the practitioners should not only know the
medical side of a condition, but also the psychological and social impacts of the
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disease. Participants also emphasised the need for general practitioners to continue
professional development especially with respect to management and treatment of
chronic illness. In a disease like FM, where the diagnosis has no pathological
quantification, there is a sense of helplessness and/or disempowerment in doctors to
treat a condition they are not sure exists.

Etiology of Fibromyalgia
The etiology of FM is multifactorial but specific etiology is still elusive. FM
has been subjected to scientific scrutiny in the past 1 0 years with more than 1 000
publications produced in peer-reviewed journals. The majority of people with FM
enjoyed a relatively pain-free and active lifestyle before the onset of FM symptoms.
Buskila and Neumann ( 1 997) have shown that the prevalence of blood relatives of
patients with FM being diagnosed themselves with FM was 26% with the prevalence
in female relatives being 4 1 %. The mean tender point counts of both young male and
young female relatives in this study were significantly higher than in controls, being
6. 1 vs. 0.2 (p < 0.0 1 ) in males and 4.4 vs. 0.4 (p < 0.0 1 ) in females. The mean tender
point counts of adult relatives were even higher than controls with 4.0 vs. 0.04 (p <
0.0 1 ) for males and 1 0.3 vs. 0.28 (< 0.0 1 ) for females. Buskila and Neumann
concluded that patients with FM do have a higher prevalence of FM and more tender
points than an age-matched group within the general population. They conclude that
this trait is the result of genetic and environmental factors.
The symptoms of FM reflect alterations in pain perception, mood and sleep
and may be a stress-related illness as its onset often coincides with a stressful
situation, either physical or psychological (Pillmer, Bradley, Crofford, Moldofsky, &
Chrousos, 1 997). Abnormalities in pain perception occur such as allodynia, which is
pain with innocuous stimulation, and hyperalgesia, which is an increased sensitivity
to pain stimuli. Both of these abnormalities are present in patients with FM. Recent
attention for an explanation of this pain is on the central nervous system, rather than
on peripheral causes.
The main symptom of FM is chronic widespread pain. At the 1 oth World
Congress on Pain, FM was frequently referred to as the classic example of the
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' central pain state' . This indicates that peripheral tissue causes of pain cannot be
easily identified in most FM patients and suggests that most of the action is at the
level of the spinal cord and above (Bennett, 2002a). Researchers are therefore
focusing more on the role of the central nervous system rather than on the
musculoskeletal system in an effort to explain the symptoms of FM. A disorder of
the central

processing

of sensory information from the nociceptor and

mechanoreceptor systems can result in numerous neurophysiological changes that are
observed in FM sufferers.
Tissue damage does not need to be present for a patient to experience pain.
Schug (2002) suggests that pain should not be considered to be acute or chronic, but
rather as physiological or pathological pain. He describes physiological pain as
having only a biological function like pulling away from heat to protect the body and
pathological pain as having no biological function as healing is complete. Schug
observes that spontaneous pain occurring in the absence of an apparent stimulus is
caused by the upregulation of the lack of inhibition and that pain sensitisation is an
exaggerated response to pain. Littlejohn (1998) describes FM as the result of central
sensitisation, an increase in the excitability and responsiveness of neurones in the
spinal cord. This central sensitisation leads to an increase in the activities in higher
brain centres and is perceived as more intense and prolonged pain. This
hyperexcitability is mediated by the activation of neurones with N-methyl-D
aspartate (NMDA) receptor sites by some excitatory amino acids (Pillmer et al.,
1997). The release of these amino acids and their effect on the dorsal horn neurones
are increased by some neuropeptide transmitters like dynorphin, Substance P (SP)
and calcitonin gene-related peptide (Pillmer et al., 1 997).
Bennett ( 1 998a) uses the terminology "disordered sensory processing" to
encompass the concept of allodynia where light touch evokes severe pain.

He

suggests this non-nociceptive pain is usually dependent on central sensitisation that
has been induced by prior or ongoing nociception and that an understanding of this
non-nociception pain is relevant to the current understanding of FM. Different
treatment strategies from those used to treat nociceptive pain are required for the
treatment of non-nociceptive pain.
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Bennett (2002a) comments that an understanding of the detailed mechanisms
of neurochemical receptor interactions will be central to the development of new
drugs for treating chronic pain conditions. As a rheumatologist, Bennett (2002a) is
increasingly convinced that FM is primarily a neurological disorder that is presenting
as a musculoskeletal pain syndrome.
Staud (2002) sought to obtain evidence that input into central nociceptive
pathways is abnormally processed in individuals with FM. It was concluded that
central pain processing is abnormal, that pain memory is increased, that FM pain
correlates with heat and mechanical 'wind-up', and that these differences are due to
clearly established biological mechanisms (Staud, 2002). This is one reason why pre
emptive analgesia is currently of great interest to pain researchers, because
pretreating with an analgesic agent, peripheral and central sensitisation associated
with major tissue insult or disease may decrease (Sidebotham, Schug, & Petcu,
1997). These authors state that unrelieved pain can be the most distressing of human
conditions and should attract the time and effort of medical researchers.
Nociception is activity induced m neural pathways by stimuli that are
potentially harmful. Nociception is not a passive, one-directional process, but a
complex interaction between ascending and descending pathways that has the ability
to alter the relationship between stimulus and response (Rao, 2002). Nociceptive
stimuli from the periphery are relayed to the central nervous system via either
unmyelinated C fibres or myelinated Ao fibres that terminate in the dorsal horn.
These fibres synapse with dorsal horn interneurons and projection neurones (Rao,
2002). Willis and Westlund (1997) explain that a subset of dorsal horn neurones
project supraspinally via the spinothalamic tract and other pathways, thus forming
the basis of pain perception in the brain.
The neuropharmacology of the dorsal horn neuron is complex, with
excitatory and inhibitory neurotransmitters present. The complicated detailing of
these neurotransmitters and the research findings in relation to chronic pain are far
beyond the scope of this literature review. However, Substance P-mediated
neurotransmission has been the subject of animal studies replicating chronic pain
(Rao, 2002). Rao remarked that the role of Substance P-mediated neurotransmission

- 56 -

in human nociception processing is controversial. Substance P is a neuropeptide
stored in the secretory glands of sensory nerves and is released by axonal
stimulation. Substance P has multiple biological effects that include stimulation of
muscle, pain nociception, immune cell functions, plasma extravasation and many
other inflammatory effects (Luber-Narod et al., 1 997). Several studies (Russel et al.,
1 994; Vaeroy, Helle, Forre, Kass, & Terenius, 1 988) have shown that the
neuropeptide Substance P occurs in the cerebrospinal fluid of patients with FM two
to three times higher than in control subjects. Substance P lowers the threshold of
synaptic excitability, which allows for the unmasking of normally silent interspinal
synapses (Coderre, Katz, Vaccarino, & Melzack, 1 993). De Vane (200 1 ) describes
the physiological role of Substance P as a modulator of nociception that is involved
in the signalling of the intensity of noxious or aversive stimuli.
Recent genetic studies with mice and the development of Substance P
antagonists have redefined this neurotransmitter as an integral part of the central
nervous system pathways implicated in psychological stress (De Vane, 2001 ).
Current research focus is on clinical applications of Substance P antagonists to
enhance treatment of diseases linked with emotional response and with the
interpretation of sensory input into the brain (De Vane, 2001 ).
The concept of neurogenic inflammation is based on the release of Substance
P and related peptides by an axon reflex mechanism. Saban, Saban, and Bjorling
(1 997) investigated peptide-induced release of inflammatory mediators by the
urinary bladder and concluded that the peptides evaluated induced changes that may
directly regulate the participation of these peptides in the pathogenesis of cystitis.
Callsen-Cencic and Mense (1 997) also questioned whether alterations in the
expression of neuropeptides and nitric oxide synthase in the neuronal pathways to the
bladder might be involved in the hyperexcitability of the bladder with the
development of cystitis.
Rao (2002) describes how the behavioural state of central sensitisation may
be the result of alterations in the ascending or descending neural pathways of the
brain and spinal cord. Behbehani ( 1 995) describes the major components of the
descending nociceptive system. He describes the periaqueductal gray as a central
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structure in this linkage, linking the cortex and other higher structures with the dorsal
horn and processing both ascending and descending nociceptive information. The
monoamines, serotonin and noradrenaline, have a central role in this descending
modulation. The place of the descending system in chronic pain is a subject for
current research in seeking answers for management for chronic pain in FM. Rao
(2002) cites a number of studies showing reduced spinal noradrenaline outflow
results in chronic hyperalgesic states in laboratory animals.
As well as neurotransmitter abnormalities, hormonal and biochemical
abnormalities are detectable in patients with FM (Clauw, 1 995a). Insulin-like growth
factor I (IGF 1/somatomedin C) is a hormone produced in the liver, primarily in
response to the growth hormone. Most patients with FM have low serum levels of
IGF I. Bennet (1 993) suggests a disruption of the neuroendocrine axis that controls
growth hormone production could be the link between disturbed sleep and muscle
pain because this hormone is produced mainly during level IV sleep. Studies have
shown that treating these patients with human growth hormone leads to an
improvement of symptoms (Bennett, Clark, & Walczyk, 1 998b). Bennett (2004)
notes that suboptimal growth hormone secretion, resulting in a state of adult growth
hormone deficiency, may occur in chronic inflammatory disease, chronic
corticosteroid use and FM. He describes the need to evaluate the under- and over
secretion of growth hormone for practising rheumatologists.
The hypothalamic-pituitary-adrenal (HPA) axis has been described as a
complex brain-to-body pathway involving the hypothalamus, pituitary and adrenal
glands. Adler, Kinsley, Hurwitz, Mossey, and Goldenberg ( 1 999) describe the HPA
axis, and the autonomic nervous system, as the major pathways for the body's
responses to stressful conditions such as pain, exercise, trauma or infection. Both
systems are influenced by genetic factors, environmental factors and chronic illness
(Adler et al., 1 999). Crofford and colleagues (1 994) examined basal and stimulated
HPA axis and related hormone levels in patients with FM. Their results showed that
HPA function is altered in patients with FM. Crofford (2002b) refers to the evidence
of the HPA axis involvement in acute and chronic pain and questions whether the
HPA axis abnormalities in FM reflect pre-existing vulnerability to the FM spectrum
of the disease or if chronic somatic symptoms as seen in FM alter HPA axis activity.
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Further studies by Adler and colleagues (1999) have shown that patients with FM
have an impairment of the hyp othalamic-pituitary portion of the h yp othalamic
axis and the sympathoadrenal

adrenal

system.

This results in

reduced

adrenocorticotrophic hormone (ACTH) and epinephrine responses to h yp oglycaemia.
Neeck and Riedel (1 999) postulate that the distortion of the hormonal pattern
m FM patients can be attributed to hyp eractivity of the corticotropin-releasing
hormone (CRH). The authors suggest that this hyperactivity is driven and sustained
by the stress from chronic musculoskeletal pain and/or by changes in the CNS
mechanism of nociception. Neeck and Riedek ( 1 999) concluded from their studies of
the entire endocrine profile of sixteen FM patients and seventeen controls that the
pattern of hormonal deviations in patients with FM is a CNS adj ustment to chronic
pain and stress and is a specific entity of FM.
Martinez-Lavin (2002) suggests that dysautonomia may play a central role in
the pathogenesis of FM because autonomic nervous system (ANS) dysfunction is
frequently found in patients with FM. Martinez-Lavin describes the ANS as a
dynamic system with intense and instantaneous onset of action and dissipation that
works closely with the endocrine system, especially the hyp othalamic-pituitary
adrenal axis and the growth hormone axis. Because the ANS regulates the function
of most of the organs and systems of the body, it is the main homeostatic system.
Martinez-Lavin (2002) proposes a pathogenic model of 'sympathetically maintained
pain' suggesting that the hyp eractive sympathetic nervous system can result in
constant fatigue, morning stiffness, sleep disorders, intestinal irritability and other
FM symptomatology. Raj , Brouillard, Simpson, Hopman and Abdollah (2000) have
shown abnormal responses to two tests of autonomic nervous system functioning in
patients with FM. The authors comment that further research is needed to ascertain if
dysautonomia has an influence in the pathogenesis of FM or if dysautonomia results
from FM.
Using neuroimaging to measure the change in regional cerebral blood flow
produced by pain in patients with FM, Bradley, McKendree-Smith, Alberts, Alarcon,
Mountz and Deutsch (2000) identified lower than normal blood flow levels to two
major pain processing areas in the brain, the thalamus and the caudate nuclei.
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Kwiatek, Bamden, Tedman, Jarrett, Chew, Rowe and Pile (2000) confirmed, in their
work using single-photon-emission computed tomography (SPECT) brain scans on
cerebral blood flow, that there is reduced regional cerebral blood flow (rCBF) in the
right thalamus as well as the pontine tegmentum in the brain stem of patients with
FM. The authors conclude that the pathophysiological significance of these changes
in FM patients needs to be clarified with further research.
Because FM patients suffer other symptoms, such as sleep abnormalities,
fatigue, irritable bowel and bladder symptoms and others as well as pain, Clauw and
Chrousos (1997b) and Littlejohn (1996) question how the pathophysiology of these
other symptoms is related to central sensitisation. Various hypotheses have been
considered and published by researchers but this is still an ongoing area of active
debate and research as knowledge in the area of pain medicine continues to grow.

Etiology of Bladder Symptomatology in FM
Al-Chaer (2000) describes visceral pain as having the capacity to become the
consuming focus of one's life. Al-Chaer describes the clinical impact of pain from
internal organs (visceral pain) as outweighing somatic pain because of the high
incidence of algogenic (pain causing) conditions, which affect the viscera, and the
tendency of these conditions to be chronic or recurrent. McMahon (2004) describes
the sensory innervation of the viscera as serving a number of important functions,
including the transmission of visceral sensations such as pain. He comments that the
transduction properties of visceral afferents are not stable and can be altered by
numerous factors. These altered properties of all neurobiological systems are
described as forms of plasticity. McMahon (2004) describes the functionally relevant
forms of plasticity in the context of visceral sensory neurones as those that affect the
encoding and transmission of sensory information, and comments on the increased
excitability of sensory neurones causing functional consequences and contributing to
chronic pain states.
Butrick (2004) describes the visceral silent afferents as all having the capacity
to transmit pain. He notes that 10% of the afferents are silent in the skin compared
with 30%-80% of the visceral afferents being silent. These silent afferents can
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become active with prolonged stimulation and have a major role in tissue
sensitisation (Butrick, 2004). Cervero (1 994) states that the bladder does have the
highest neural density and the greatest proportion of silent C-fibres of any viscera.
Cervero and Laird ( 1 999) question the conventional view of visceral pain as
simply a variant of somatic pain, based on the belief that a single neurological
mechanism is responsible for all pain. The authors acknowledge that the two
pathways have much in common, but note that there are important differences. They
comment on the lack of specialised clinicians with expertise in the management of
visceral pain leading to a range of treatment by a range of specialists treating visceral
pain as a symptom and not as a distinct neurological entity.
Cervero and Laird ( 1 999) comment that, although the mechanisms of visceral
pain differ between organs and organ systems, there are two common principles that
apply to visceral pain. The first is that, because neurological mechanisms of visceral
pain differ from those mechanisms in somatic pain, the findings from somatic pain
cannot therefore be extrapolated to visceral pain. The second principle is that the
perception and psychological processing of visceral pain is different from that of
somatic pain. Cervero and Laird refer to five important clinical characteristics of
visceral pain as: not all viscera are sensitive to pain; it is not always linked to visceral
injury; it is diffuse and poorly localised; it is referred to other locations; and it is
accompanied by motor and autonomic reflexes such as nausea and muscle spasm.
Cervero and Laird (1999) refer to the challenge to established paradigms on
the transmission of visceral pain, stating that there are two distinct classes of
nociceptive sensory receptors that innervate internal organs. The first class of
receptors has a high threshold to natural, mainly mechanical stimuli, where stimulus
intensity and nerve activity are evoked entirely by stimuli within the noxious range.
These high threshold receptors have been identified in a number of organs and organ
systems, including the ureter, urinary bladder and uterus. The second class of
receptors has a low threshold to natural, mainly mechanical, stimuli where nerve
activity of these low threshold receptors is evoked by stimulation of different
intensities from innocuous to noxious (Cervero & Laird, 1999). These receptors have
also been described in organs, including the urinary bladder (Cervero & Laird, 1 999).
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Cervero and Janig (1992) also suggest that a large component of the afferent
innervation of internal organs consists of afferent fibres that are usually quiescent
and become activated only when inflammation is present. This theory proposes that
these sensory receptors contribute to the signalling of chronic visceral pain, with long
term alterations of spinal reflexes and abnormal autonomic regulation of internal
organs.
Overall, visceral pain is not the focus of this FM study. However, the
symptoms of visceral pain from the urogenital system are to be considered. Although
both irritable urinary symptoms and irritable bowel syndrome are listed as associated
symptoms of FM, more research is being undertaken in the area of irritable bowel
syndrome than in the urogenital pain arena. Cervero and Laird (1999) cite a number
of studies lending support to the hypothesis that functional abdominal syndromes
such as irritable bowel syndrome may be the result of visceral hyp ersensitivity that
causes patients to become more aware of gastrointestinal activity. These authors
suggest that this heightened awareness could be the result of sensitisation of the
peripheral nociceptors or of some alterations of the central processing that result in
an increase in the activation of visceral nociceptive pathways.
Costa, Glise and Graffer (2004) acknowledge that, through neural
information from the viscera, the central nervous system plays an important role in
health and disease, but that not much of the visceral afferent information reaches our
conscious experience, except in circumstances where it produces unpleasant
sensations such as pain, discomfort and nausea.
Giamberardino, De Laurentis, Affaitati, Lerza, Lapenna and Vecchiet (200 1 ),
from the Department of Medicine and Aging from the University of Chieti, in Italy,
researched the clinical observation that algogenic conditions of one internal organ
can affect reactivity to painful stimuli of other visceral areas, with over-lapping of
sensory proj ections. Results indicate that algogenic conditions of the female
reproductive organs enhance pain and referred hyp eralgesia from the urinary tract.
The authors point out that the female reproductive organs, and the urinary tract, have
common sensory proj ections to spinal cord segments. Giamberardino and colleagues
(2001) suggest increased afferent signals from one visceral domain, such as the
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reproductive organs, towards the central nervous system, increase the excitability of
viscero-visceral convergent neurones in the spinal cord. This then results in the
central effect of the input from the second internal organ, the urinary tract being
amplified and resulting in 'viscero-visceral hyperalgesia' . These researchers have
provided evidence of an interaction of sensory nerves from different viscera resulting
in the development of pain symptoms.
Ishigooka, Zermann, Doggweiler, Schmidt, Hashimoto and Nakada (200 1)
explored the potential of chronic bladder irritation in an animal model, resulting in
central sensitisation. Bennett (200 1) states that the understanding of visceral pain
leading to central sensitisation is gaining ground in both the clinical and
experimental arenas. He comments that this is of particular importance to
rheumatologists who endeavour to treat and manage the associated symptoms of FM
such as irritable bowel and bladder syndromes.
Researchers (Yoshimura, Seki, Chancellor, de Groat, & Ueda, 2002)
hypothesise that in some chronic bladder conditions, the hyperexcitability of the C
fibre afferent pathways, which during bladder filling are normally silent, may be the
mechanism for bladder pain and urgency. Yoshimura and colleagues (2002) consider
C-fibre afferent pathways in urinary frequency and pain in painful bladder
syndromes as targets for treatment of this condition. Their focus is on the modulation
of activity of bladder afferent pathways, preventing bladder pain by interfering with
the steps involved in altering C-fibre activity. Yoshimura and colleagues (2002)
suggest that a mechanism by which pain is induced involves chronic tissue
inflammation that can lead to some functional changes in C-fibre afferents, and that
the normally silent fibres appear to have specific functions in signalling noxious
events in the bladder. Their study concludes that the hyperexcitability of C-fibre
afferent pathways is likely involved in pain associated with painful bladder
syndrome. This area of urogenital pain is a maj or focus for pain researchers in this
early 21 st century.
Felson, (2003/2004) as president for the Society for Basic Urological
Research, comments he is encouraged by the research on pain and sensory
mechanisms in both bladder processes, sensation and pain, and urothelial cell
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function. Felson describes their urological societal research as attempting to
understand the fundamental disease processes as this is what translates into
treatments and cures.

Hypotheses Explaining Fibromyalgia
Chaitow (2003) summarises a number of hypotheses explaining the evolution
of FM. He refers to the chronobiological hypothesis by Moldofsky, the genetic
hypothesis by Goldstein, the integrated hypothesis by Bennett, the nociceptive
hypothesis by Wolfe and the stress hormone hypothesis by Goldenberg and Adler. A
brief synopsis of each hypothesis is delineated here.
Moldofsky's chronobiological hypothesis suggests that FM is the result of
altered biological rhythms,

including diurnal physiological

functions and

environmental influences, together with psychosocial and behavioural influences
(Chaitow, 2003). Goldstein's hypothesis considers a genetic predisposition in the
etiology FM. Chaitow (2003) lists a number of studies where genetically acquired
traits such as j oint hypermobility and mitral valve prolapse are reported as more
common in the FM population than in the general population. There are also
indications of familial tendencies in the development of FM. Bennett's integrated
hypothesis (Chaitow, 2003) considers blending both the central and peripheral
nervous system etiologies. The nociceptive hypothesis by Wolfe (Chaitow, 2003)
proposes pain amplification resulting from chronic pain stimulus, progressing under
the influence of genetic factors, somatic disease, sleep disturbance and psychological
factors with the evolution of FM.
Clauw and Williams (2002) present a model that unifies some studies and
hypotheses on the role of altered central nervous function. The model, known as the
Chronic Multisymptom Illness (CMI} , is described by the authors as the constellation
of stress-mediated symptoms and syndromes that can occur in two forms within the
individual. The first form is described as a systemic or widespread symptom
expression and includes FM and chronic fatigue syndrome (CFS). The second format
is described as single organ or single region symptom expression and includes
conditions such as migraine or tension headaches and irritable bowel syndrome.
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Clauw ( 1 995a) also presents a unifying hypothesis to describe the spectrum
of symptoms and syndromes that are associated with FM. He comments that,
although multiple non-rheumatic features initially seem unrelated, they can be
divided into four categories based on the underlying cause and clustering of cohorts
of patients. Clauw describes these four categories as: neurologic as seen in sleep
disturbance, paresthesias, vestibular and cognitive symptoms and mood disturbances;
smooth muscle dysmotility as seen in irritable bowel, bladder symptoms, and
migraine headaches; increased skeletal muscle tone as seen m myalgias, TMJ
syndrome and tension headaches; and irritative or inflammatory symptoms as seen in
cystitis, rhinitis, and pharyngitis. Clauw ( 1 995a) postulates that a different effector
arm of the nervous system results in specific symptomatology mediating each group
of symptoms. This integrated hypothesis is the basis of the theoretical framework for
this thesis.
In detailing this integrated hypothesis, Clauw ( 1 995a) suggests that
genetically vulnerable individuals may be asymptomatic throughout life until a
'triggering' event, although some may have always been aware of some of the allied
conditions such as migraines or cystitis. Many may stop exercising as a result of this
'triggering' event and that may increase the symptoms. Clauw describes the resultant
adaptive stress response activating both the hypothalamic pituitary adrenal (HP A)
axis and the sympathetic system.
Clauw ( 1 995a) states that once the latent CNS hyperactivity is apparent then
all or some of the effector arms of the central nervous system can be involved. Clauw
suggests that an elevated ratio of excitatory to inhibitory neuromodulators is
responsible for this spectrum of conditions, the region of the central nervous system
being affected being reflected in the symptomatology. More than one of the effector
arms of the central nervous system can be activated at any one time. Clauw ( 1 995a)
cites studies by Mayer and Raybold, White, Stevens and Upton and Whorwell,
Lupton, Erduran and Wilson in demonstrating this concurrent activation by studies
on irritable bowel syndrome where there is both diffuse smooth muscle dysmotility
of the intestines, oesophagus, bladder and bronchus as well as increased visceral
nociception. The literature discussed in the etiology of bladder symptomatology in
this thesis indicates both neurogenic inflammation and increased visceral nociception
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are involved in the irritative and bladder pain sensations in women with FM. Because
several arms of the nervous system contribute to specific symptoms, Clauw (1995a)
suggests that a multi-disciplinary approach for examining symptoms and systems
concurrently is more likely to provide effective treatments.
It is obvious from the various hypotheses that there are numerous evolving
concepts in the etiology of FM. In summary, the evolution of understanding of the
plasticity of the nervous system, the interaction between somatic and visceral
pathways and the expansion of information on neurotransmitters are together
increasing our understanding of etiological factors in the development of FM and
therefore in management strategies.

Treatment /Management of FM
Clauw (2000) commented that not all health care professionals are interested
in the diagnosis and management of patients with FM while others see the FM
patient as difficult. Clauw suggests that this perception of difficulty may be because
the physician is unable to improve the condition of the patient, or their demands
exceed the physician' s capabilities. He recommends the early diagnosis of FM,
before the chronicity of the condition results in dysfunction and disability.
Millea and Hollaway (2000) suggest that the physician' s supportive
counselling skills and openness to try new treatment strategies with refractory cases
are an important part of the management strategy for FM. Bauman, Fardy and Harris
(2003) discuss patient-centred care being about the sharing of the management of an
illness between the patients and their doctor and the evidence of this patient-centred
care having a favourable impact on chronic health conditions, including chronic
musculoskeletal conditions. The main features of this patient-centred care, featuring
doctor-patient interaction, include shared goal setting, with written management
plans, supportive community-based programs with a focus on health promotion and
healthy lifestyles. Effective patient-centred care results in a partnership between the
doctors and patients where the patients can talk freely about the emotional and
psychological issues related to their chronic condition and not just the associated
physical symptoms.
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The pain of FM is not caused by peripheral inflammation, but rather by a
central nervous system defect and therefore different treatment interventions are
necessary (Clauw, 2000). The author encourages extended medical consultations
with FM patients until there is an understanding on the part of the physician of the
problems the patients are experiencing and for the patients to understand that the
treatment will involve patient participation.
There is no one specific treatment for FM. Once the patient is diagnosed with
FM, the treatment should be individualised, with regular assessment to monitor
treatment efficacy. The condition is managed by a number of specific approaches to
address the symptoms. This multimodal approach includes education, psychological,
exercise and medication regimes. Education about the condition is paramount and it
is extremely validating for the patient to receive a diagnosis usually after a long
search for an answer to their pain and the impact of associated symptoms. Although
FM is not life threatening, it is a quality of life threatening condition, and treatment
and management must focus on all aspects of appropriate medical and self
management techniques. The approach to address specific symptoms is imperative.
One example is the symptom of bladder irritability. Education on normal bladder
function, good bladder habits and bladder management strategies would be included
for women with these specific bladder symptoms.
A six-year prospective study of a cohort of patients with FM has shown that
some symptoms of FM can persist for years, but some aspects of quality of life
improve over time because of coping strategies patients can develop with or without
professional assistance (Baumgartner, Finckh, Cedraschi, & Vischer, 2002a). A
longitudinal study (Fitzcharles, DaCosta, & Poyhia, 2003) examining the outcome of
FM with standard medical care was favourable, with almost half of the sample
reporting clinically meaningful improvement. The authors suggest that, because of
the current thinking on the pathogenesis of FM of central dysregulation of the pain
processing mechanisms, it may be possible that with time there could be a resetting
of the pain threshold. Fitzcharles and colleagues (2003) suggest that some treatment
interventions may facilitate the shift of this pain threshold towards normal.
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Littlej ohn and Walker (2002b), in considering a realistic approach to
managing patients with FM, note that, because FM probably arises from a disordered
neurophysiology, the effects embrace thoughts, emotions and cognitions because of
the influence of central control inputs. The biopsychosocial model of pain combines
the notions that, at the physiological level, changes are initiated by trauma or
pathology, whilst at the psychological level variables are reflected in the attention to
internal sensations and this attention and behavioural responses can be influenced by
social and environmental variables (Nicholas, 2000). The Council of the Australian
Pain Society has recently published a paper on Pain Management Programs for
Chronic, Persistent or Long Lasting Pain (Speldewinde & O'Callaghan, 2002). This
program is based on the bio-psycho-social model as the authors state that simple
analgesics, opioids and interventional techniques often help with the nociceptive
component, but do not always address the larger psychological aspects of an
individual's suffering.
Bennett (2002e) also emphasises a rational approach to the management of
FM by adopting a holistic approach based on the bio-psycho-social approach to
management. He discourages treating the diagnosis of FM as a unified entity, but
rather recommends that attention be given to twelve separate management issues.
These are listed as diagnosis and evaluation, education, pain, fatigue, sleep,
psychological disorders, endocrine dysfunction, dysautonomia, deconditioning,
cognitive dysfunction, the existential crisis and associated syndromes. Bennett
(2002e) states that the concept that FM symptomatology results from the
amplification of incoming sensory impulses has revolutionised the understanding of
FM and created a more rational approach to treatment.
A review of multi-disciplinary treatment studies for patients with FM (Oliver,
Cronan, & Walen, 200 1) has shown that these programs are generally effective.
Based on these findings, the authors have recommended that future researchers
utilise reliable and valid measures designed for patients with FM. Creamer, Singh,
Hochberg and Berman (2000) have shown that a non-pharmacological intervention
for FM that included education, relaxation, and Qi Gong movement therapy weekly
for eight weeks resulted in significant improvement in signs and symptoms in FM.
Results from an evaluation on comparing the efficacy of pharmacological and non-
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pharmacological treatments of FM by Rossy and colleagues ( 1999) have shown that
the optimal intervention for FM includes exercise and cognitive behavioural therapy
as well as appropriate medications for the symptoms of sleep deprivation and pain.
A pilot study by Pfeiffer and colleagues (2003) to determine the effects of a
1 .5-day multi-disciplinary outpatient treatment program for FM has shown that
improvements compared favourably with those results from longer interventions.
The program was divided into an introductory program including education on FM
and self-management techniques, occupational therapy focusing on energy
conservation and ergonomics and physiotherapy focusing on stretching techniques,
posture, body mechanics, strength, endurance and aerobic exercise. The efficacy of
the program was assessed by the use of validated outcome measure assessment tools.
This short intervention program (n=78) did show a significant improvement on the
Fibromyalgia Impact Questionnaire score (5 1.3 - 44.7, p < 0.002) but did not
significantly improve depression (p < 0.06), life fulfilment (p < 0.53) and physical
impairment (p = 0. 1 1 ).
Sprott (2003) notes that because subgroups within the FM population have
been determined, uniform recommendations for treatment cannot be given. He
recommends individual adapted measures to accommodate the differences between
FM sufferers within the subgroups. Sprott (2003) asks the question as to why FM
patients respond differently to different treatments. He suggests it may be due to the
differences in the etiological pathogenic mechanisms within the identified FM
subgroups and lists these as disturbances in the inhibitory system, neuro-endocrine
disturbances, neuropeptide disturbances and decreased secretion of growth hormone.
Sprott reminds us that treatment regimes are based on an unknown etiology and that
a long term effective intervention must focus on managing the symptoms associated
with FM.

Patient Education
Understanding the implications of a diagnosis of FM is very important for the
patients who often have spent many years, many dollars and emotional energy
seeking a diagnosis or a solution for their pain and dysfunction. It is important that

- 69

patients understand what FM is, that it is not life threatening, that there is no ' cure,'
that it is non inflammatory, that they may always be symptomatic and that they must
take responsibility for their own well being and FM management. Patient education
on FM is available through many resources, support, education and pain management
groups.
Ramos-Remus, Salcedo-Rocha, Prieto-Parra and Galvan-Villegas (2000)
report that the prevalence and morbidity rate of rheumatic diseases are increasing
with non-medical causes playing an important role in the morbidity and disability of
patients. They suggest because the maj ority of rheumatic diseases have no cure and
many have poor outcomes that contributing factors to this may include comorbid
conditions, drug side effects and the non-medical causes of morbidity. In addressing
this issue, the authors suggest that the outcome of chronic disease may be influenced
by the action of the person with the disease as much as by the health professional and
therefore suggest that chronic diseases may respond to lifestyle modification as well
as medical intervention.
Hill ( 1 997) defines patient education as any combination of learning
experience designed to improve patients' behaviours and, as a result, improve their
health status and long term outcome. Ramos-Remus and colleagues (2000) define
self-management as activities that a person undertakes to improve health, to prevent
disease and to decrease the chance of illness. They detail the goal of self
management programs as remodelling interpretative structures to improve the
patients' behaviours and to increase their self-efficiency. The authors describe
interpretive structures as those a person uses to interpret and respond to any event.
They further describe these structures as culturally acquired within a personal,
cultural, social, political and economic environment and as significant personal
factors in the knowledge, attitudes and behaviour used by individuals. This
interpretive framework within the disease context is described as the way society and
patients perceive, categorise or give meaning to a disease (Ramos-Remus et al.,
2000).
The timing of any patient education program is important. Ramos-Remus and
colleagues (2000) recommend that patients with chronic disease should commence
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these programs following adequate time for the reaction of diagnosis, denial period
and acceptance of the disease. They describe patient education as a strategy rather
than one program and recommend that education is implemented as programs and
assessed as interventions. The aim is to reshape the interpretive structures of patients
and not just to provide educational information.
A study on the impact of a health education program on the quality of life of
persons with FM (Bosch, Saenz, Valls, & Vinolas, 2002) has shown that health
education modified the patients' perception of quality of life, reduced their pain,
increased their understanding of FM and reduced dependence on the health system.
Another prospective randomised study (Langer, Ehlebracht-Konig, & Mattussek,
2003) demonstrated that patient education leads to an improvement of knowledge,
self-efficacy, self-help activities, improvement in helplessness and pain, and reduces
both temporary and permanent disability.
Jain and colleagues'(2004) recommendations for patient education include
being informed about FM and sources of support, knowing of early warning systems
to prevent crashes, establishing a simple, serene, slow and supportive environment,
relaxation and stress management, keeping the body warm, conserving energy, and
avoiding aggravating factors. Patients are encouraged to establish personal
boundaries, to maximise sleep and maintain a balanced diet.
Patient education extends into the arena of pain management. Cooper, Booker
and Spanswick (2003) discuss one strategy for education in pain management to
improve pain outcomes for patients that differs from the routine clinical practice.
Rather than their focus being on the abolition of pain, it is on the restoration of
function despite pain. Patients are made aware that activity-related pain does not
equate with activity-related tissue damage, allowing them to confidently reintroduce
physical activity into their daily routines (Cooper et al., 2003).
Exercise
Exercise is always recommended as part of the prescription for the
management of FM. For many FM patients, fear that movement of an already painful
body will increase their pain and disability often prevents them from undertaking
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exercise training and/or programs. Jain et al (2004) have stated that exercise must be
specific to the pathophysiology of FM and that the exercise intensity should be
adapted to the patients' individual capacity and limitations. Individualised exercise
programs should include warm up and cooling times, stretching, strength training,
endurance training to increase conditioning, balance, pacing and patient control over
the intensity and duration of the exercises (Jain et al., 2004). Clauw (2000)
recommends a step approach towards exercise intervention, beginning with a non
demanding and short exercise period.
The Cochrane Musculoskeletal Group (Busch, Schachter, Peloso, &
Bombardier, 2002a) systemically reviewed the efficacy of exercise training as a
treatment for FM. They concluded that supervised exercise training does have
beneficial effects on physical function and symptoms in patients with FM. A recent
study (Richards & Scott, 2002) concluded that prescribed aerobic exercise is a
simple, effective, inexpensive and available treatment for FM. However, the
researchers found that compliance to an exercise program is a problem that may need
to be addressed by cognitive behavioural therapy and the provision of explanations
for initial increase in symptoms.
Gowans, deHueck, Voss and Richardson (1999) evaluated the efficacy of a
six-week exercise and educational program for patients diagnosed with FM. The
randomised controlled trial study (n=4 l ) showed that short term exercise and
educational programs could produce some immediate and sustained benefits for
patients. The subject's physical function was assessed by a modified six-minute walk
test with a significant improvement in the intervention group (p < 0.05). Similarly the
program increased the intervention group subjects' sense of well being as indicated
by the visual analog scale in the Fibromyalgia Impact Questionnaire (FIQ) that
measured 'days felt bad' (p < 0.05). The intervention group also showed significantly
greater decreases in morning fatigue as measured by the FIQ visual analog scale that
gauged fatigue on waking (p < 0.05). It is difficult to monitor whether the benefits
were related to the exercise, education or both, because both interventions were
given. The authors reflect that further studies will be needed to show if such gains
can be improved and sustained for sufficient time to be clinically beneficial to FM
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patients. Further studies are also needed to distinguish between the effects of each
intervention.
Gowans and deHueck (2004) recommend further investigation into the
benefits of low intensity exercise and the development of strategies for long term
compliance with exercise regimes by people with FM. The authors also encourage
enhanced access to community exercise programs and progression exercise
instruction specific for people with FM.
Persell (2002) determined that a 1 2-week graded aerobic exercise plan
resulted in more improvement in a validated self-rated change in global impression
scale and decreased tender point counts compared with a relaxation and stretching
program for adults with FM (n= 1 36). For the primary outcome, the improvement in a
validated self-rated change in global expression scale, 24/69 patients (35%) in the
exercise group and 1 2/67 ( 1 8%) in the relaxation group improved (p = 0.03).
Similarly, a study by Gandhi, DePauw, Dolny and Freson (2002), examining
the effects of a 1 0-week (20 session) exercise program on quality of life of women
with FM (n = 2 1 ), concluded that significant improvements were made in the range
of motion (p = 0.0003) and in the FIQ scores (p = 0.0049) of the exercise groups, but
the tender point count and the tender point severity scales were unaltered. This area
of research between physical activity and health-related quality of life and outcomes
is complex. Although the beneficial effects of participating in regular exercise are
known, the dose response relationships between physical activity and health-related
quality oflife are unclear (Brown et al., 2004).
One influence on exercise prescription could be the fatigue factors that
accompany FM. Bujak, Mikdashi, Kalappa, Keyser, and Handwerger (2002)
considered aerobic capacity in their studies of people with FM. Aerobic capacity is
determined by measuring peak oxygen intake. If a person scores more than 27%
below their expected oxygen intake, they are considered to have functional aerobic
impairment. In this study, functional aerobic impairment was observed in 6 of the 1 1
FM study participants, but in none of the 1 1 controls. Bujak and colleagues (2002)
are continuing to look for molecular mechanisms underlying this impairment to
develop interventions that may improve aerobic capacity.
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The majority of patients who have experienced the symptoms of FM for some
time tend to be deconditioned muscularly because of their inability to exercise
without exacerbating the pain. Although the exercise emphasis for FM management
has been mainly on aerobics, a recent pilot study (Rooks, Silverman, & Kantrowitz,
2002) has shown that a program of progressive strength training and cardiovascular
exercise was safe and well tolerated in women with FM. This study also showed that
the introduction of progressive strength exercises, together with cardiovascular
endurance training, did not exacerbate their FM symptoms. Patient characteristics
that may impact on the success of an exercise program for FM and similar conditions
have been listed by Ambrose, Lyden and Clauw (2003) as: a readiness to adopt a
new exercise regime that may increase pain at the beginning; the ability to accept
self-management for their FM; unrealistic expectations; fear of an increase in pain
and fatigue; and past experiences with exercise and social support.
Recommendations from the 6 1h International Conference on Chronic Fatigue
Syndrome, Fibromyalgia and Related Illnesses included a low level aerobic interval
exercise as an exercise alternative for people with FM (Lapp, 2003). This exercise
regime involves exercising for 3 to 5 minutes followed by the same time period
resting to allow the body to recover and then exercise and rest again. This option for
exercising is often more palatable for the FM sufferer who can experience a flare up
of symptoms due to excessive exercise (Lapp, 2003).
For women with bladder irritability symptoms associated with FM, their
ability to exercise is often inhibited by the anxiety of urinary urgency and urinary
frequency. The fear of not being able to get to the toilet in time to void, the anxiety
of an urge or stress incontinent episode and/or the increased pressure and pain on the
bladder resulting from exercising, all contribute to poor compliance to any exercise
program. To date, there have been no studies on the effect of exercise specifically on
the bladder irritability symptoms of FM.

Pharmacological Treatment of FM
Clauw (2000) comments that, in clinical practice, the view is widely held that
the interventions of education, exercise and cognitive behavioural therapy are more
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effective when they are combined with symptom-based pharmacological therapy.
Barkhuizen (200 1 ) lists symptoms amenable to pharmacological therapy as pain,
sleep disturbance, mood disturbance, fatigue and associated disorders. Until there is a
clearer understanding of the pathophysiologic mechanisms causing the symptoms of
FM, pharmacological treatment should be aimed at individual symptoms
(Barkhuizen, 200 1 ). He suggests guarding against polypharmacy and prescription for
symptoms that impact on activities of daily living and quality oflife.
Barkhuizen (2001 ) notes that, even though evidence-based medicine dictates
that the use of medication should be based on the results of randomised placebo
controlled clinical trials, FM poses a challenge to researchers because it is a complex
disorder with multiple symptoms, lacking clear etiology and objective physical
findings. Jain and colleagues (2004) anticipate that the optimal therapy for FM in the
future will be the use of a limited cocktail of low dose medications which each target
a specific receptor known to be involved with the pathogenesis of FM. Duggan
(2002), in his presentation on Central Transmitters: Prospects for Pain Control, spoke
of the most centrally acting drugs affecting brain function by their action at the
synapses by modifying the release, action or inactivation of neurotransmitters.
Russel (2003) describes FM as a syndrome that is underserved by the medical
profession and the pharmaceutical industry. He asks questions regarding the
management of FM, such as what kinds of biochemical and physiological changes
predispose people to developing FM and can these changes be manipulated by
physiological or psychological interventions? Russel also asks which steps in the
nociceptive process could be altered to produce clinical benefits. For now, the
complexity of FM defies pharmacological cure or significant relief of symptoms.
Anti-inflammatory medicines are non-effective in reducing pain, as FM is not
an inflammatory disease. A trial of non-steroidal anti-inflammatory drugs is often
used to manage peripheral pain such as that resulting from osteoarthritis. Narcotic
medications are controversial in the management of FM and other chronic pain
conditions. There does remain some concern about the addictive properties of
opioids. They may increase cognitive dysfunction or gastrointestinal problems and
remain a controversial topic for treatment of FM (Barkhuizen, 200 1 ).
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Analgesic therapy includes the use of tricyclics antidepressants with
documented analgesic effects (Goldenberg, Mayskiy, & Mossey, 1 996). A meta
analysis of nine studies on the use of antidepressants in FM (Arnold et al., 2000)
found a moderate improvement in pain and sleep and a modest improvement in
fatigu e, tenderness and stiffness. Another meta-analysis of 1 3 published, good
quality, randomised, placebo-controlled trials (O'Malley, Balden, Tomkins, Santoro,
& Kroenke, 2000) suggests that antidepressants reduce the symptoms of FM. The
authors have suggested further research to assess the relative efficacy of different
types of antidepressants as well as whether the efficacy is independent of an effect on
depression. Lawson (2002) suggests that tricyclic medications are most effective
when administered with other therapies such as selective serotonin reuptake
inhibitors which affect the modulation of the neurotransmitters, serotonin and
noradrenaline.
The selective serotonin reuptake inhibitors have been shown to have a
minimal effect on pain in FM, but some benefit in the emotional component of pain
and mood disorders (Jung, Staiger, & Sullivan, 1 997). Sleep hygiene measures are
usually implemented before medication for poor sleep patterns. Medication to
improve sleep includes pure sedatives acting on benzodiazepine receptors, sedating
antihistamines and sedating antidepressants (Barkhuizen, 200 1 ).
Data presented by Crofford and Arbor (2002c) showed improvement in the
core symptoms of FM of pain, sleep and fatigue from a double-blind, placebo
controlled study on the new drug pregabalin. This study involved 529 patients
diagnosed with FM. Pregabalin-treated patients trialling 450mg/day for eight weeks
showed significant improvements in pain compared to those who received placebos.
Jancin (2004) cites Buskila at the annual 2004 European Congress of Rheumatology
in describing pregabalin as an efficient agent that gives significant improvement in
the widespread pain, sleep disruption and fatigue due to FM. Buskila commented that
these improvements and a good safety profile were as much as could be expected of
any proposed therapy, given the gaps in the current understanding of the basis of FM
(Jancin, 2004). Crofford (2002c) speaks of the need for new treatment options that
are both effective and well tolerated because of the debilitating and difficult to treat
symptoms of FM.
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Many of the available medications for pain have been developed for lessening
acute rather than chronic pain. Mechanisms that lead to chronic pain are different
from those of acute pain. Clauw, when interviewed by Meisler (2000), suggested
that, within the next three to five years, we can expect to see new classes of
medications that will be developed for the management of chronic pain alone.
Clauw, presenting at the 2003 American College of Rheumatologists Annual
Scientific Meeting (Ross, 2003), has suggested that the drug milnacipran, which was
in its phase II clinical trial and had shown to provide statistically significant
improvement of pain in FM, could dramatically change the way FM is treated. The
phase II study was a 12-week randomised, double-blind, placebo-controlled trial at
several centres across the United States of America (n= l 25). The results showed
37% of FM patients reported a 50% reduction in pain compared to 14% of placebo
patients (Franklin, 2003). Further studies need to be completed to confirm these data.
Milnacipran belongs to a group of drugs known as SNRis (serotonin norepinephrine
reuptake inhibitors). Milnacipran is a dual acting reuptake inhibitor that acts on two
neurotransmitters, norepinephrine and serotonin, which are involved in the central
modulation and processing of chronic pain (Kranzler, 2003).
Littlejohn (2004) comments that pharmacological information to date
suggests that drugs such as duloxetine, a serotonin and norepinephrine reuptake
inhibitor, may be more efficacious in the treatment of FM. A recent randomised,
double blind, 12-week trial (Arnold et al., 2004) has shown that duloxetine-treated
patients improved significantly more (p = 0.027) on the total score of the
Fibromyalgia Impact Score (FIQ) but not on the FIQ pain score (p = 0. 130). In this
trial, the intervention group also showed a significant decrease in Brief Pain
Inventory average pain severity scores (p = 0.008), Brief Pain Inventory average
interference from pain score (p = 0.004), number of tender points (p = 0.002), and
FIQ stiffness score (p = 0.048) (Arnold et al., 2004). The duloxetine-treated patients
also significantly improved in mean tender point pain threshold (p = 0.002), Clinical
Global Impression of Severity (CG I-Severity) scale and Patient Global Impression of
Improvement (POI-Improvement) scale (p = 0.033) (Arnold et al., 2004). The men in
this study did not show any significant improvement on any efficacy measures. The
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researchers recommend further studies to study the long term efficacy of duloxetine
in FM.
Recent trials of duloxetine have also shown it to be effective for women with
stress urinary incontinence (Cardozo, 2004). Cardozo refers to duloxetine as the first
pharmacological agent that has been developed in large randomised controlled trials
for the management of stress incontinence in women. Michel and Peters (2004)
describe lower urinary tract function as being tightly managed by a complex neural
network. They describe the pelvic nerves as suppliers of key signals for micturition,
and the hyp ogastric and pudenda! nerves as suppliers of key signals for urine storage.
Urethral closure depends on an intact striated urethral sphincter that is innervated by
the pudenda! nerve. The tone and contraction of the striated urethral sphincter is
increased by the central neurotransmitters of serotonin and noradrenaline.
Duloxetine, as a powerful and balanced serotonin and noradrenalin reuptake
inhibitor, is thought to increase the concentrations of these neurotransmitters, with a
resultant increase in the activity of the striated urethral sphincter and increased
bladder capacity (Michel & Peters, 2004 ). Results of the randomised placebo
controlled trials (van Kerrebroeck, 2004) show that duloxetine 80mg/day is an
effective and safe treatment for women with urinary incontinence
The Food and Drug Administration Arthritis Advisory Committee of the
United States of America has proposed guidelines for use in the design trials of drugs
for FM (Franklin, 2003). This advisory committee has recommended that trials of
FM treatments should last at least six months and that all patients entering the trial
should meet the 1 990 diagnostic criteria set down by the American College of
Rheumatology. The committee recommended that the drug manufacturers
demonstrate an effective end point as indicators for the treatment for FM. This end
point could include some improvements in pain, patient global assessment and
function (Franklin, 2003). It was also suggested that end points for symptom-specific
indicators for pain, sleep difficulties and fatigue be included.
Sewitch, Dobkin, Bematsky, Baron, Starr, Cohen and Fitzcharles (2004)
identified the determinants of medication non-adherence in women with FM (n=
127). Sixty (47%) women were non-adherent to medication, with 20 (33.3%) being
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intentionally non-adherent and 24 (40%) unintentionally non-adherent. Unintentional
non-adherence was predicted by community status, not being under a rheumatologist
care plan, decreased disease activity, less use of instrumental coping and increased
patient-physician discordance, while intentional non-adherence was predicted by a
shorter time under a rheumatologist's care and greater patient-physician discordance
(Sewitch et al., 2004).

Cognitive Behavioural Therapy

Price (2004) describes pain as having many neurological and psychological
dimensions that are processed in the brain. This subsequently triggers pain as a
sensation and evokes an emotional response to that pain. Price concludes that there is
no single, all-encompassing pain response centre existing in the brain. He states that
although pain sensations are activated by neurones in the brain, these sensations
occur within the context of psychological and physical factors that are responsible
for the cognitive and evaluative component of pain. Price (2004) likens the sensory
dimension of pain being embedded in the emotional dimension in the same way that
height is a determinant of weight.
The Australian Association for Cognitive and Behavioural Therapy
(Australian Association for Cognitive and Behavioural Therapy, 2004) defines
cognitive behavioural therapy (CBT) as a focused approach to the treatment of
different types of emotional, behavioural and psychiatric problems which assists
individuals in identifying unhelpful thoughts and behaviours and learning healthier
skills and habits.
Cognitive behavioural therapy is one method used to assist patients with FM
to cope with their symptoms and to improve their quality of life by focusing on self
control and coping strategies. In one randomised controlled study, (Williams, Cary,
Groner, Chaplin, Glazer, Rodriquez and Clauw, (2002), the cognitive behavioural
therapy consisted of six hour-long group sessions with an experienced therapist that
focused on teaching patients skills to improve their physical functioning. Results
from this study found that 25% of the patients who had behavioural therapy
experienced a significant increase in physical functioning after the treatment
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compared with only 1 2% of patients who did not receive it. Both groups of patients
had the same level of pain one year following treatment. Williams and colleagues
(2002) suggest that previous studies have shown mixed results because of the
differences in how the therapy was administered. Their data suggests that the
inclusion of cognitive behavioural therapy in a medical regime for FM can benefit
physical functioning in a subset of patients.
A meta-analysis of 49 studies of FM treatments (Rossy et al., 1 999) found
that cognitive behavioural therapy and exercise were superior to pharmacological
agents. The authors conceded that it is likely that the cognitive behavioural therapy
and exercise produced positive results because they targeted more than one
symptom. Long term relief of symptoms is seldom achieved for patients with FM.
The current management philosophy is to assist the patient to adapt to a lifestyle
dispersed with pain, fatigue and numerous other associated symptoms. As noted
previously, there is some evidence that FM can be helped but not cured by a multi
disciplinary approach incorporating education,

aerobic exercise,

cognitive

behavioural therapy and management of associated syndromes (Bennett, 2002b ).
Nielson and Jensen (2004) examined the association between the treatment
process variables of beliefs, and coping strategies and treatment outcomes of pain
severity, activity level, emotional distress and life interference related to a four-week
multi-disciplinary FM treatment program. Outcomes of the intervention resulted in
an increased sense of control over pain, a belief that one is not necessarily disabled
by FM, knowledge that pain is not necessarily a sign of some damage, decreased
guarding, increased exercise, seeking support, activity pacing and use of self
statement for coping. Nielson and Jensen (2004) observe that their findings were
consistent with a cognitive behavioural model of FM.
The research on the sub-grouping of Fibromyalgia patients on the basis of
pressure-pain thresholds and psychological factors (Giesecke et al., 2003) has
implications

for

rehabilitation

interventions

for

FM

patients.

Uniform

recommendations for treatment for all FM sufferers cannot be given because of the
diversity within the patient group (Sprott, 2003). Sprott recommends individual
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adapted measures should be emphasised to differentially treat these FM subgroups
when identified.

Fibromyalgia and Bladder Symptoms
Irritable bladder symptoms similar to the irritative bladder symptoms of
interstitial cystitis (IC) are listed as one of the associated disorders of FM (Littlejohn,
1996). These symptoms include urinary frequency, urinary urgency, nocturia and
pelvic pain in the absence of infection. Although the focus of this current research on
FM is not on the development of knowledge of the neurobiology of bladder pain and
its associated symptoms of urgency, frequency and nocturia, a brief overview of
some recent research findings related to lower urinary tract sensation is important as
background for this study.
Rothenberg (1999) describes FM as a condition that involves the loss of pain
regulation in the central nervous system resulting in pain amplification. Abnormal
levels of central nervous system neurotransmitters then result from this excessive
pain stimulation. The imbalance of neurotransmitters affects the body's hormonal
response to stress, resulting in abnormalities in the autonomic nervous system.
Rothenberg comments that these abnormalities in tum affect the involuntary
functions and that their impact contributes to conditions such as irritable bowel and
irritable bladder.
With all neurologic reflex mechanisms efferent activity results from afferent
input (Fowler, 2002). Adequate sensory input is a prerequisite for conscious bladder
control (Wyndaele & De Wachter, 2003). Sensory nerve cell bodies from the dorsal
root ganglion project to the lower urinary tract and the spinal cord. The motor
innervation of the bladder and urethra originates from the lumbosacral area (S2-S4)
and travels by the parasympathetic pelvic nerves. The sensory nerves from the
bladder run with the motor supply. P oorly localised sensations of pain and distension
enter with the sympathetic fibres at a higher level (Abrams, 1997).
Sensory receptors are present in the human bladder in the detrusor muscle
and in the suburothelial layer. The sensory nerves supplying the bladder are
myelinated A-delta or unmyelinated C-fibres (Wyndaele & De Wachter, 2003).
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Wyndaele and De Wachter note that both the afferent A-delta and C-fibres in the
pelvic and hypogastric nerve are able to signal non-painful sensations during bladder
fillings and suggest that these afferents may also signal noxious events resulting in
abnormal symptoms such as urgency and pain. They further comment on the
plasticity of the bladder afferents where the number of active primary afferents is not
static, resulting in changes in bladder sensation in various pathological conditions.
Wyndaele (1998) and Wyndaele and Wachter (2002) studied cystometrical
sensory data from a normal population during cystometric bladder filling. The
normal pattern of bladder sensations on filling is described during cystometry as
three distinct sensations. The first sensation is described as just that of the bladder
filling, the second as the first desire to void and the third as a strong desire to void. A
fourth sensation of pain can be added if bladder filling continues after the volume of
full bladder sensation.
Wyndaele and De Wachter (2003) report the first sensation of filling
occurring at a mean of 40% of bladder filling and the first desire to void at a mean of
59% of total bladder capacity. They refer to this system of sensations as warnings
that enable us to integrate bladder function in every day life. It has been suggested
that if this system of sensations malfunctions, where the first sensation of filling is
absent, then the other sensations occur at significantly smaller volumes (Wyndaele,
1993) and this may cause urgency (Klein, 1988). Wyndaele and De Wachter (2003)
suggest that, if the sensations come at too low volumes, they may cause frequency
and nocturia. These authors describe urgency as a pathological sensation where one
experiences a continuous desire to void sometimes even after micturition. In many
women diagnosed with FM, the cause for this urgency cannot be identified.

Urinary Definitions
The standardisation of measurements and a consensus on terminology help to
prevent confusion, assist in understanding the pathophysiology of conditions and
define what is normal and abnormal (van Kerrebroeck & Weiss, 1999). Urogenital
symptoms of FM include urinary frequency, urinary urgency, nocturia, bladder
and/or pelvic pain and vulvodynia. These urogenital symptoms associated with FM
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are often referred to as the irritable bladder syndrome, interstitial cystitis or lower
urinary tract symptoms. Urinary definitions used in this study will conform to the
standards recommended by the International Continence Society except where
specifically noted.
The International Continence Society (ICS) is recognised as the international
governing body for the standardising of urological terminology. The following
urinary definitions are from the Standardisation of Terminology of Lower Urinary
Tract Function: a report from the standardisation sub-committee of the International
Continence Society (ICS) (Abrams et al., 2002b). These definitions are compatible
with the WHO publication ICIDH-2 (International Classification of Functioning,
Disability and Health) published in 2001 and the ICDl O, the International
Classification of Disease. The following definitions are from the Standardisation of
Terminology in Lower Urinary Tract Function from the ICS.
Lower Urinary Tract Symptoms
The urogenital tract symptoms of FM are lower urinary tract symptoms
(LUTS} and are defined from the individual's perspective. Urinary symptoms as
defined by the International Continence Society (ICS) are divided into the three
groups of storage, voiding and post micturition symptoms. Definitions relevant to
this study are listed here.
Storage symptoms are experienced during the storage phase of the bladder
and include:
•

increased day time frequency, the complaint by the patient who considers that
she/he voids too often by day.

•

nocturia, the complaint that the individual has to wake at night one or more
times to void.

•

urgency, the complaint of a sudden compelling desire to pass urine which is
difficult to defer.

•

urinary incontinence, the complaint of any involuntary leakage of urine.

•

stress incontinence, the complaint of involuntary leakage of urine on effort or
exertion or on sneezing or coughing.

- 83 -

•

urge urinary incontinence, the complaint of involuntary leakage accompanied
by or immediately preceded by urgency.

•

mixed urinary incontinence, the complaint of involuntary leakage of urine
associated with urgency and also with exertion, effort, sneezing or coughing.

•

other types of incontinence which may be situational such as the report of
incontinence during sexual intercourse or giggle incontinence.
Bladder Sensation Definitions

•

Normal is where the individual is aware of bladder filling and increasing
sensation up to a strong desire to void.

•

Increased is where the individual feels an early and persistent desire to void.

•

Reduced is where the individual is aware of bladder filling but does not feel a
definite desire to void.

•

Absent is where the individual reports no sensation of bladder filling or desire
to void.

•

Non-specific is where the individual reports no specific bladder sensation but
may perceive bladder filling as abdominal fullness, vegetative symptoms or
spasticity.

•

Voiding symptoms are experienced during the voiding phase.

•

Post-micturition symptoms are experienced immediately after micturition
such as feeling of incomplete emptying being a self-explanatory term for a
feeling experienced by the individual after passing urine.
Genital and Lower Urinary Tract Pain
Pain discomfort and pressure are part of a spectrum of abnormal sensations

felt by an individual. The ICS terminology report recommends that genital and lower
urinary tract pain should be characterised by type, frequency, duration, precipitating
and relieving factors and by location as defined in the following:
•

Bladder pain is felt suprapubically or retropubically usually increasing with
bladder filling and may persist after voiding.

•

Urethral pain is felt in the urethra and the individual indicates the urethra as
the site.

•

Vulval pain is felt in and around the external genitalia.
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•

Vaginal pain is felt internally, above the introitus.

•

Perineal pain is felt in the female, between the posterior fourchette (posterior
lip of the introitus) and the anus.

•

Pelvic pain is less well defined than, for example, bladder, urethral or
perinea! pain and is less clearly related to the micturition cycle or to bowel
function and is not located in any single pelvic organ.
Syndromes as described in the ICS terminology report are varying

combinations of symptoms that cannot be used for precise diagnosis. The use of the
word, 'syndrome', is justified only if there is at least one other symptom in addition
to the symptom used to describe the syndrome. The syndromes are functional
abnormalities for which a precise cause has not been found. It is expected that
appropriate assessment has excluded obvious pathologies. The ICS terminology
report lists two syndromes, the urogenital pain syndrome and the symptom syndrome
suggestive of lower urinary tract dysfunction.
Urogenital Pain Syndromes
These are all chronic conditions. Pain is the major complaint, together with
complaints including lower urinary tract, bowel, sexual, or of a gynaecological
nature:
•

Painful bladder syndrome is the complaint of suprapubic pain related to
bladder filling, accompanied by other symptoms such as increased daytime
and night-time frequency, in the absence of proven urinary infection or other
obvious pathology.

•

Urethral pain syndrome is the occurrence of recurrent episodic urethral pain
usually on voiding, with daytime frequency and nocturia, in the absence of
proven infection or other obvious pathology.

•

Vulval pain syndrome is the occurrence of persistent or recurrent episodic
vulval pain, which is either related to the micturition cycle or associated with
symptoms suggestive of urinary tract or sexual dysfunction and where there is
no obvious pathology or proven infection.

•

Vaginal pain syndrome is the occurrence of persistent or recurrent episodic
vaginal pain which is associated with symptoms suggestive of urinary tract or
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sexual dysfunction and where there is no proven vaginal infection or other
obvious pathology.
•

Perineal pain syndrome is the occurrence of persistent or recurrent episodic
perineal pain, which is either related to the micturition cycle or associated
with symptoms suggestive of urinary tract or sexual dysfunction and where
there is no proven infection or other obvious pathology.

•

Pelvic pain syndrome is the occurrence of persistent or recurrent episodic
pelvic pain associated with symptoms suggestive of lower urinary tract,
sexual, bowel or gynaecological dysfunction and where there is no proven
infection or other obvious pathology.
Symptom Syndromes Suggestive of Lower Urinary Tract Dysfunction
Urgency, with or without urge incontinence, usually with frequency and

nocturia, can be described as either the overactive bladder syndrome, urge syndrome
or urgency-frequency syndrome.
Measuring Signs Suggestive of Lower Urinary Tract Dysfunction
The bladder diary records the times of micturitions and voided volumes,
incontinence episodes, pad usage, fluid intake, degree of urgency, the degree of
incontinence and other relevant information. The following measurements can be
extracted from bladder diaries:
•

Daytime frequency is the number of voids recorded during waking hours and
includes the last void before sleep and the first void after waking and rising in
the morning.

•

Nocturia is the number of voids recorded during a night's sleep. Each void is
preceded and followed by sleep.

•

Nocturnal polyuria is defined by the nocturnal urine volume >20-30% of the
total 24 hour urine volume.

•

Twenty-four-hour frequency is the total number of daytime voids and
episodes of nocturia during a specified 24-hour period.

•

Maximum voided volume is the largest volume of urine voided during a
single micturition.
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Urodynamic Observations and Conditions

Urine flow is defined either as continuous or intermittent. The continuous
flow curve is defined as a smooth arc-shaped curve, or a fluctuating one where there
are multiple peaks during a period of continuous urine flow.
•

Flow rate is defined as the volume of fluid expelled via the urethra per unit
time. It is expressed in ml/sec.

•

Voided volume is the total volume expelled via the urethra.

•

Maximum flow rate is the maximum measured value of the flow rate after
correction for artefacts.

•

Voiding time is the total duration of micturition.
(Abrams et al., 2002b)

Lower Urinary Tract Symptoms

Lower urinary tract symptoms (LUTS) can be classified as storage symptoms,
emptying symptoms or both (Blaivas, 2000). Urinary frequency, urgency and pain
are classified as storage symptoms. Sensory urgency is described as an
uncomfortable need to void unaccompanied by detrusor instability.
Within the medical literature, lower urinary tract symptomatology in the male
population has been more extensively studied than that for the female population. An
Austrian study (Schatzl et al., 2001 ) compared the prevalence and severity of lower
urinary tract symptoms (LUTS) in both sexes and determined their effect on
everyday life as 'bothemess'. The women's results (n= 1 1 9 1 ) showed the mean
increase in LUTS from the youngest (20-39 years) to the oldest (> 70 years) age
group was 23 .6% (3.9%/decade). In all decades, the irritative storage symptoms were
higher in the women's group. The researchers reported that urinary urgency and
frequency were more bothersome in older individuals, while nocturia and voiding
symptoms were almost equally bothersome for both younger and older study
participants.
Gillespie (2004) reviews the literature on the generation of excessive sensory
urges of the bladder. Urological opinion is that low bladder tone during the filling
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phase is maintained by reducing the parasympathetic excitatory micturition reflex
and encouraging the inhibitory sympathetic elements to facilitate 'accommodation'
(Ruch, 1960). Gillespie explains the bladder as rhythmically active during the filling
phase, the activity being generated in the bladder wall, and describes this as
' autonomous' activity in the non-micturition phase. Gillespie notes that this rhythmic
activity is an intrinsic property of the bladder wall and that the frequency and
magnitude of these transient contractions could be affected by parasympathetic and
sympathetic neural inputs. This autonomous activity entails waves of contraction and
localised stretches of the bladder wall. These complex events may involve a network
of pacemaker cells and connecting interstitial cells motivated by excitatory and
inhibitory neural inputs (Gillespie, 2004). Modulation by central nervous system
activity can affect the amplitude and frequency of the autonomous activity with
resultant changes in bladder sensations.
Lower urinary tract symptoms (LUTS) in women can produce significant
bother and affect their quality of life (Scarpero, Fiske, Xue, & Nitti, 2003). Scarpero
and colleagues determined whether the degree of bother caused by lower urinary
tract symptoms correlated with a woman's quality of life and whether this varies with
a woman's age and continence status. Using the American Urological Association
Symptom Index (AUASI), this study has shown a strong correlation between urinary
symptoms and problems caused by these symptoms (n= 1232, p < 0.001) and also
that the correlation existed throughout various age groups and was independent of
their continence status. A similar pattern was shown for the correlation between
urinary symptoms and quality of life. With the diversity of symptomatology of
diseases such as FM that do not yet have absolute classifications or
biological/biochemical markers, how do we give advice to people with these
symptoms? How do we treat 'bother'?

Urinary Frequency
Increased urinary daytime frequency is described by the International
Continence Society as the complaint by the patient who considers that she/he voids
too often by day (Abrams et al., 2002b ). The incidence of urinary frequency in
community-dwelling women (n= 886) was reported at 20% (Glenning, 1985).
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Significant correlations between urinary frequency and bother have been shown in
another community-dwelling population (Swithinbank et al., 1999). In this study (n =
2075), over 50% of women found voiding nine times a day or more was a problem
for them. The mean age of responders was 52 years with an age range of 19-97 years.
The authors found that the most prevalent symptoms were not necessarily the
symptoms the women reported as being most problematic. Swithinbank and Abrams
(2000) found only 5% of women with a voiding frequency of 1 to 6 times a day and
17% of women who voided 7 to 8 times a day found it bothersome.

Urinary Urgency
Urinary urgency is described by the International Continence Society as the
complaint of a sudden compelling desire to pass urine which is difficult to defer
(Abrams et al., 2002b). Urgency is described as a pathological sensation that is
experienced as a continuous desire to void, as a sensation that does not necessarily
ebb post micturition and one that is experienced differently from the sensation of
bladder fullness (Wyndaele & De Wachter, 2003). A large study (Swithinbank et al.,
1999) on community-dwelling women in Britain (n =2075) has shown that one of the
most common urinary symptoms was urgency (6 1 %). Only 37% of these women
with urgency reported this symptom as problematic. The authors comment that this
study has highlighted the importance of prevalence studies on urinary symptoms as
well as the perceived impact caused by the symptoms. This perceived impact may be
more useful in assessing the demands for treatment.
Treatment for sensory urgency firstly includes the treatment of detectable
conditions. When there is no obvious abnormal pathology, a pharmacological
approach using drugs that impair bladder sensation and/or neurotransmitters of pain
signals may be considered (Blaivas, 2000).

Nocturia
Nocturia, as described by the International Continence Society, is the
complaint that the individual has to wake at night one or more times to void (van
Kerrebroeck & Weiss, 1999). The authors of the Standardisation of Terminology in
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Nocturia for the International Continence Society (van Kerrebroeck et al., 2002)
comment that although a person may consider that one night time void is normal,
they still do have nocturia. The authors also note that, in the situation where the
desire to void may not be the trigger that wakes people at night yet they need to void
when they wake, these individuals are still considered to have nocturia.
Nocturia is a condition that is now recognised as a clinical entity in its own
right and not a symptom of some other disorder (van Kerrebroeck et al., 2002). It has
been reported as one of the most common causes of sleep disturbance (Middlelkoop,
Smilde van den Doel, Neven, Kamphuisen, & Springer, 1 996).

Schatzl and

colleagues (2000) have shown that the number of people with nocturia of two or
more times increased with age: below 30 years (3 . 1 %), between 30 to 59 years
(7.2%) and over 60 years (26.7%). The age-adjusted extrapolation to the general
population (> 20 years of age) of women in Austria showed that 1 1 .8% of women
experience nocturia of two or more times and that the nocturia affects the quality of
life of two thirds of these women (Schatzl et al., 2000).
Weiss and Blaivas (2003 ) list pathological conditions such as cardiovascular
disease, diabetes mellitus, lower urinary tract obstruction, anxiety, primary sleep
disorders, and behavioural and environmental issues as factors that may result in
nocturia. They attribute nocturia to nocturnal polyuria, diminished nocturnal bladder
capacity or a combination of both factors.
Middlelkoop and colleagues ( 1 996) have reported the prevalence of nocturia
to be 58% and 66% in women and men of 50 to 59 years and 72% and 91 % in
women and men over 80 years of age. A recent study on nocturia and its effect on
health-related quality of life and sleep (Coyne et al., 2003) found that nocturia was
widely prevalent and increased with age. It was demonstrated that incremental
increases in the number of voids per night had increased negative effects on sleep,
symptom bother and health-related quality of life. Lose, Alling-Moller and Jennum
(2001 ) have shown that the prevalence of nocturia is more common in parous women
and increases with age, with more than 50% of women > or

=

to 80 years of age

experiencing nocturia. The authors note that although nocturia is one of the most
bothersome of the lower urinary tract symptoms, with a significant impact on quality
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of life, few women seek medical assistance because they accept it as part of aging
(Lose et al., 200 1). Swithinbank and colleagues (1999) in their large British study (n
=2075)

found 19% of women reported nocturia as a urinary symptom with 63%

finding the nocturia troublesome. The mean age of responders was 52 years with an
age range of 19 to 97 years.
The impact of nocturia on quality of life in a Dutch population has revealed
that nocturia can lead to sleep insufficiency with subsequent decrease in mental and
physical health. Researchers (van Dijk et al., 2004) selected 1 000 adults after
stratification to complete a written questionnaire. The 8 19 respondents were
distributed over three groups: a target group (n= 189) who were bothered by >/= one
void per night, a reference group I (n= 120) with no bother but >/= two voids per
night and a reference group II (n=5 l 0) with 0- 1 voids per night. The results have
shown that the perceived impact on life was highest in the target group (p < 0.05).
The target group also showed more sleep problems and scored lower on quality of
life scores than reference groups I and II (p < 0.05). Van Dijk and colleagues (2004)
suggest that doctors routinely check for nocturia when patients present with sleep
problems. This would be particularly pertinent for FM sufferers, many of whom
already experience insomnia and unrefreshed sleep that is unrelated to their bladder
symptomatology.
Fiske, Scarpero, Xue and Nitti (2004) studied 1232 patients showing that as
the number of nocturia episodes increases, the bother increases (p < 0.0001) and is
independent of age and continence status. Fiske and colleagues (2004) propose from
this study that clinically significant nocturia in women be classified as two or more
episodes per night. They also suggest that two episodes of nocturia be considered
mildly clinically si gnificant, three episodes as moderate and four or more episodes to
be severe nocturia. This classification system is given as a guide only in the
diagn osis and treatment of women with nocturia.
Kobelt, Borgstrom and Mattiasson (2003) assessed the effect of nocturia on
productivity, vitality and utility in a selected group of professional active individuals
with nocturia compared with matched controls. The researchers tested the hypothesis
that a lack of sleep due to frequent sleep interruptions could decrease a person' s
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daytime energy and activity levels. The study group (n=203) with nocturia
experienced a lower level of vitality and utility with greater impairment of work and
activity. Symptom severity correlated with all three measures of productivity, vitality
and utility. The women participants were more affected than the men. The
researchers concluded that waking at night to void diminished the participants overall
well being, vitality and productivity and resulted in a significant level of indirect and
tangible costs (Kobelt et al., 2003).
Walmsley and Staskin (2003) stress the importance of considering the non
urologic etiologies in the differential diagnosis of a patient presenting with nocturia.
The authors comment that this is even more important if the patient has failed to
respond to lower urinary tract directed therapy or if surgery is being considered.
Voiding diaries are an essential part of the assessment of patients with nocturia as
they give information on low nocturnal bladder capacity, increased night time urine
production and behavioural and environmental factors. Because of the insomnia
already experienced by people with FM, the increased burden of nocturia may have
an increased detrimental effect on their hours of effective sleep. As previously
mentioned in this text, it is now recognised that sleep deprivation is a very serious
health and safety risk factor within our communities and workplaces. The impact,
therefore, on women already struggling with non-bladder symptoms of FM can have
significant bother and health effects.
Bladder Pain
Bladder pain is felt suprapubically or retropubically, usually increasing with
bladder filling, and may persist after voiding, while painful bladder syndrome is the
complaint of suprapubic pain related to bladder filling, accompanied by other
symptoms such as increased daytime and night time frequency, in the absence of
proven urinary infection or other obvious pathology (Abrams et al., 2002b). Two
types of pain have been described in the bladder: a sharp pain suprapubically or in
the perineal region; a painful pressure in the lower abdomen (Wyndaele & De
Wachter, 2003). Blaivas (2000) describes these two types of pain as one that occurs
immediately before, during or after voiding, and the pain that is felt when micturition
is delayed. Blaivas comments on the many other permutations of pain that may not
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be associated with the lower urinary tract but are included with the differential
diagn osis.

Fibromyalgia Bladder Irritability and Interstitial Cystitis
Data from their study examining clinical features and peripheral nociception
in parallel cohorts of FM and IC patients suggested to Clauw and colleagues (1997a)
a significant overlap in symptomatology in both IC and FM. A questionnaire
questioning the presence of 47 different symptoms that are common in FM was
completed by 60 FM patients, 30 IC patients and 30 controls. The authors suggest
that the data, together with near identical common natural histories, demographics
and response to therapy, indicate that both FM and IC may share some common
pathogenic etiologies.
Lutgendorf,

Kreder,

Rothrock,

Hoffman,

Kirschbaum,

Sternberg,

Zimmerman and Ratcliff (2002b) showed that the abnormalities of the hypothalamic
pituitary-adrenal feedback system resulted in poor regulation of the inflammatory
response. This suggests that dysregulation of the HPA feedback mechanism could
result in inadequate regulation of inflammation in IC, allowing chronic inflammation
to become established. In commenting on this study, Bennett (2002c) notes that, as
IC symptoms are exacerbated by stress, dysregulation affecting the stress response
system could contribute to the pathophysiology of IC. Bennett also comments on the
relevance of these findings to understanding the association of FM with some other
inflammatory states as IC is a common morbidity with the FM syndrome.
The urogenital symptoms experienced by women with FM have numerous
descriptive terms. Interstitial cystitis (IC) is the term often used in the literature
describing the urogenital symptoms of FM. The irritable bladder symptoms
experienced by women with FM are similar to the irritative bladder symptoms of IC.
These urinary symptoms include urinary frequency, urinary urgency, nocturia and
pelvic pain in the absence of infection with the most definitive symptom being pain.
Sand (2004) suggests that, in all women who present with chronic pelvic pain (CPP)
and with the urinary symptoms of urgency and frequency, IC should be suspected as
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(Wesselmann, 2004) an isolated or concurrent etiology m the absence of other
pathologic entities such as infection or tumour.
Urogenital pain often goes together with voiding disturbances and sexual
dysfunction (Wesselmann, 2000). A study on the relationship between some bladder
symptoms and sexual activity in women (Patel et al., 2004) concluded that women
who experienced urinary frequency and/or urge incontinence were less sexually
active. The authors also noted that women who expressed a greater degree of bother
related to abdominal pain or genital pain were less likely to enjoy sexual activity and
were more likely to experience sexual thoughts or fantasies. As women with FM
often experience both abdominal pain from irritable bowel symptoms and genital
pain, this study highlights a possible impact on their capacity to sexually express
themselves as women.
Women with FM also experience chronic pelvic pain. Vulvodynia,
dyspareunia and vaginismus are common and can be multifactorial (Weiss, 2000).
Vulvodynia is a chronic pain disorder characterised by constant or recurring
complaints of vulvar pain or discomfort. This study examines vulvodynia symptoms
and dyspareunia and their impact on women diagnosed with FM.
Effective outcome measures for urogenital symptoms need to be revisited and
developed as our knowledge of these symptoms and their impact improves. This is
important not only in the primary areas of urological disease, but also in the areas
where urinary symptoms are associated symptoms of other conditions such as FM.
There is currently no questionnaire available specifically to aid in assessing the
urological symptoms or impact on women with FM. Such a questionnaire would
assist in determining the nature of the problem, the extent and frequency of the
symptoms, and the impact the condition has on the patients' well being and activities
of daily life. Pre-and post-treatment validated questionnaires for these specific
conditions can clearly indicate treatment outcomes. Such questionnaires can also be
helpful in prevalence studies for the wider population (Graham & Dmochowski,
2002). The current study tests the Interstitial Cystitis Symptom and Problem Index
(ICSI/ICPI) within the FM population for reliability and validity to provide such a
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questionnaire for this specific FM population of women with irritable bladder
symptoms.

Interstitial Cystitis
Wein and Hanno (2002) describe IC as an elusive disease that evades
diagnosis, defies a defining etiology and resists treatment. The characteristics of IC
are similar to those of an acute urinary tract infection, being suprapubic pressure and
pain, urgency and frequency of voiding. The most dominant symptom of IC is pain.
Ratner (2001 a), in describing a severe case, notes frequency occurring as often as 60
bathroom visits per day and nocturia as often as every 20 to 30 minutes, leading to
chronic sleep deprivation. Ratner (2001 b) describes patients when a diagnosis is not
made as being left to manage severe, debilitating symptoms with no support. Failure
to diagnose IC can lead to depression with some patients left in such pain that they
commit suicide (Ratner, 2001 a). Ratner (2001b) explains that IC can be an organ
specific disease in some patients while it may be a systemic condition in other
patients. A majority of patients with IC report dyspareunia (Ratner, Slade, & Greene,
1994).
In 2004 researchers at the University of Maryland School of Medicine
(Interstitial Cystitis Association, 2004) completed the first total description of the
structure of a toxin known as the antiproliferative factor (APF) which inhibits the
growth of bladder epithelial cells. This finding may lead to a diagnostic test for IC as
APF was found in the urine of approximately 95% of IC sufferers.
Because of the lack of a definitive diagnostic marker and a lack of distinct
pathophysiology for IC, a diagnosis of IC is made on a constellation of clinical
features as well as exclusionary criteria as with FM. MaLossi and Chai (2002) have
posed the question of how do you treat a disease that has an unknown etiology? The
multitude of etiological theories has resulted in many different treatment regimes
developed from a trial and error approach. It is recommended that treatment be
guided by an objective assessment of IC symptoms (MaLossi & Chai, 2002). One of
the validated questionnaires they recommend is the ICSI/ICPI so clinicians can
monitor symptoms through different treatment regimes.
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Recently in the United States of America, the Social Security Administration
announced an official Policy Interpretation Ruling for IC for the processing of IC
specific disability claims (Chesnut & Perilli, 2003). Instead of defining the disease in
terms of quantifiable disease markers, a ruling emphasises the functional limitations
that a given disease imposes on those who have the condition. It is of interest that
this is occurring at a time when more and more syndromes like IC, IBS, vulvodynia
and FM are being diagnosed without unique disease markers.
Both FM and IC share common features such as similar demographics,
irritable bowel syndrome, headaches, history and aggravating factors. Data from the
study by Clauw and colleagues (Clauw et al., 1997a) indicate that IC and FM have
significant overlaps in symptoms including an increased peripheral nociception. The
authors speculate that IC that has been treated until now as a specific bladder
condition may be part of the disorder of the central processing of sensory information
as seen in FM. Blaivas, Chaikin, Evans and Sant (1999) reinforced this speculation at
a symposium on the management of the painful bladder syndrome. In discussing the
etiology of bladder pain, these presenters spoke of some patients' pain being
mediated by central pain mechanisms in the spinal cord and other patients suffering
chronic centralised pain 24 hours a day because of the up-regulation of the spinal
cord.
Ratner (2001 b) acknowledges that the relationship between IC and other
associated related disorders will become known when the pathophysiology of each
disorder becomes known. Ratner writes that some IC patients are at greater risk of
developing certain disorders. She lists these disorders as irritable bowel syndrome,
vulvodynia, FM, endometriosis, chronic fatigue immune dysfunction syndrome,
asthma, sensitive skin and migraines. It is because of the possible common
etiologies, that Ratner (2001 b) questions whether IC is a systemic disease in some
patients and an organ-specific bladder disease in others. Alagiri, Chottiner, Ratner,
Slade and Hanno (1997) have shown the twelve most common conditions associated
with IC. Vulvodynia and FM are ranked fourth and fifth on this list of associated
conditions.
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Wesselmann and Burnett ( 1 999) describe chronic non-malignant pain
syndromes of the urogenital tract of longer than six months duration as well
described, poorly understood and frustrating for both patient and physician.
Wesselmann and Burnett are very conscious of the controversy that surrounds these
pain syndromes and describe the controversy as ranging from questioning the
existence of symptoms to the dismissing of the symptoms as psychosomatic. The
authors comment strongly that much of this controversy is offset by the extensive
available literature confirming their organicity. They acknowledge that cures for
urogenital pain are uncommon but caution toward invasive and irreversible
procedures.

Instead,

they

encourage

further

research

into neuroanatomy,

neurophysiology and neuropharmacology (Wesselmann & Burnett, 1 999).
Falvey (200 1 ) also indicates concern for delay in diagnosis because of the
misconception that the symptoms are psychological and notes the delay in a
diagnosis can prevent the use of some coping strategies which may be used if a
definite diagnosis was given. Falvey also reports on the patients with IC being very
sensitive to sensory stimuli, with the resultant lower tolerance threshold which may
be seen to be over-reacting to underlying pathology. Because of these factors,
Falvey (200 1 ) encourages a conceptual shift by those who treat IC patients to
consider that negative psychological effects are the result of, and not the cause of, the
disease.
Burkman (2004) comments that because the pathogenesis of IC is unclear and
multi-factorial, this often delays diagnosis and can impact on treatment options and
resultant quality of life for the patient. In the USA, women see an average of eight
clinicians during a five to seven year period before obtaining an accurate diagnosis of
IC (Curhan, Speizer, Hunter, Curhan, & Stampfer, 1 999). According to Sand (2004),
women with IC are frequently misdiagnosed with, and are treated for, either
recurrent urinary tract infections or an overactive bladder syndrome. This may also
be the case with FM women who have the bladder irritability symptoms of urinary
urgency, frequency and pain.
A population-based study among patients with Sjogren's syndrome has
demonstrated a strong association of Sjogren's syndrome with interstitial cystitis-like
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symptoms (Leppilahti et al., 2003). The O' Leary-Sant interstitial symptom and
problem index questionnaire (O'Leary et al., 1997) was used to assess the symptoms
and symptom impact. The researchers' results suggest the possibility of a shared
etiology of the two conditions.
Wesselmann (2001) observes that IC shares many features with other chronic,
non-malignant visceral pain syndromes. Wesselmann advocates a different approach
to successfully treat chronic visceral pain associated with IC. This approach
concentrates on three separate concepts: that a spectrum of insults can lead to chronic
visceral pain; that the different underlying pathogenic pain mechanisms may require
different pain management strategies; that the multiple different pathogenic pain
mechanisms may co-exist in the same patient and can require different pain
management regimes (Wesselmann, 200 1 ). It is anticipated that this conceptual
approach to treatment may result in new insights into the pathophysiology of IC and
the development of new treatment options for patients with IC and for patients with
other chronic visceral pain syndromes (Wesselmann, 200 1).
Brookoff ( 1 997) discusses the consequence of bladder inflammation in IC as
hypersensitivity of the chemosensitive afferent bladder nerves resulting in
hyperalgesia. Following further inflammation, mechanoreceptive nerves in the
bladder wall generate pain signals in response to a small increase in intravesicular
pressure resulting in allodynia. With time, the persistent pain signals from the
bladder to the central nervous system result in changes to the dorsal horn of the
spinal cord, resulting in central sensitisation where the dorsal horn can transmit pain
signals to the brain with minimal peripheral stimulation. Brookoff ( 1997) describes
how, with this persistent pain over years, the pain signal becomes embedded in the
central nervous system and the condition can become incurable. Brookoff comments
that, although patients with severe pain from IC may not be cured, their pain can be
eased.
Elbadawi (1997) presents a critique of current concepts of IC and presents a
proposal regarding the responses invoked by neurogenic inflammation. His proposal
encompasses sensory nerve excitation, the release of neuropeptides and activated
differential secretion of potent mast cell mediators. Radziszewski, Borkowski and
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Majewski (2002) state that, although no etiopathogenesis-based treatment has been
proposed for bladder conditions of interstitial cystitis, painful bladder or overactive
bladder, it is tempting to think that these conditions may represent different
manifestations of 'neurogenic inflammation of the bladder' where previously silent
C-fibres may be engaged.
Dysregulation of the hypothalamic-pituitary-adrenal axis may be linked to
interstitial cystitis symptomatology. One study (Lutgendorf et al., 2002a) measured
salivary and urinary cortisol levels in 48 patients with interstitial cystitis and in 35
age-matched controls. Although salivary or cortisol levels were similar in both
groups, in the cystitis group the morning cortisol levels were linked to less pain and
the higher urinary-free cortisol levels represented less overall symptomatology.
Patients with morning cortisol levels less than 1 2.5 nmol/L were almost 1 3 times
more likely to have higher urinary urgency. As a result of these findings, the
researchers suggest that the regulation of the hypothalamic-pituitary-adrenal axis
may be associated with IC symptomatology. Fitzpatrick, DeLancey, Elkins and
McGuire ( 1 993) recognised a sub-group of patients in whom interstitial cystitis and
vulvar vestibulitis co-existed and suggested that the co-existence of these non
infectious inflammatory syndromes involving a disorder of the urogenital sinus
derived epithelium have a common etiology.
Parsons and Koprowski ( 1 99 1 ) have shown that a variant of the interstitial
cystitis syndrome, with decreased significant pain, can be clinically improved by
retraining of the individual' s voiding pattern. Chaiken, Blaivas, and Blaivas ( 1 993)
confirm the short term effects of behavioural therapy in selected patients with
symptoms of interstitial cystitis. The treatment consisted of diary keeping, timed
voiding, controlled fluid intake, and pelvic floor muscle training techniques.
Of interest is the paper by Kusek and Nyberg (2001 ) on the epidemiology of
IC where the authors suggest a broader definition of chronic pelvic pain of the
bladder, but recognise that specificity may be problematic, as there are numerous
causes of chronic pelvic pain not related to the bladder. Hanno (2003) suggests that
the current clinical definition of IC is too restrictive for clinical use and results in
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many patients being undiagnosed and untreated. Hanno (2004) suggests that a new
paradigm is needed through which we can view this chronic pain syndrome.
In March 2003, a group of renowned IC specialists met in Japan for the
International Consultation on Interstitial Cystitis to formulate a restatement of the
diagnostic criteria for IC. As mentioned in the introduction, the final consensus from
the 2003 International Consultation on Interstitial Cystitis adopted the term IC/CPPS
to signify the symptom complex of chronic pelvic pain (CPPS) with urinary urgency
and/or urinary frequency (Diokno et al., 2003).
The original NIDDK research criteria for IC have been universally used in
research settings and through time have become widely adopted as a definition of the
disease, although there is disparity in clinics around the world and no consensus as to
the best practice in diagnosing IC for clinical purposes (Payne, Terai, & Komatsu,
2003). Payne and colleagues comment on the problem of this research criteria being
used for clinical diagnosis having resulted in the under diagnosis of IC for many
patients, with a resultant lack of appropriate treatment.
The International Consultation on Interstitial Cystitis in 2003 also considered
the current status of diagnostic markers and potential use of these diagnostic markers
in IC for understanding the etiology and pathophysiology of IC, to enable a definitive
diagnosis of IC and to allow for a rational treatment algorithm (Keay, Takeda,
Tamaki, & Hanno, 2003). The most promising diagnostic marker that comes closest
to meeting all of these criteria is the antiproliferative factor (APF) which appears to
be made by bladder epithelial cells from IC patients, but not by asymptomatic
controls.
As mentioned in Chapter 1 of this thesis, The International Consultation on
Interstitial Cystitis in Monaco in 2004 has developed a draft algorithm for the
treatment of painful bladder syndrome, including IC. The group also worked on an
all-encompassing definition and a review of the painful bladder. This review
included discussions on definitions, bladder diaries, urological investigations,
medication, trans-electrical nerve stimulation, diet, education, hydrodistension,
neuromodulation, intravesical botulinum A, augmentation, cystectomy and referral to
pain clinics (A. Rosamilia, personal communication, September 8, 2004).
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As well as the International Consultation on Interstitial Cystitis being
established, the Interstitial Cystitis Clinical Research Network (ICCRN) was formed
in 2003. The ICCRN is the combination of two programs from the National Institute
of Diabetes and Digestive and Kidney Diseases (NIDDK), the Interstitial Cystitis
Database Study and the Interstitial Cystitis Clinical Trials Group. The ICCRN was
established by NIDDK' s division of Kidney, Urologic and Hematologic Diseases to
develop and conduct randomised clinical trials for the evaluation of new therapies for
IC. The ICCRN comprises 1 0 clinical centres throughout the United States of
America, and a data coordinating centre for protocol development, quality control,
data analysis and data management quality (National Institute of Diabetes and
Digestive and Kidney Diseases, 2004).
The Bladder Research Progress Review Group was also formed in the United
States of America by the NIDDK of the National Institute of Health to examine the
current state of bladder research in their country and to develop a plan for future
bladder research. The significant financial investment in this research will have an
effect on the quality of life of many people and will dramatically decrease the
psychological, emotional, societal and financial burden of bladder disease. The aim
of this group is to outline future critical research on the basic science of the lower
urinary tract and clinical studies of bladder disease and conditions. This group will
be vigorously investigating the neurovascular influences of the lower urinary system
because the nervous and vascular systems are involved in almost every disorder of
the lower urinary tract.

Fibromyalgia and Pelvic Symptomatology

Fibromyalgia and Chronic Pelvic Pain

Establishing a differential diagnosis in this group of women with chronic
pelvic pain is difficult. Chronic pelvic pain (CPP) can be specifically of bladder
origin. The Standardisation of Terminology in Lower Urinary Tract Function from
the International Continence Society (Abrams et al., 2002b) defines pelvic pain
syndrome as the occurrence of persistent or recurrent episodic pelvic pain associated
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with symptoms suggestive of lower urinary tract, sexual, bowel or gynaecological
dysfunction and where there is no other obvious pathology. The American College of
Obstetricians and Gynaecologists (American College of Obstetrics & Gynaecology,
2004) has recently developed new guidelines for the clinical management of chronic
pelvic pain. Their proposed definition of chronic pelvic pain lists the symptoms of
non cyclical pain of at least six months duration involving the pelvis, anterior
abdominal wall, lower back and/or buttocks, with these symptoms being serious
enough to cause disability or to need medical care (American College of Obstetrics
& Gynaecology, 2004). Where there is no clear indication of the etiology for pain,
treatment is directed at the relief of symptoms.
Stone and Mountfield (2000b) offer possible etiological explanations as
undetectable irritable bowel, the vascular pain from dilated pelvic veins, and altered
spinal cord and brain processing of stimuli in women with chronic pelvic pain.
Howard (2003) writes that disorders of the reproductive tract, gastrointestinal
system, urological organs, musculoskeletal system and the psychoneurological
system may be responsible for CPP in women. He questions why, for some women,
these disorders lead to a chronic syndrome while with others the condition is cured
with initial treatment regimes. Howard suggests that the different responses may be
due to changes in visceral nerves or to altered nociceptive processing.
Because of the different etiological possibilities for CPP, the treatment of
chronic pelvic pain may consist of two approaches. One approach is to treat the
chronic pain as a diagnosis and the other is to treat the disorder that is causing or
contributing to the pain (Howard, 2003 ). This author suggests that pain is no longer a
symptom after 4-6 months and that, after this period of time, the symptom becomes
the disease, chronic pain. In these cases, Howard recommends the diagnosis of
chronic pain that allows pain-directed therapies to begin with the result that the
patient may move toward a more normal existence that is not dominated by pain.
CPP syndromes affect an estimated 9 to 1 5 million women in the United
States of America (Mathias, Kuppermann, Liberman, Lipschutz, & Steege, 1 996).
Studies have shown that IC is the cause of CPP in a large number of these women
(Burkman, 2004). Burkman describes IC as a chronic pelvic pain symptom (CPPS)
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of bladder origin discernible by the symptoms of urinary frequency, urinary urgency
and pelvic discomfort or pain in the absence of obvious bladder pathology such as
bladder cancer or urinary tract infections. However, a differential diagnosis can be
extremely difficult.
Because of the prevalence of this CPP condition, and health costs associated
with it, Stone and Mountfield (2000b) state that randomised controlled trials of
medical, surgical and psychological interventions are urgently required. Pelvic pain
in women can be either acute or chronic. The issues of undiagnosed chronic pelvic
pain in women are significant. One study by Zondervan, Yudkin, Vessey, Dawes,
Barlow and Kennedy (1 999) revealed that 28% of patients with chronic pelvic pain
were never given a diagnosis. Mathias, Kuppermann, Liberman, Lipschutz and
Steege (1 996) showed that in the United States of America 6 1 % of patients with
chronic pelvic pain had an unknown etiology. Stones, Selfe, Fransman and Hom
(2000a) estimate, according to a population-based estimate, that chronic pelvic pain
affects 15% of women.
These women, as well as experiencing pain, suffer the psychosocial impact of
chronic pelvic pain affecting changes in mood, disruption of activities of daily living
and relationships issues. A study by Zondervan (2001 b) has shown that there is high
symptom-related anxiety in women with chronic pelvic pain and emphasised the
need for more information about, and the possible causes of, this condition. The
study known as the Oxfordshire Women' s Health Study Survey in the United
Kingdom showed a substantial overlap between chronic pelvic pain, urogenital
symptoms and irritable bowel syndrome. This study showed approximately half of
the women with chronic pelvic pain had at least one other symptom; 39% had
irritable bowel syndrome while 24% had genitourinary symptoms.
Sand (2004) observes that CPP can result from the combination of urogenital
syndromes such as vulvodynia and IC. The difficulty of differential diagnosis in this
area of pelvic pain and lower urinary tract pain and symptoms is evident. The
possible diagnostic blend of FM, chronic pelvic pain, lower urinary tract pain,
vulvodynia and irritable bowel syndrome pain is indeed perplexing to both clinicians
and researchers.
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Fibromyalgia and Vulvodynia
The International Society for the Study of Vulvovaginal Disease (ISSVD)
(National Vulvodynia Association, 2002b) defines vulvodynia as chronic vulvar
discomfort or pain, especially that characterised by complaints of burning, stinging,
irritation, or rawness of the female genitalia. Vulvodynia is highly individualised. It
can vary in its persistence and its location. Pain can be spontaneous, constant or
intermittent, localised or diffuse. Vulvodynia can have a major impact on quality of
life, impacting on activities of daily living and sexual activities.
Rodke ( 1996) comments on the experiences of patients with vulvodynia who
experience all of the problems of a chronic pain syndrome without the assurance of
knowing what causes their pain and if there is any relief available. Pezzone (2003 ),
in workshop discussions on vulvodynia, details chronic pelvic pain disorders,
inclusive of those affecting the pelvis, such as irritable bowel s yndrome and
interstitial cystitis and those affecting the pelvic floor, such as vulvodynia, urethral
syndrome and prostatodynia. He notes that many of the conditions share a common
predisposition, a shared etiological factor and a possible cross-sensitisation via neural
cross talk. Pezzone suggests that the frequent overlapping of irritable bowel,
vulvodynia interstitial cystitis and other chronic pelvic pain disorders may indicate
irregular neuronal interactions allowing the irritation of one organ to co-sensitise
other organs.
Wesselmann (2002) questions whether there is a connection between IC and
vulvodynia, noting that they often occur in the same patient with the conditions
developing simultaneously or one preceding the other. The author notes that vulvar
vestibulitis (pain at the introitus) is more commonly associated with IC.
At the joint meeting of the American Pain Society and the Canadian Pain
Society in Vancouver 2004, implications for the classification, assessment and
diagnosis of women with vulvodynia were presented (Fisher, Robert, Jarrell,
Carlson, & Taenzer, 2004). Chronic vulvar pain was described as a medical issue
that has been neglected by the scientific community and, as a result, consensus on a
classification system with validated terminology and diagnostic criteria does not
exist. The authors note that the term 'vulvodynia' is used inconsistently and is
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applied to vulval conditions with known and unknown etiologies, a former example
being vulvar dermatoses and the latter being vulvar vestibulitis syndrome (VVS) and
dysesthetic vulvodynia (DS).
Fisher and colleagues (2004) considered the pain profiles of women with
unexpected chronic vulval pain and found considerable overlap in the characteristics
of their pain, with resultant questioning of the validity of the separate terminology
for VVS and DV. For this current study, the terminology 'vulvodynia' is used to
describe chronic vulvar discomfort or pain, especially that characterised by
complaints of burning, stinging, irritation, or rawness of the female genitalia as
described by the International Society for the Study of Vulvovaginal Disease. A
study by Pukall, Baron, Khalife and Binik (2004) showed that women with vulvar
vestibulitis syndrome (VVS) reported significantly higher pain intensities and
unpleasantness ratings in response to palpation to non-genital body areas, suggesting
that these women may have a more generalised sensory abnormality. A
rheumatologist undertook the physical examination and the examination technique
used was one typically used for the diagnosis for FM.
Dyspareunia, one of the distinguishing characteristics of vulvar vestibulitis
syndrome (VVS), is currently classified in the Diagnostic and Statistical Manual of
Mental Disorders (DSM) as a sexual disorder rather than as a pain disorder (Pukall,
Kao, & Binik, 2004). The DSM excludes dyspareunia from the category of Pain
Disorder even though it meets all of the criteria for inclusion. The DSM specifies two
types of pain, sexual and non sexual but Pukall and colleagues correctly note that
many chronic pain conditions, such as FM, that interfere with sexual functioning are
not classified as sexual dysfunction. Pukall and colleagues recommend that
vulvodynia be evaluated from a pain perspective with a resultant multi-modal
approach to treatment.
The first epidemiological study on chronic vulvar pain by the National
Vulvodynia Association in the United States of America (National Vulvodynia
Association, 2002a) suggested that almost 20% of American women have suffered
from chronic vulvar pain at some time in their lives. Some 40% of these women did
not seek any treatment for their condition. The National Institutes of Child Health
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and Human Development in the United States have commenced a randomised
placebo-controlled trial on the use of tricyclic antidepressants for chronic vulvar pain
(National Vulvodynia Association, 2002a).
Masheb, Brondolo and Kerns (2002) conducted a multi-dimensional
evaluation of women with chronic vulval pain. Participants (n= 13 l ) included 57
women with vulval discomfort and 74 healthy controls. Their findings suggest that
the experience of persistent vulvar pain, rather than the level of intensity of pain,
accounted for disturbances in functioning and feelings of well being. The analysis of
data from standardised measures of pain severity, physical functioning and affective
disorder confirmed the concomitant dysfunction in these domains (Masheb et al.,
2002). There was no relationship between pain severity and affective distress. Their
findings also showed that although these women scored in the range for marital
satisfaction, they were not as maritally satisfied as their peer group.
There is no cure for vulvodynia. Some treatments offer symptom relief such
as tricyclic antidepressants, anticonvulsants, nerve blocks, interferon, biofeedback
and diet modification (National Vulvodynia Association, 2002b). McKay, Kaufman,
Doctor, Berkova, Glazer, and Redko (2001 ) showed that electromyographic
biofeedback of pelvic floor musculature is an effective approach to vulvar
vestibulitis, a part of the spectrum of vulvodynia. The aim of the biofeedback
exercises is to rehabilitate and strengthen dysfunctional pelvic floor muscles, to
relieve ongoing spasm in the muscles and to break the cycle of chronic vulvar pain
(Rodke, 1 996).
A further study (R. Anderson, Wise, & Namazi, 2002) suggests that some
patients with vulvodynia may experience improvement in vulvar and/or urinary
symptoms following a combination

of surface electromyography assisted

biofeedback, internal myofascial release and progressive relaxation. Pudendal nerve
blocks are also used for pain relief in women who suffer from chronic vulvar pain. If
the women respond positively to the initial diagnostic block, then a series of
pudendal blocks may be taken as the most appropriate therapeutic approach
(Daneshfar, 2004).
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Fibromyalgia and Sexuality

FM is a chronic disease. With the genitourinary symptoms experienced by
women with FM, the possibilities and implications of sexual difficulties or
dysfunction are significant. Webster (2003), in her findings from a study on
understanding the changes in sexuality experienced by women with IC, describes the
experience of women with IC as having to make major changes in most dimensions
of their lives. She lists the major psychological self-care strategies adopted by
women with IC as information seeking on their condition, self-validation, being
responsible for their own health and rejecting psychological explanations (Webster,
2003). Webster considers broader definitions of sexuality than some, describing
sexuality in terms of being integrated, individualised and a unique expression of
oneself.
Sex makes an important contribution to the quality of life in many patients
who live with chronic disease and to their partners (Mcinnes, 2003). Mcinnes
describes a number of biological, psychological, and social effects that can impact on
people with chronic disease. She includes the biological alterations of sexual desire,
sexual capacity and activity being altered through interference with neural integrity
of the genitalia as well as medication side effects, limitations on sexual response and
activity due to pain and fatigue and the negativity of altered body image. The
psychological effects can include anxiety, loss of self-esteem, depression, or grief of
the loss of the 'old' self. Mcinnes (2003) refers to the precipitation of an emotional
crisis with alterations to sexual function and sexual relationship that result from the
limitation or cessation of sexual activity because of chronic illness.
Mcinnes (2003) defines sex as a vital part of day-to-day living with chronic
illness, providing important boosters for patient's quality of life and allowing the
patient with chronic illness to feel normal again. The improvement of doctor-patient
communication about sexual issues, recommended by Mcinnes, places the emphasis
on doctors for an attitudinal change towards sexual health issues, acquiring
knowledge especially on the impact of illness on sexuality and acquiring the skills to
implement these skills (Mcinnes, 2003). A study on the constructions of sexuality for
midlife women living with chronic illness (Kralik, Koch, & Telford, 200 1 ) has
shown that the issues of sexuality are an important health concern for women with
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long term illness and emphasises that the women should be given the opportunity to
openly discuss sexuality issues with their health professionals.
Vulvodynia can have a major impact on quality of life of women with FM,
impacting on activities of daily living and sexual activities. Vulvodynia is listed as an
associated FM condition (Wallace & Wallace, 1 999). Vulvodynia can result in
dyspareunia which is recognised as a sexual pain disorder (A. Graziottin, 2003 ).
Graziottin describes the psychosexual factors of loss of libido and arousal disorders
as associated with, or secondary to, sexual pain disorders. The author advocates that
the psychobiology of this experience of sexual pain should be addressed with an
integrated, comprehensive and patient-centred perspective.

Measurement of Urological Symptoms

This review has considered issues and challenges in relation to the
measurement of genitourinary symptoms in this population of women diagnosed
with FM, thereby providing an information passage through the process of this
research. This research was initiated because of the lack of measurement tools for the
genitourinary symptoms of this population. To assess effective intervention therapy
for these difficult to manage urinary symptoms, it is imperative that current updated
measurement tools are developed as our knowledge in the urological area increases.
Scientifically validated health outcome measures were first applied to
urological patients early in the 1 990s with the development of the new benign
prostatic hyperplasia symptom index. This provided a better understanding of the
patients' perception of their disease and helped optimise clinical decision making to
achieve outcomes that mattered most to the patients (O'Leary, Barry, & Fowler,
1 992). The authors encouraged the development of such indexes for other disease
entities in urology that demand a quantitation of the illness experience from their
patients' perspective. Litwin (2002) comments that, in the treatment of urogenital
diseases, the traditional goal has been to maximise survival but now, for patients with
non life threatening conditions, their quality of life has taken on new meaning and
value.
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Shojania, Mariani and Lindberg (2002) describe science as grinding slowly
with each new observation and investigation seeking 'truth'. They describe our best
versions of truth as coming about as a continuum, noting that in one year much is
observed and reported, some of which lasts and some which does not. Shojania and
colleagues (2002) also comment that, although it is sometimes difficult to separate
those that are transient from those that have more perseverance, scientific truth is a
moving target, a work in progress. So too are measures of health status a moving
target. Guyatt, Kirshner and Jaeschke (1 992) speak of the health status measurement
literature as a jungle. They referred to it as an underbush of confused terminology
and contradictory conceptualisation.
The ICSI/ICPI is a disease specific instrument focusing on the symptoms and
impact of urinary dysfunction in the IC population. Most symptom questionnaires
give a numerical score to the symptom under study. The symptom index is the group
of items used to measure symptoms that are related (Graham & Dmochowski, 2002).
A symptom score is the numerical value derived from the use of the index (Hines,
1 996). Graham and Dmochowski (2002) ask how we can be confident about the
score generating a true reflection of the symptoms. Psychometrics that measure the
response to phenomena that is not easily quantifiable govern the development of
such questionnaires. The validity and reliability of such questionnaires are
determined by statistical methods. The symptom score is a reflection of the
questionnaire used to obtain the score. The psychometric testing of the
questionnaires provides the assurance that symptom questionnaires actually measure
symptoms (McDowell & Newell, 1 996).
Van der Vaart, de Leeuw, Roovers and Heintz (2003) comment that the
consequences of symptoms for a person's well being are also determined by the
individual's psychosocial adjustment to the symptoms. They note that this is
especially true for chronic conditions that are not life threatening, but which threaten
quality of life where the effect is felt in physical, social and emotional functioning.
Van der Vaart and colleagues (2003) therefore recommend measurements of well
being or health-related quality of life as well as symptom measurements in outcome
assessments of treatment for urogenital dysfunction. The ICSI/ICPI reflects this
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recommendation in that it measures both the symptoms and the problems of the
urological dysfunction of women with IC.

The Interstitial Cystitis Symptom and Problem Index
The Interstitial Cystitis Symptom Index (ICSI) and the Interstitial Cystitis
Problem Index (ICPI) are dual tools for quantifying the severity and impact of
interstitial cystitis. O'Leary, Sant, Fowler, Floyd, Whitmore and Spolarich-Kroll
(1997) developed this index specifically for IC patients. The development of this
index was preceded by a pilot study and a subsequent study using a longer initial
questionnaire. These preliminary studies indicated the symptoms that best described
IC were burning, frequency, nocturia, bladder pain and back pain. The urgency
symptoms affected 90% of the IC patients. Seventy per cent of the IC patients had
daytime frequency compared with 16% without IC. Eighty per cent of the IC patients
experienced nocturia compared with 10% without IC. Ninety-six per cent of IC
patients experienced bladder discomfort, pressure or pain compared with 27%
reporting occasional pressure and 15% reporting pain (O'Leary & Sant, 1999).
The final ICSVICPI captures the most important voiding and pain symptoms
and indicates the extent of how problematic these symptoms are for patients with IC.
The four symptoms of urinary frequency, urinary urgency, nocturia and pain are used
in both of the indices, the symptom index and the problem index. These items
compared well with a larger panel of items to discriminate between patients with
interstitial cystitis and controls. O' Leary and colleagues (1997) showed excellent
internal consistency and test-retest reliability for both questionnaires in a community
population with a convenience sample of patients with IC. A following study
(Lubeck, Whitmore, Sant, Alvarez-Horine, & Lai, 2001) evaluated the psychometric
properties of the ICSI in a prospective clinical drug trial in patients with IC and was
found to be a valid, reliable and responsive measure of IC symptoms.
This ICSI/ICPI developed for the interstitial cystitis population will be tested
for reliability and validity within the FM population for women who experience
these same symptoms of urinary frequency, urinary urgency, nocturia and bladder
pain. Recommendations by Graham and Dmochowski (2002) for such validation of
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instruments within specific populations include adequacy of instrument testing,
simplicity of use and application to clinical practice.

Summary
In summary, Rothenberg (1999) describes FM as a syndrome that involves a
loss of pain regulation in the central nervous system that may cause pain
amplification. The excessive pain stimulation appears to then lead to abnormal levels
of central nervous system neurotransmitters such as serotonin, norepinephrine and
Substance P . The imbalance in these neurotransmitters can then produce problems
with the body's hormonal response to stress, resulting in inappropriate levels of
cortisol, catecholamines, growth hormones and possibly thyroid hormones. All of
these can cause abnormalities in the autonomic nervous system. Rothenberg ( 1999)
highlights these abnormalities as contributing to irritable bowel syndrome, neurally
mediated hypotension, irritable bladder symptoms, vascular headaches, chronic
fatigue and non-restorative sleep disorders.
Littlejohn and Morand (2002) have predicted that the impetus from the
current Bone and Joint Decade will increase research within the discipline of
rheumatology with resultant greater understanding of disease mechanisms and a
subsequent increase in treatment options. This research on FM and bladder
irritability will increase our knowledge of the urinary symptoms and their impact on
women with this condition and will extend the awareness of this problem to a more
multi-disciplinary medical arena. The validation of the ICSI/ICPI instrument within
the FM population will assist in determining the nature of sensory urinary symptoms,
the extent and frequency of the symptoms and the impact these symptoms have on
the patients' activities of daily living and quality of life. Having a validated outcome
measure for sensory urinary symptoms in the FM population should encourage
further intervention research into this debilitating condition.
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CHAPT ER 3

FRAME OF REFERENCE

Theoretical Framework

Theoretical frameworks provide a structure for guiding systematic enquiry
and examining relationships amongst relevant variables. These theories and
relationships are then validated through research and form the basis for further
development and possible refinement of the theories (Polit & Hungler, 1 989). These
authors describe theories as efficient mechanisms for bringing together and
summarising known facts from various studies to more effectively explain scientific
findings. The authors also comment that research performed within the context of a
theoretical framework is more likely to result in effective and significant findings.
The benefit of theoretical frameworks is that they enable a research finding to be
presented in a more generalised and meaningful way that allows the researcher to
combine his/her observations and facts in a more organised format.
The Theory
The theoretical framework and measurement model for this study on FM and
bladder irritability is based on previous research findings and relevant theory related
to Fibromyalgia (FM), central nervous system sensitisation, irritable bladder sensory
symptomatology, interstitial cystitis and instrument development. The literature
provides direction for the study design and the Interstitial Cystitis Symptom and
Problem Index (ICSI/ICPI) instrument validation methods used within the FM
population.
The theoretical framework guiding this investigation is based on three
specific areas of literature:
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•

the genitourinary symptoms of women with FM

•

the similarity of these symptoms to symptoms experienced by women with
the condition of IC

•

the involvement of central nervous system mechanisms that contribute to the
pathogenesis of FM that are similar to the mechanisms underlying IC.
Although the musculoskeletal features of FM define the condition, there are

many other symptoms that are apparent in individuals with this condition. The
urogenital symptoms of FM are urinary urgency, urinary frequency, nocturia and
pelvic pain. IC is a condition characterised by symptoms of urinary urgency, urinary
frequency, nocturia and pelvic pain. Both conditions can be classified as non
infective sensory disorders of the lower urinary tract.
Research by Clauw and colleagues (1997a) suggests that the central nervous
system mechanisms thought to contribute to the pathogenesis of FM may be
operative in IC. The postulation that these conditions may share a similar etiology
and the evidence that both conditions have similar clinical symptomatology provide
rationale to undertake a study to validate, for use within the FM population, an
instrument developed for the IC population. This instrument, the Interstitial Cystitis
Symptom Index and Problem Index (ICSVICPI), has been developed and validated to
measure lower urinary tract symptoms and their impact in patients with IC (O'Leary
et al., 1997).
Aaron and Buchwald (2000) noted numerous clinical conditions that share
common symptomatology such as pain. They described the frequency of ten clinical
conditions among patients with chronic fatigue syndrome (CFS), FM and
temporomandibular disorder (TMD) and found that patients with FM had
significantly more symptoms characteristic of interstitial cystitis than did patients
with CFS or TMD. A survey by Alagiri, Chottiner, Ratner, Slade and Hanno (1997)
also showed that of 2682 patients with IC, 25% reported having comorbid FM. This
overlap of IC and FM symptomatology gives further impetus for this current study to
validate an outcome measure for the FM population that has been found to be valid
and reliable for use within the IC population.
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IC

FM

Bladder symptomatology
overlaps in IC and FM

Figure 1: Overlap of Sensory Urinary Symptoms in Interstitial Cystitis (IC) and Fibromyalgia
(FM)

Currently there is no validated instrument to measure lower urinary tract
sensory symptoms or their impact on women diagnosed with FM. Lose and
colleagues (1998) suggest that research on lower urinary tract symptoms in adult
women is limited by the lack of standardised outcome variables for use within this
population. They encourage studies that lead to the development and standardisation
of outcome measures and comment that success in this regard will enhance
knowledge of actual treatment as well as stimulate the development of new treatment
options.
Often the scientific evaluation of the outcome of intervention is based on pre
test and post-test evaluation. Lose and colleagues (1998) note that the reliability of
some methods and measurements is often unclear,

leading to inaccurate

interpretations of the results of the intervention. They state that the reliability of a test
depends on the accuracy and reproducibility of the method. Valid and reliable
measurement scales not only guarantee consistency in measuring patient progress,
but provide a basis for the development of evidence-based practice (O'Connell et al.,
2002). This study has used the ICSVICPI through two study phases to provide a
validated and reliable tool for the measurement of sensory urinary symptoms and
their impact in women with FM.
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The theoretical links that describe the common pathogenic mechanisms
between the two conditions of FM and IC provide a foundation for the psychometric
testing of the instrument. The development of a valid and reliable instrument to
measure these urinary symptoms will provide a means of subsequent testing
regarding these conditions in future research.

The Framework
The theoretical framework underpinning this research on bladder irritability
symptoms in women diagnosed with FM is displayed in Figure 2. The literature
indicates that the majority of research studies on FM in the last decade have focused
on the central sensitisation of the central nervous system, as the most likely
etiological factor in the development of FM. An adaptation of the integrated
etiological hypothesis proposed by Clauw (1995a) is the basis of the theoretical
framework for this study.
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Figure 2: Theoretical Framework
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Multifactorial Etiology of Fibromyalgia
The following discussion gives direction and momentum to this theoretical
framework, commencing with the multifactorial etiology of FM. Many factors
impact on the human system to initiate and to maintain the central nervous system
hyperexcitability state seen in FM. These include genetic influences, environment,
physical and psycho-social stress, infection, inflammation, trauma, immunological
response and continued nociceptive stimuli.
Studies have shown that genetic factors may predispose people to a genetic
susceptibility for the development of FM. Buskila and Neumann (1997) have found
that blood relatives of FM patients have a higher prevalence of FM and more tender
points than an age-matched group within the general population.
Pillmer, Bradley, Crofford, Moldofsky and Chrousos (1997) suggest that FM
may be a stress-related illness, because it is often associated with a stressful physical
or psychological situation. Littlejohn (2004) notes the influence of psychosocial
impact on patients with FM. He refers particularly to studies of the stress axis, with
emphasis on the hypothalamic-pituitary-adrenal axis which displays abnormalities in
many patients with FM. Littlejohn describes the pathophysiology of FM as a range of
complex and integrated neurobiologic mechanisms which are responsive to stress
and emotion. Wallace and Wallace (1999) note that, when FM patients are asked
what they think caused their FM, the most common replies are trauma, infection and
stress.

Central Nervous System Hyperexcitability
As a peripheral cause of pain cannot be easily identified in most FM patients,
it has been suggested that most of the 'action' is at the level of the spinal cord and
above (Bennett, 2002a). Researchers are therefore focusing more on the role of the
central nervous system rather than on the musculoskeletal system in an effort to
explain the symptoms of FM. A disorder of the central processing of sensory
information from the nociceptor and mechanoreceptor systems can result in
numerous neurophysiological changes that are observed in FM sufferers. Yunus and
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Inanici (Baldry, 2001) define central sensitisation as hyp erexcitability of the central
nervous system neurones which results from peripheral noxious stimuli. This can
lead to an exaggerated response to a normally painful stimulus known as
hyperalgesia. Similarly, allodynia, a painful response from a normally non
nociceptive stimulus such as touch, can occur. There is also an increased duration of
response after a brief stimulus (Staud, 2002).
Clauw ( 1995a) notes that once central nervous system hyp erexcitability is
apparent, then all or some of the effector arms of the central nervous system can
become involved. He suggests that the elevated ratio of excitatory to inhibitory
neuromodulators is responsible for the resultant spectrum of conditions, the region of
the central nervous system being affected being reflected in the symptomatology. A
clinical spectrum of FM encompassing neurogenic inflammation, increased
peripheral and visceral nociception, neuroendocrine disturbances and autonomic
nervous system dysfunction can result, with symptoms being evident in any or all of
the effector arms of the central nervous system (Clauw, 1995a). This etiologic
hypothesis presented by Clauw is delineated in Figure 3.

Genetic predisposition

Inciting or aggravating event

Central nervous system hyperactivity

Nocturia

Increased
peripheral and
visceral
nociception

N euroendocrine
disturbances

Figure 3: Etiological Hypothesis for Fibromyalgia. Adapted from Clauw (1995a)
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These four mechanisms of neurogenic inflammation, increased peripheral and
visceral nociception, neuroendocrine disturbances and autonomic dysfunction, may
all individually or collectively impact on bladder symptomatology and influence
lower urinary tract function in women with FM.

Neurogenic Inflammation
Neurogenic inflammation is described as 'inflammation caused by an
injurious stimulus of peripheral neurons and resulting in the release of neuropeptides
that affect vascular permeability and help initiate pro-inflammatory and immune
reactions at the site of injury' (Medical Dictionary Online, 2004). The concept of
neurogenic inflammation is based on the release of Substance P and related peptides
by an axon reflex mechanism. Investigation on peptide-induced release of
inflammatory mediators by the urinary bladder, has shown that the peptides
evaluated induced changes which may directly regulate the participation of these
peptides in the pathogenesis of cystitis (Saban et al., 1997). Similarly, Callsen
Cencic and Mense (1997) questioned whether alterations in the expression of
neuropeptides and nitric oxide synthase in the neuronal pathways to the bladder
might be involved in the hyperexcitability of the bladder with the development of
cystitis.
A theory by Cervero and Janig (1992) suggested that a large component of
the afferent innervation of internal organs consists of afferent fibres that are usually
unresponsive to stimuli until they are activated by inflammation. Cervero and Janig
suggest these sensory receptors contribute to the signalling of chronic visceral pain,
to long term alterations of spinal reflexes and to abnormal autonomic regulations of
internal organs.
Butrick (2004) states that IC is not an end organ disease but a visceral pain
syndrome involving chronic neurogenic inflammation, primary afferent overactivity
and central sensitisation which lead to the perpetuation of pain. Butrick (2004) cites
Birder and deGroat who have shown that neuronal-like properties of urothelial cells
enable cells to have a sensory function and interact chemically with afferent nerves.
Brookoff ( 1997) believes the consequence of bladder inflammation in IC is
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hypersensitivity of the chemo-sensitive afferent bladder nerves resulting in
hyperalgesia. With increasing inflammation, mechanoreceptive nerves in the bladder
wall can generate pain signals in response to a small increase in intravesicular
pressure, resulting in allodynia (Brookoff, 1997).
Elbadawi (1997) describes responses brought into play by neurogemc
inflammation as sensory nerve excitation, the release of neuropeptides and activated
differential secretion of potent mast cell mediators. Radziszewski and colleagues
(2002) consider that the painful bladder may represent different expressions of
'neurogenic inflammation of the bladder' where previously silent C-fibres may be
activated.

Increased Peripheral and Visceral Nociception
The altered properties of visceral afferents that result from the instability of
the transduction properties of these nerves are described as forms of plasticity that
can affect the encoding and transmission of sensory information (McMahon, 2004).
This increases chronic pain states by increasing the excitability of sensory neurones.
Butrick (2004) showed that silent visceral afferents become activated with prolonged
stimulation and produce tissue sensitisation and pain in the bladder. The bladder has
the highest neural density and the greatest proportion of silent C-fibres than any other
viscera (Cervero, 1994).
Cervero and Laird ( 1999) suggest that increased awareness of visceral
hyperactivity could come about from sensitisation of the peripheral nociceptors or of
alterations of central processing with an increased activation of the visceral
nociceptive pathways. Giamberardino and colleagues (2001 ) further showed that
algogenic conditions of one internal organ can affect reactivity to painful stimuli of
other visceral areas, such as in the female pelvic reproductive organs and urinary
tract. Yoshimura and colleagues (2002) hypothesise that the hyperexcitability of the
C-fibre afferent pathways may be the mechanism for bladder pain and urgency and
are focusing on treatment of these symptoms by modulating the activity of bladder
afferents pathways.
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In a study on the relationship between FM and interstitial cystitis, Clauw and
colleagues ( 1997a) showed significant overlaps in symptoms, which included
increased peripheral nociception. They suggested that IC may be part of the disorder
of central processing of sensory information. This theory was discussed within a
forum at a urology symposium on management of the painful bladder syndrome
where bladder pain in IC was described as being mediated by central pain
mechanisms in the spinal cord (Blaivas et al., 1999). Likewise, Wesselmann (2001)
revealed the similarities between IC and other chronic, non-malignant visceral pain
syndromes in her conceptual common approach to treatment for both conditions.
Other studies have implicated the urogenital system in the central nervous system
sensitisation process. These studies, already referred to in the literature review of this
thesis, include articles by Al-Chaer (2000), Costa, Glise and Graffer (2004), Bennett
(2002c) and Ishigooka and colleagues (2001).

Neuroendocrine Disturbances
As well as neurotransmitter abnormalities, hormonal and biochemical
abnormalities are detectable in patients with FM (Clauw, 1995a). The hypothalamic
pituitary-adrenal (HPA) axis is a complex brain-to-body pathway and is central to the
stress response. FM is characterised by an under active stress response. Clauw
(1995a) suggests that the decreased capacity in response to stressors in both the
neuroendocrine and autonomic nervous systems provides a pathway where stressful
events could exacerbate symptoms associated with one or more of the effector arms
of the nervous system.
Jain and colleagues (2004) describe a loss of adaptability and stress tolerance
associated with dys function of the HP A axis in patients with FM. In relation to the
abnormalities apparent in the HPA axis in FM, Crofford (2002b) questions whether
the axis abnormalities reflect pre-existing vulnerability to the FM condition or
whether the chronic pain alters the HP A axis activity.
Bennet ( 1993) suggests a disruption of the neuroendocrine axis that controls
growth hormone production could be the link between disturbed sleep and muscle
pain because this hormone is produced mainly during level IV sleep. Sleep
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disturbance with FM is intricately linked with voiding at night. Whether nocturia is
due to bladder sensation messages or to the 'just in case' voiding when one is already
awake is as yet unknown. Results of a study by Lutgendorf and colleagues (2002a)
suggest that the dysregulation of the HPA axis may be linked to interstitial cystitis
symptomatology.

Autonomic Nervous System Dysfunction
The autonomic nervous system (ANS) is described as a dynamic system with
intense and instantaneous onset of action and dissipation that works closely with the
endocrine system, especially the HPA axis and the growth hormone axis (Martinez
Lavin, 2002). Because the ANS regulates the function of most of the organs and
systems of the body, it is the main homeostatic system of the body. Abnormal
sensory symptomatology of the lower urinary tract in women with FM may be partly
due to abnormalities of the ANS. Martinez-Lavin (2002) suggests that dysautonomia
may play a central role in the pathogenesis of FM because autonomic nervous system
dysfunction is frequently found in patients with FM.
Zermann, Ishigooka, Doggweiler and Schmidt ( 1998) describe lower urinary
tract function as a complex multi-level and multi-neuronal interaction, involving
facilitation and inhibition at many levels of the CNS. They further describe the
coordination of lower urinary tract function as being mediated by reflex pathways
regulated in the lumbo-sacral and thoracolumbar spinal cord as well as by reflex and
voluntary mechanisms in the brain stem and cortex (Zermann et al., 1998). These
researchers note that, in research on the central innervation of the lower urinary tract,
the spinal cord and pontine micturition centre have been investigated thoroughly
while the role of the higher centres has been ignored.
Recent experiments on the whole bladder of the guinea pig (Gillespie,
Harvey, & Drake, 2003) show neurogenic control by two separate mechanisms, the
parasympathetic system fundamental to micturition and a second system generating
non-micturition activity, with the central nervous system coordinating both systems.
The bladder is rhythmically active during the filling stage (Gillespie, 2004). Gillespie
describes the activity generated in the bladder wall at this time as autonomous
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activity. This activity involves contraction and localised stretches of the bladder wall,
thought to be initiated by a network of pacemaker cells and connecting interstitial
cells that are impacted upon by excitatory and inhibitory neural inputs. Gillespie
(2004) suggests that escalation of autonomous activity as excessive excitatory inputs
or failure of inhibitory inputs may contribute to uncontrolled bladder activity in the
filling phase.
Gillespie (2004) proposes a hypothesis that bladder overactivity is due to
inappropriate non-micturition activity. He suggests that this autonomous bladder
hypothesis may make it possible to control the initiation and modulating of
pathological non-micturition activity without interfering with the micturition reflex.
This area of etiological research into sensory bladder neurology is ongoing.
In summary, the mechanisms of neurogenic inflammation, increased visceral
nociception, neuroendocrine disturbances and autonomic dysfunction all have the
capacity, individually or collectively, to influence the functioning of the lower
urinary tract of women within this FM population. These mechanisms do not
function in isolation. Pillemer and colleagues ( 1997) demonstrate this in their
description of triggering events which may initiate changes in the HPA axis and the
autonomic nervous system that can result in sensitisation of the central nervous
system via neuropeptides with the resultant alteration of nociceptive processing.

The Measurement Model
There is currently no questionnaire to specifically assess urological symptoms
or their impact on women with FM. Such a questionnaire would assist in determining
the nature of the problem, the extent and frequency of the symptoms and the impact
the condition has on the patient's sense of well-being and activities of daily life. Pre
treatment and post-treatment-validated questionnaires for these specific conditions
can clearly indicate treatment outcomes.
It is important that current updated measurement tools are developed as our
knowledge in the urological and FM areas increases. It is recommended that
measurements of health-related quality of life, as well as symptom measurement, be
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included in outcome measures for urological dysfunction (van der Vaart et al., 2003).
The ICSI/ICPI responds to this recommendation by measuring both symptoms and
impact of IC. This is important not only in the primary areas of urological disease,
but also in the areas where urinary symptoms are associated symptoms of other
conditions such as FM.
The measurement model is based upon literature that describes sensory
bladder symptomatology experienced by women with FM. The bladder
symptomatology

includes

urinary

frequency,

urinary

urgency,

bladder

pain/discomfort and nocturia. The measurement tool trialled for validation within the
FM population is the ICSI/ICPI, a measurement tool already validated for measuring
urinary symptoms and their impact for patients with IC. The ICSI/ICPI is a
condition-specific instrument that measures the sensory urinary symptoms of
frequency, urgency, pain and nocturia and their impact within the IC population.
Because of the apparent, reported overlap of symptoms between IC and FM,
especially the sensory urinary symptoms, the ICSI/ICPI was identified and tested for
validation within the FM population of women with urinary symptoms. The
measurement model for this validation procedure is displayed in figure 4. This
current study has tested and modified the ICSI/ICPI for the FM population,
producing a validated instrument for women with FM who experience bladder
irritability.
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CHAPTER4

METHODOLOGY

Introduction
This chapter includes the methods and procedures used to conduct Phases I
and II of this research on Fibromyalgia (FM) and bladder irritability. The first
component of this chapter describes the methods and procedures of Phase I, while
the second component describes the methods and procedures related to Phase II of
the research.

Research Plan
This research involved a two-phase program of research to validate and test
an existing instrument within a new population of women diagnosed with FM who
experienced symptoms of bladder irritability. Phase I used a qualitative research
approach. Focus groups with women who had been diagnosed with the condition of
FM and who experienced bladder irritability symptoms were conducted. Phase II
tested the instrument within this new population for reliability and validity. The
findings ofthe focus group were incorporated into the second phase ofthis study. An
example ofthis was the finding ofthe symptoms and impact ofvulvodynia in women
from the focus groups. As a result, a vulval symptoms questionnaire was developed
as a data collection method for this symptomatology for Phase II ofthe study.
Ong (1993) suggests an approach to research that draws on a wide spectrum
of methodologies which can be integrated as the most appropriate approach to the
multi-dimensional and multi-disciplinary issues encountered in the health field.
Herbert and Higgs (2004) comment that, despite the philosophical and
methodological differences between quantitative and qualitative research paradigms,
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research across the paradi gms can provide complementary ways of learning. Herbert
and Higgs note that this can be particularly relevant in the area of health care because
this area is involved with both the physical and social world of people.
Within the physiotherapy profession, Ritchie ( 1999) credits qualitative
research as a means of' adding the humanistic mission to result in the best practice in
physiotherapy' (p.25 1). This move within the physiotherapy profession embraces the
specific needs of the patients as well as developing evidence-based practice. Ritchie
discusses the obligation we have as physiotherapists to refine the art and science of
good health care through systematically combining patient-focused care and
evidence-based practice, a qualitative as well as quantitative approach to our
research.
The two research methodologies were combined in this study to enable
information from the focus group discussions to be interpreted in the development of
the data collection instrument for Phase II of the study. Barbour ( 1999) recommends
the consideration of the contributions that a qualitative component can make to
research that is mainly using quantitative methods grounded in the quantitative
paradi gm. In this study, it was important that the research did not progress towards
structured questionnaires without firstly undertaking some qualitative work to
establish relevant questions and issues. New relevant variables for the data collecting
questionnaires were identified as a result of the qualitative methodology of the first
phase of this study.

Methodology Phase I

Design
Focus groups were the method of gathering data on the symptoms and impact
of lower urinary tract sensory symptoms on women with FM. A descriptive design
was used for this phase of the study. Information from relevant literature and
qualitative methods were combined to develop the format for data collection. An
interview guide was used to outline the relevant topics for the group discussions and
to elicit thoughts, ideas and perceptions about the participants' symptoms (Appendix
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C). Group participants were all women who had been diagnosed with FM by a
rheumatologist and who had experienced sensory bladder symptoms. The conducted
interviews and discussions were to ensure that the key indicators and the way in
which the participants experienced bladder irritability were compatible with and
inclusive in the ICSI/ICPI instrument to be validated in Phase II of this research.

Why Focus Groups as the Data Collection Method?
Relevant literature and focus groups were used as the qualitative method of
data collection for this first phase of this research. Benoliel (Polit & Hungler, 1989)
describes four broad areas in which unstructured qualitative approaches have merit.
One of these areas describes a person's adaptation to critical life experiences such as
chronic illness. Portney and Watkins ( 1993) describe qualitative research as seeking
to describe the complex nature of human beings and how humans perceive their own
experiences. They continue to explain the purpose of qualitative inquiry as
examining such experiences with a holistic approach that focuses on the true nature
of the participant's 'reality'.
The focus group has been described as a guided interactional discussion for
generating rich experiential information (Carey & Smith, 1994). Basch (1987)
commented that the focus group interview is a technique of qualitative research that
determines feelings and opinions about an identified topic. The topic to be addressed
in this research is bladder irritability symptoms experienced by women who had been
diagnosed with FM.
Greenbaum (Diloroi, Hockenberry-Eaton, Maibach, & Rivero, 1994) states
the benefits of focus group data collection as allowing for the combination of
elements of group process theory and qualitative research methods as well as
enabling the group facilitator to establish a permissive environment encouraging in
depth discussion of the research topic. Krueger and Morgan (Asbury, 1995) note that,
by design, focus groups rely more on the dynamic of the group interaction to
stimulate thought processes, with resultant verbal contributions of the participants,
thereby providing the researcher with a richer and more detailed perspective.
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Based on the above rationale, and in considering the various approaches
available for qualitative data collection, the focus group was deemed to be the most
appropriate for this research project. Because of the intimacy of this research topic
on bladder function and dysfunction, individual interviews as a method of data
collection for this project were considered. However, the interactive components of a
focus group were considered and focus groups were selected as the means of data
collection because it would provide more detailed and complete information on
symptoms and impact.
Diiorio, Hockenberry-Eaton, Maibach, and Rivero ( 1994) suggest that
information from focus groups can provide an excellent basis for the development of
research instruments. The person who has the symptom can most correctly supply the
symptom and impact scale related to their condition. Basch ( 1987) describes the
benefit of focus groups in the development of quantitative instruments because the
group interaction reveals appropriate response categories, language usage,
vocabulary and vernacular used by the research participants. For this FM research,
the women in the focus groups were able to elicit thoughts, ideas and perceptions
about their bladder symptoms. They were able to describe the increased impact on
their lives that resulted from the involvement of their bladder in their overall FM
symptomatology.

Population and Sample
Participants for the focus groups in this first phase of the study were women
from Perth, Western Australia who had been diagnosed with FM by a rheumatologist
and who experienced lower urinary tract sensory symptoms.

Recruitment
Recruitment for this stage of the research was via a rheumatologist.
Following a meeting with the rheumatologist, where I explained the research and its
methodology, he was provided with copies of the Phase I information sheet for
participants (Appendix D). The rheumatologist organised for these information
sheets to be attached to a letter to FM patients from his medical practice database
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asking for expressions of interest in the FM study, or mentioned the study to
potential participants at the time of consultation (Appendix E). This method of
recruitment therefore ensured that all participants had been diagnosed with FM by a
rheumatologist. Participants were asked to telephone the researcher directly if they
were interested in the research. Through this method of recruitment, the privacy of
the patients was protected.
Potential participants were screened over the telephone. The first twenty
women who called, who expressed an interest in the phase of the study and who met
the inclusion criteria, were invited to join the focus groups. All participants
experienced at least two of the sensory urinary symptoms associated with FM. These
sensory symptoms included urinary frequency, urinary urgency, nocturia and a
constant awareness of the bladder, or discomfort, or, pain in the bladder.

The Focus Groups
The three focus groups were all conducted on university premises, which
were readily accessible for the majority of participants. Car parking on the premises
was arranged free of charge. Care was taken to ensure that the meeting room was
friendly and had an appropriate temperature. Seating was arranged around a
rectangular table setting to encourage interaction, with the moderator placed adjacent
to the participants and not at the end of the table as a leader figure. Because of the
impact of the participants' urinary symptoms, close proximity to toilets was
considered. Participants were given name badges for first names only and
introductions were given. The total number of women in the focus groups was 10.
There were four women in the first group, four women in the second group and two
women in the third group.
A co-facilitator, another women's health physiotherapist, was present and
talked to the participants prior to the commencement of the session regarding issues
of confidentiality, consent forms and the recording of, and format of, the session.
Information was also given about the purpose of the study and benefits of the
research. Prior to the commencement of the session, all participants signed consent
forms for participation in the study (Appendix F). The co-facilitator's role included
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minimising interruptions, recording the session, providing refreshments and acting as
an observer of non-verbal behaviour or other non-recordable dynamics within the
group. These observations were imparted to the researcher/facilitator at the
debriefing session between the facilitator and co-facilitator following the focus
groups.
The three focus groups, with the total number of ten participants, resulted in a
sense of completeness of information and experience on the research topic. The
discussions from these three focus groups provided multiple aspects of living with
FM and its associated bladder symptoms. After the third focus group, most of the
information given became repetitive, suggesting that most 'new' information had
been obtained. Information redundancy was achieved.

Data Collection and Protocol
All three focus group sessions were audiotaped to enable accurate retrieval of
data. The semi-structured interview, based on the relevant literature and validated
questionnaires planned for use in the second phase of this research, was used to elicit
information about the participants' bladder and non-bladder FM symptomatology.
The interview guide used for the focus groups was partly derived from the Interstitial
Cystitis Symptom Index and Problem Index, the voiding and pain indices being
validated for use within the FM population. This was to ensure that the key
symptoms and the impact on these women were compatible with, and inclusive in,
the ICSI/ICPI instrument.
Questions from the Fibromyalgia Impact Questionnaire, the Kings Health
Questionnaire and the SF-36 Health Questionnaire were also used during the focus
groups. These questionnaires formed part of the main data collection instrument for
Phase II of this research. The rationale for adding relevant sections of these
questionnaires to the interview guide was to expand the collected data to include
issues concerning the effect of bladder problems on physical as well as psycho-social
aspects of women's lives. Demographic information questions were also included in
the interview guide.
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Questions from the interview guide were discussed at length to ensure
participants' understanding of symptom descriptions, symptom comprehension, word
comprehension, and the arrangement of numerical values in relation to symptoms
and impact. All relevant information from the focus group participants was
considered in refining the instrument for data collection for Phase II of this research.
Some minor changes were made in the demographic questionnaire as a result of the
focus group discussion re the comprehensibility of the questionnaire. The
interview/discussion format of the focus groups successfully encouraged participants
to become involved with the answering of questions, often followed by a discussion
of their personal experience of the specific topic.

Data Analysis
Ingleton and Seymour (2001) refer to the various mechanical and creative
processes interwoven into the production and analysis of data. The analytical process
of this qualitative study reflects this intertwining of personal knowledge and
experience of the researcher as a physiotherapist continence adviser, the study
participants' comments, conversations, accounts and experience of their personal
experience with FM and the information, and interpretation from the relevant
literature.
Goldman and McDonald (Henderson, 1995) comment that qualitative
analysis begins during the group session itself. They recommend that the group
moderator be continually alert to analytical implications during the process of the
focus groups. This was certainly the case in the collection of the data from this focus
group of women with FM and bladder irritability. As the semi-structured interview
was based on validated FM and urinary symptom and problem indexes, the questions
were directed to the participants' symptom range and the impact of the symptoms on
their lives. The shared symptom and impact experience of these women seemed to
give them not only permission to talk about an intimate and often taboo subject, but
also to share their stories, which they did, almost with a sense of urgency. Henderson
(1995) acknowledges that the perceptions, beliefs, opinions and attitudes that result
from data collection in focus groups are subjective. Henderson also comments that
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the different backgrounds of qualitative practitioners provide a conversion
mechanism giving interpretation to what respondents say.
Portney and Watkins ( 1993) describe qualitative data analysis as primarily an
inductive process reflecting a constant interplay between the observed reality and
theoretical conceptualisation of that reality. Because of the narratives involved in
interview response, qualitative data have to be reduced to derive meaning from them
for summary and presentation (L. G. Portney & Watkins, 1993). A process of coding
and content analysis can achieve this process.
Coffey and Atkinson ( 1996) refer to coding as condensing the bulk of the
data set into units for analysis by creating categories and generating concepts from
within our data. Essentially coding is a method of organising qualitative data.
However, Coffey and Atkinson ( 1996) suggest that coding data can be part of the
analytical process as giving codes to data and generating concepts enable us to
rigorously review what our data are saying. The authors continue by acknowledging
that, as coding links different segments of the data together, it creates categories of
data defined as being about a particular theme or concept. Coffey and Atkinson
( 1996) recognise therefore that codes, data categories and concepts are related to one
another.
Computer software packages such as NUD.IST are used for the coding of the
qualitative data. Coffey and Atkinson (1996) refer to this computer software use as
'the code-and-retrieve program'. These programs allow the researcher to identify
segments of data by attaching code words to them. The data are then explored for
segments that can be identified by the same code. Coffey and Atkinson discuss the
move from coding to interpretation in various stages. The first stage is the retrieval
and categorisation of the data. The second stage is the playing with, exploring,
splicing and linking the created codes and categories. The next stage is the
interpretation, described by the authors as the transformation of the coded data into
meaningful data.
This was the process used for the data analysis from the transcripts of the
three focus groups for this research. With the assistance of NUD.IST software, data
were identified, coded, retrieved and all segments identified by the same code were
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collected together for further analysis. This involved the identifying of themes,
patterns and responses and finally led to the interpretation.
The interpretation and testing of emergent ideas in qualitative analysis are
described by Ingleton and Seymour (2001) as the researchers demonstrating that
'they have opened up their minds to a range of possible interpretations of qualitative
data, and therefore have captured, as far as possible, the essence of the everyday
world under study' (p. 23 1). This 'capturing' of the essence of the world of
symptoms and impact of urinary irritability on women with FM began.
The 80 pages of transcripts for this research were transcribed, read and re
read by me as the primary investigator to ensure absolute immersion into the data.
Through the reading and the re-reading of the transcripts, thoughts and recollections
of the group dynamic and expression were noted. Fallowing detailed analysis of the
transcripts, primary codes were identified. As recommended by Miles and Huberman
( 1984) the codes were first developed as chunks of words that go together and
reconfigured as the data expanded. These primary codes were then superimposed on
to the transcripts to verify their placement. My academic supervisor (LK) and a
second research investigator (AP) verified these codes as being representative of the
data, following numerous meetings where the coding was revisited.
Emerging themes from the coded data were recurrent. My academic
supervisor and a third individual with qualitative research experience (J W) reviewed
thematic configuration and participated in discussions of the interpretation of these
emerging themes. The development of an audit trail and the use of second and third
researchers to verify coding of the data established the rigour of the data analysis. An
audit trail is the researcher's progressive documentation of the data collection, the
categorising and organising of the data and the data analysis (Macnee, 2003).
Lincoln and Guba (1985) describe the audit trail as a method of confirmability, the
consistency and repeatability of the decisions taken during the process of data
collection and analysis. Some of the findings from Phase I were instrumental in some
changes to the data collection instrument used in Phase IL
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Methodology Phase II

Design
This phase of the research involved the testing of the Interstitial Cystitis
Symptom and Problem Index (ICSI/ICPI) within the FM population for reliability
and validity. A cross-sectional study design of a group of women with FM and
bladder irritability was used to test the ICSI/ICPI instrument for reliability and
validity for use within the FM population. The instrument for data collection was a
self-administered questionnaire. This questionnaire included a demographic
questionnaire (Appendix G), the ICSI/ICPI (O'Leary et al., 1997) (Appendix A), the
Fibromyalgia Impact Questionnaire (Burckhardt, Clark, & Bennett, 199 1) (Appendix
H), the Kings Health Questionnaire (Kelleher, Cardozo, Khullar, & Salatore, 1997)
(Appendix I}, the Medical Outcomes Study 36-Item Short-Form Health Survey (SF36) (Ware & Sherboume, 1992) (Appendix J) and the Vulval Symptoms Assessment
Scale (Appendix K). The vulval symptom assessment scale was developed as a result
of the findings from the focus group of Phase I of this research to gauge the extent of
vulval symptoms and their impact in this study population.
The rationale for including the Fibromyalgia Impact Questionnaire, the Kings
Health Questionnaire and the SF-36 questionnaires was to expand the collected data
to include issues concerning the effect of bladder problems on physical as well as
psycho-social aspects of women's lives, the impact of the condition of FM on these
women and their general health. The demographic questionnaire outlined socio
demographic information and illness and disease specific factors. As there is no gold
standard for assessing lower urinary tract sensory symptoms of women with FM,
validity was assessed by comparing the ICSI/ICPI with the score that patients
obtained from similar reliable measures such as the Kings Health Questionnaire
(Kelleher et al., 1997), the Fibromyalgia Questionnaire (Burckhardt et al., 199 1) and
the SF-36 Questionnaire (Ware & Sherboume, 1992). It was anticipated that women
with more FM and bladder symptoms would score higher in the ICSI/ICPI.
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Population and Sample I Inclusion and Exclusion Criteria
Data were collected via the self-administered questionnaire administered to
90 women who met the inclusion criteria. Women were recruited from two
Australian state capital cities, Melbourne and Perth.
Inclusion Criteria
• All subjects were female and between the ages of eighteen years and sixtyfive years inclusively
• All subjects experienced at least two sensory bladder symptoms.
•

Rheumatologists have diagnosed all subjects in the study with fibromyalgia.

• All subjects in the study have undergone a non-invasive urological screening
by a urologist or urogynaecologist to eliminate conditions with abnormal
pathology.
• All subjects understand spoken and written English.
Exclusion Criteria
Subjects were excluded from the study if any of the following criteria applied:
• Under the age of eighteen years or over the age of sixty-five years. The
increase in urinary symptoms in the aged is well documented. Therefore the
inclusion of women over sixty-five years of age in this study could create a
significant confounding factor.
•

Pregnancy

• Current urinary tract infection
•

Recurrent urinary tract infection

• A diagnosis of bladder conditions with abnormal pathology resulting from the
urological screening.
•

Neurological disorders (apart from that due to FM)

•

Presence of a urinary catheter

•

Drugs that can cause irritative symptoms eg. cyclophosphomide or
tioprofenic acid

• Carcinoma of the bladder
• Inability to understand spoken and written English.
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Recruitment
A number of different methods of recruitment were employed. In Perth,
women were recruited through referral by rheumatologists. This study' s research
proposal was presented to Perth rheumatologists at their monthly research meeting,
explaining the need for participants in the study who had been diagnosed with FM by
rheumatologists. Research information letters (Appendix L) were sent to 12
rheumatologists with follow-up visits to eight of the practitioners.
A number of rheumatologists assisted the recruitment process by sending
letters to their FM patients asking if they were interested in finding out more about
the study and, if so, to contact the researcher directly. Some rheumatologists
mentioned the study to patients during consultation if the patient met the
rheumatological inclusion criteria of the study. General information sheets for
surgeries, as well as notices on rheumatology clinic waiting room notice boards,
were made available to the participating medical practices (Appendix M).
Two media releases from the Edith Cowan University public relations
department were distributed during the recruiting period to local newspapers and
media outlets (Appendix N). This resulted in excellent coverage by a number of the
local newspapers. Recruitment advertisements continued in the community sections
of some of the community newspapers during the recruitment period. Similar
advertisements were also placed in: the "Arthritis Today" newsletter of the Arthritis
Foundation of Western Australia; "Pipeline", the newsletter of the Continence
Foundation of Australia (WA); the Australian Physiotherapy Association newsletter;
and the Women's Health and Continence Physiotherapists national group newsletter.
Information on the study and recruiting information was published in the Gazette of
Edith Cowan University and on the post graduate discussion board of the University.
Details of the research project, together with requests for recruitment assistance,
were emailed to eleven of the Western Australian Divisions of General Practice of
Medicine. The Women's Information Service from the State Government's Office
for Women's Policy also publicised the research through their monthly newsletter.
Recruitment in Melbourne, Victoria was very successful following a short
presentation at a Fibromyalgia one-day meeting in Melbourne organised by Arthritis
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Victoria. Approximately 500 people attended the meeting. Information sheets, with a
tear off 'expression-of-interest' section, were available at the meeting. The research
information was also emailed to all members of the Victorian Rheumatology
Association via the association's office in Melbourne.
Approximately 500 women expressed an interest in the study during the
recruiting period of 18 months. An initial tel ephone interview with all of these
women confirmed their continued interest in the study and ensured they met the
preliminary inclusion criteria. Many women did not meet the inclusion criteria for
the study, but wanted to talk with someone about their condition and management of
FM. These women were offered information about services such as the FM support
groups and/or the Continence Advisory Service. A total of 120 women was recruited
for the study. Of this number, 90 women completed both st eps of Phase II of the
study, 70 women from Perth and 20 women from Melbourne.

Data Collection and Protocol
All participating women were mailed information packs pnor to their
screening appointment. Included in the pack were information sheets on this phase of
the study (Appendix 0), a consent form (Appendix P), a three-day bladder diary with
instructions on use (Appendix Q), details of their appointment and a thank you
message for their participation. Melbourne participants were also sent the data
collecting questionnaire and asked to complete it after their screening.
Participation in the study was described as two steps: firstly, a non-invasive
urological screening and secondly, a questionnaire completion. All of the women
understood that, if there were any abnormalities in the findings from the screening,
they would be referred to their general medical practitioner for investigation and
would be unable to participate in the study. Perth participants were screened at a
metropolitan urology clinic under the direction of a urologist and urology nurse. A
urogynaecologist screened Melbourne participants at a Melbourne continence clinic.
The urological screening (Appendix R) involved a subjective assessment, the
interpretation of the three-day bladder diary, a mid-stream urine sample, urinary flow
rate reading and a bladder scan. In the absence of other bladder pathology, and
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following the assessment by the urologist, urogynaecologist or continence nurse,
these women were recruited into the study.
The subjective assessment involved taking a detailed medical history with
particular emphasis on current bladder and FM symptoms and medications. This
assessment was conducted by either the urologist, urogynaecologist or continence
nurse following the urine sampling and flowmetry. The three-day bladder diary,
completed by all participants prior to their appointment, provided semi-quantitative
data on micturition patterns including fluid intake and urinary output. Frazer (2003)
describes the frequency/volume charts as an excellent and simple method of
displaying symptoms, while Abrams and Klevmark

( 1996) describe the

frequency/volume charts or urinary diaries as the most important tool in the
investigation of lower urinary tract symptoms.
Although it required commitment and time by participants to complete a
three-day bladder chart prior to their urological assessment, it was necessary because
previous results have shown poor agreement between subjectively estimated
frequency and chart-determined frequency (McCormack, Infante-Rivard, & Schick,
1992). A recent study by Ku, Jeong, Lim, Byun, Paick and Oh (2004) has shown that
seven days, the most commonly recommended diary duration, does not affect patient
compliance, but rather this extended seven-day diary is associated with patient
burden. Nygaard and Holcomb (2000) have shown that the results of the first three
days of the bladder diary correlate with those of the last four days indicating that this
three-day diary is an appropriate outcome measure for lower urinary tract symptoms.
The increased patient burden on the FM study participants in this study was therefore
not necessary and a three-day bladder diary was deemed sufficient.
Free flowmetry provided a measure of the speed of the bladder emptying. The
urinary flow rate is a composite measure of the interaction of the detrusor pressure
and the urethral resistance. As urine flow rates are dependent on voided volume, with
the larger the voided volume resulting in the greater flow rate in millilitres per
second, all participants were asked to refrain from voiding for at least an hour prior
to testing. The free flowmetry was combined with the measurement of residual urine
by ultra sound bladder scanning to give evidence of voiding efficiency. The urologist
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cited various reasons for non inclusion in the study for twelve ofthe women. These
included patient histories of autoimmune disease, Bornholm disease, Behcet's
syndrome, coccygectomy, other neurological symptomatology, recurrent urinary
tract infections and minimal urinary symptoms
Following the urological screening, recruited participants were asked to
complete the self-administered questionnaire. Some questionnaires were completed
immediately after the screening, while others were posted back to the researcher in
the provided addressed, stamped envelope. To ensure data for the test-retest of the
ICSI/ICPI, a repeat ICSI/ICPI questionnaire was sent to the participants as soon as
the first questionnaire was returned to the researcher. Participants were asked to
complete this second ICSVICPI questionnaire and return it to the researcher as soon
as possible. The average time from the mailing out of and receiving the second
ICSI/ICPI questionnaire back was ten days. A number of participants did not return
the retest questionnaire before 30 days and a few were not returned. Because of the
possibility ofchanging symptoms within the month in this FM population, any retest
ICSVICPI questionnaires returned after four weeks were not included in the
test/retest analysis. Eighty-three ofthe 90 (92%) study participants participated in the
retest sample.
Data Analysis
Assessment was made for internal consistency reliability, test-retest reliability
and concurrent validity of the ICSI/ICPI instrument. Reliability indicates the
reproducibility of a scale, indicating what proportion of a patient's test score results
are true and what proportion is caused by individual variation (Penson & Litwin,
1997). Internal consistency reliability is a measure of the similarities of a person's
response across several items and indicates the homogeneity of the scale while test
retest reliability measures the question response stability over time (Penson &
Litwin, 1997). Validity refers to the degree to which the scale measures what it is
supposed to measure. Concurrent validity is described by Penson and Litwin as a
more quantitative approach to assessing the performance ofinstruments and involves
correlation ofscale scores with results from other established tests.
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Cronbach 's alpha coefficient was used to assess internal consistency
reliability. A criterion of at least 0.70 was pre-set as the acceptable level for internal
consistently reliability (Nunnally & Bernstein, 1994). Internal consistency reliability
also involved assessment of inter-item correlation with an expected value of between
0.30 and 0.70 (Carmines & Zeller, 1979). Item-to-total correlations were examined to
determine whether 50% of these values achieved a correlation of between 0.40 and
0.70 (Carmines & Zeller, 1979). Stability over time was assessed using the test-retest
procedure as estimated by the intra-class correlation (ICC). Examining the simple
correlations between the ICSI/ICPI and other similar instruments provided evidence
for concurrent validity assessment.
Factor analysis was undertaken to assess the internal structure of the scale
and to identify relevant subscales for use in the FM population. Multiple regression
analysis was also used to identify factors associated with bladder symptoms.

Ethical Considerations (Phase I and Phase II)
Ethics approval for this research was obtained from the Edith Cowan
University Committee for the Conduct of Ethical Research. All participants in both
phases of this study were fully informed of the purpose of the study and were
provided with an information sheet describing the process of their involvement.
Informed consent forms were signed and dated by all participants and the researcher.
The consent form indicated that the subject was free to discontinue participation at
any time during the study without prejudice.
Taped interviews from Phase I were transcribed by the researcher. The tape
recordings were then erased. There were no names or identifying information on the
questionnaires in this study. Medical assessment forms from the urological screening
for Phase II of this study were secured in a locked filing cabinet in the researcher's
office. All hard copy raw data and signed consent forms were secured in locked
filing cabinets. Consent forms and data files were stored separately. Only the
researcher and principal supervisor had access to these records. Code numbers were
used on all documents and computer data entries to ensure participants' privacy.
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Only the researcher and primary supervisor had password access to the computer
data.
The researcher acknowledged the sensitivity and personal nature of this area
of research and at all times acted in a professionally appropriate manner. The
researcher has worked clinically in the urology area as a physiotherapist continence
adviser, assessing and treating pelvic floor dysfunction for the past fifteen years.
Continence Foundation brochures were made available to all women who requested
information on bladder symptoms and/or good bladder habits. Information on FM
support groups was made available to women who requested information on group
support.
Following the analysis of Phase II data, the findings of both phases of the
study were reviewed, recorded and form the essence of the following chapters on
findings and discussion of this study on FM and bladder irritability.
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CHAPTERS

RESULTS AND DISCUSSION: PHASE I

Introduction
This chapter documents the findings from the qualitative analysis of Phase I
of the research. It also describes the participants in terms of their demographic
characteristics, the preparation of the data for analysis, the analysis steps and the
results. The results are interpreted in relation to existing literature.

Who Participated?
Sixteen women were recruited for the focus groups. To accommodate
personal commitments and preferences, the focus groups were offered at different
times during the day. Some women were unable to keep their appointments to
participate in the groups. The final numbers in the three focus groups were four, four
and two, totalling ten participants (n = 10). Each focus group was of two hours
duration

Demographic Characteristics of the Focus Group Participants
The majority of the women were Australian born (seven of ten). The
women's ages ranged from 25 to 58 years with an average age of 47 years. The
number of biological children per woman ranged from zero to three, with an average
number of two children per woman. Most of the women had tertiary qualifications
(seven of ten). Occupations included professional positions (four), homemaker
(three), clerical (one), retired (one), and one was receiving a disability pension. All
participants reported being treated for FM by a rheumatologist between 1993 and
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200 1. However, all women had experienced pain and disruption for years before the
diagnosis was given. Main health concerns apart from FM were listed as osteoporosis
(three), headaches (two), gastric reflux (two), osteoarthritis (two) and tinnitus (two).
Prescription drugs included antidepressants for sleep enhancement and reduction of
pain (four), hormone replacement therapy (three), anti-inflammatory medication
(two), thyroxine (two), aldactone (two), ditropan (one) and cholesterol medication
(one). Five women were postmenopausal, one was perimenopausal and four were
premenopausal.

Non-Bladder Symptoms
The findings from this study confirmed those found in other qualitative
studies on the experience of people diagnosed with FM. Raymond and Brown (2000)
depicted the patient's journey as a continuum that included the onset of symptoms, a
search for a diagnosis, and a phase of coping with the illness. Asbring (200 1)
described FM as a chronic disease that can result in a radical disruption in a woman's
biography that can have profound consequences for her identify. Both the FM
journey and the resultant adaptive changes were evident in these Australian women
who participated in these focus groups.
The findings from this study reveal the enormity of the impact that FM has on
the lives of women. The unpredictability of the symptoms and the resultant
constantly changing management strategies undertaken by these women demonstrate
the notable impact of FM on their lives. So challenging and unpredictable is it that it
becomes difficult for women to predict symptomatology and therefore plan their
lives. FM seemed to encroach from all corners of their living space, impinging on
their every experience and tethering them within restricted physical, emotional,
social and psychological boundaries. The impact of these four components is
depicted in Figure 5 below as a puzzle image.
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Figure 5: The Tethering Effect of Non-Bladder Symptoms on Women with Fibromyalgia

Although tethered and contained by these restrictions, the women still
enj oyed a certain freedom of movement, expression and experience within limited
boundaries. The women described the impact of this symptomatic tethering even
before the discussion included their bladder symptoms. They lived within the
confines that FM and its bladder effects dictated to them. This is their story.

Emerging Themes

The Physical Impact of Fibromyalgia
Pain was the dominant FM feature experienced by the women in the focus
groups. Their pain was evident in the way they sat, the way they moved and
emotionally in the description of their pain. The pain from the pelvis, from the back,
from the neck, the feet, the ribs, the pain that caused these women to drag themselves
through most days , was all consuming. The women described their pain as
interfering and impacting in all aspects of their lives.
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When you get the real FM pain, you get it everywhere, your hands hurt,
your feet hurt, your head, your back, your vulva, your legs, your internal
organs hurt, your cheeks hurt. It is all part of the syndrome isn't it? Like
the whole body. (Focus group 1 E)

From migraines to trying to walk down the stairs, from early morning
stiffness heralding the start of their day, the women were exhausted. Within the
groups, the collective impact on each other validated the expression and experience
of their pain. Early in the discussion, there was a sense of awareness and relief that
there were other women who lived similar lives affected by FM. The head nodding in
affirmation when one woman talked of not knowing what it was like to live without
pain reflected the ongoing non-verbal agreement between these women.
I was going to the doctor because the pain was so intense ... and I was
doing my exercises in the morning because after midday I am of no use to
anybody. I had to talk to myself with positive thoughts in my mind...!
don't know what it is to live without pain. (Focus group 1 F)

Their descriptions of the relentlessness of their pain was consistent with the
statement by Hathaway (2004) in his article on 'Chronic Pain and Fibromyalgia:
trapped in a World of Hurt' where he described pain as 'a relentless taskmaster that
demands constant consultation before even the most mundane activities are
attempted' (p. l ).
For the majority of women in the group, sleep was a luxury. Unanimously the
women agreed that when they were able to obtain more sleep they felt better "all
around". Four to six hours sleep each 24 hours allowed them to function "to a certain
extent during the day". Most of the women knew that if they did not get sufficient
sleep their pain could be worse. This pain contributed to less sleep and finally total
exhaustion. This was reflected by reports of 'dragging one's self through each day'.
There was an initial resistance to the use of medication to improve sleeping patterns.
However, the women eventually had to accept the use of medications in order to
sleep. Four of the ten participants were on antidepressant medication to improve the
quality of their sleep.
I have been much better since I have been on doxipine this year. I am
really anti medication. I have to be honest about that. But this year I
really gave in and it just got so bad, !just wasn't coping ...Jjust got to the
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point where I was so tired and run down that I went on to doxipine.
(Focus group 2, All)

The need to be self-sufficient and non-reliant on drugs prompted the women
to seek alternative treatments or to just charge ahead with their lives and suffer the
consequences. Four of the women in the groups had tried non-prescription
medication to try to find relief from their symptoms. Physiotherapy treatment was
popular with some ofthe women, providing them with short term relief.
The primary approach for treatment of FM is a change of lifestyle to ease
demands on the body and medication for pain and sleep management. The majority
ofwomen in the groups were very self-sufficient, goal setters and self-driven. It was
ofinterest to note that, of the ten women in the focus group, seven had completed a
tertiary education.
The pain and fatigue ofFM resulted in significant muscle deconditioning and
poor aerobic fitness levels for most ofthe participants. They spoke of their inability
to be involved in family physical activities and were aware that their partners' lives
were also affected by their illness.
The Emotional Impact of Fibromyalgia
The diagnosis of FM usually follows years of looking for answers and
solutions to a pot-pourri ofsymptoms. Although FM research has discovered some of
the biological markers of FM, some are illusive and some techniques necessary for
locating the diagnostic markers are too invasive. As a consequence, people with FM
are often classified as experiencing psychosomatic symptoms or possessing poor
coping skills to deal with life issues. This was the experience of some ofthe women
in the focus groups.
I went and asked my GP if he would take my FM seriously. I asked him if
he had heard of FM and did he believe in it. And I sat down and he said
that he didn 't know enough, "but this is what I know and yes I believe in
it "... Ijust think it would be fantastic to wake up one morning and know
that /felt alive, awake and well. It would be fantastic! (Focus group 3, S)

For all women, the diagnosis of FM was a validation of their symptoms and
distress, accompanied by a feeling of relief because a diagnosis had finally been
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obtained. However, their diagnosis also triggered a sense of foreboding about their
health future. At the time of diagnosis, most women were given pamphlets about
their condition, a prescription for medication and advice to increase their exercise
and change their lifestyle. Some were given the diagnosis and told that there was no
treatment for the condition and they would have to make changes in their lives to
accommodate FM. Five of the ten women had not met or heard of anyone else
having this diagnosis. The feeling of isolation and sense of 'where to from here' was
overwhelming for them. This sense of aloneness was compounded by a lack of FM
knowledge, support and understanding from their general medical practitioners.
The women in the focus groups were driven in their search for answers to
improve their health and to improve the quality of their lives. Through their pain and
disability they maintained seeking, hopeful and generous personalities.
I feel more inspired by talking about what research is out there to
actually help the problem. And that is what I like about Dr _ 's group that
we talk about things that actually help. E talks about DHEA and we talk
about other things. There is urgency for us to get on and try and make do
and get on with life. (Focus group 1 V)
Ijust think it would be fantastic to wake up one morning and think, 'Ifeel
alive and well '! It would be fantastic. I hobble into the shower and I
hobble out ofmy car at work. (Focus group 2 All)
The emotional impact of FM on the women was more than adapting to the
physical distress they endured. It was coping with a disability that affected all
sections of their lives. For one young woman, FM even impacted on her future plans
of becoming a mother.
It is funny because I now have concerns because I am thinking ofstarting
a family in the next couple ofyears. I have concerns about do I want a
female child because I am frightened of passing on these things that I
have lived with. I would prefer not to and would it be different if I had a
son. Can I still pass that sort of thing on to a male child? (Focus group 2
J)
This grieving for future loss and constant adaptation was intertwined with
grieving for the loss of lifestyles they enjoyed prior to the onset of FM. The grieving
in some was hidden behind well-developed coping facades. The common experience
of FM shared by the women in the focus groups was very disarming for some,
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resulting in tears of frustration and pain. The unspoken permission to just 'be
herself, the anger tethered and controlled for so long and the anguish of living with
constant pain were quietly evident during the discussions and at times erupted into
hostility demanding of answers.
The women's frequent use of humour lightened many of the more difficult
moments. Comments such as 'I stopped trampolining sometime ago' or 'Mum and I
find retail therapy is a great help' created relief through laughter and light-hearted
response.

The Social Impact of Fibromyalgia
Kitzinger ( 1994) wrote that group participants of a focus group provided an
audience for each other that greatly enhanced communication and enriched data
collection. She concentrates on the interaction amongst research participants and
describes this interaction as the participants becoming co-researchers, taking the
research topics into new and unexpected directions.
This interaction was apparent in the focus groups. Because the women shared
a common diagnosis, they shared an understanding of each other's challenges. They
communicated, they agreed, they disagreed, they questioned and demanded answers.
There was a collective response as well as individual responses from the women,
especially in this area of the social impact of FM.
Your comment earlier about having your FM in perspective... that is fine
until someone asks you how you are. They want you to say fine. Don 't
they! I mean they don 't want to hear you say, 'I am bloody awful again
today '. Do you know what I mean? You actually have to learn to mask it
and get on with it. Otherwise people would think you are a
hypochondriac. (Focus group 2, All)
FM is often described as an invisible illness as the majority of women with
this condition appear physically normal. For the majority of women with FM there is
no obvious disability. Sveilich (2005) reveals that people who live with unseen
illnesses and chronic conditions 'often conceal their physical challenges and project
themselves to the world in a particular manner that is contrary to the way they feel.
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These individuals choose to wear the mask of normalcy and often appear just fine,
despite having to contend with a host of invisible and difficult challenges' (p. 20). In
Soderberg and Lundman's study (200 1), women described other people viewing
them as healthy beings.
Most of the women in the focus groups fought to maintain this illusion of
wellness within their family, work and community groups. Therefore, normal
expectations were placed upon them. These women fought to maintain a normal day
to-day existence with their family and work environments. For a few of the women
these expectations were insurmountable, but for others there was no option but to
'get on with it'.
Do you want it to control me or for me to control it? That was the
mindset I took. I think when you first find out what is going on you get
very keen and read everything and say, 'Yes, I have got that and I have
got that so poor me '. But then really on a relative scale you sort of think,
well I want to enjoy life, so let 's get on with it. (Focus group 2 All)
Patients with FM frequently report a decline in cognitive functioning,
memory and mental alertness. The women referred to this mental confusion and
forgetfulness as 'fibro-fog'. They described their episodes of cognitive dysfunction
as mental blackouts that increased when their FM was flared. They described the
effects this had on their ability to function effectively at home and in the work place.
The effects varied from emotional despair to absolute acceptance. Above all, their
resilience and determination to move on with their lives was inspiring.

The Psychological Impact of Fibromyalgia
The women in the focus groups described the psychological impact of FM in
many ways. They spoke at length of the avoidance of stress in their daily lives. Stress
can exacerbate the symptoms of FM (Davis, Zautra, & Reich, 200 1). The women in
the group attempted every day to avoid unnecessary stress, to live within their energy
restraints, tethered by the impact of their symptoms. However, for all of the women,
this loss of freedom, the fatigue and the pain increased their stress, their sense of
frustration and their anger. Most of the women were attempting to bridle this impact
with a quiet determination to move on with their lives.
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One day I am ok and the next I am not. When I am not I do my best and
when I am well I do my best as well. I take it as it comes. I can 't handle
stress any more. So I try to make my life as less stressful by not worrying
so much andjust take one day at a time. (Focus group 2 An)

The symptoms of FM can affect all organ systems of the body. The
symptoms are unpredictable and variable. As a result, these symptoms of FM layer
themselves on to their sufferers without finite definition, resulting in overall body
pain and fatigue. This psychological impact of their disability extends into their
families and work environments. The grief experienced by the women regarding the
loss of the lives they enjoyed before FM, such as camping with the children and
working in full time professional positions, was vocalised and discussed.
I used to run 5 kilometres a day. I had the muscle tone of an athlete. I
now couldn 't run to save my life. I have been on a downhill slide for the
past three or four years. It is so frustrating. I am only 25 years old and I
feel like a grandma... / get really upset because my husband met me when
I was still doing a little bit of modelling and I was a size 10 and I was
this beautiful skinny little blond and that. Now I am so self-conscious
because I have put weight on and I don 't want to do those sorts of things
and sometimes I don 't even want to be undressed in front of him and it
gives you all those sorts offeelings that I never had before. And I am so
young. That is sad. Jjustfind that so sad. (Focus group 2 J)

They talked of trying to lead normal lives, but found that sometimes it was
easier to retreat. Their anger at their loss oflife style and the frustration ofcontinuing
symptomatology were evident in all ofthe women in the groups. The blending ofthe
tolerance of their symptoms, hopes, optimism, frustration and a knowing of
ineffective medical knowledge and management of FM created interesting
interactions and comments within the groups.
Do you get angry that your children have really lost their Mum ? I get
angry because my daughter was eight when I started with the symptoms
and she has lost her Mum because there was a lot I couldn 't do with
her... You do, you do struggle on. But there are some things you would
like to do like go and run and dance around the park. But you can 't, can
you! (Focus group 2, Ja)

The physical, emotional, social and psychological impact of FM on the lives
of these women was very evident. For most of the women, the impact of FM
decreased their range of movement and choices in life, but not their resilience. They
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had learned to move effectively, to live and to enjoy their lives within the boundaries
that FM had set.
Morse ( 1997) has developed a model, ' Responding to Threats to Integrity of
Self, a five-stage model of recovery and rehabilitation. This theory was developed
for use in the understanding and supporting of patient responses to either acute or
chronic illness. The theory concentrates on the individual and how he/she seeks self
comforting strategies to manage his/her experience. The five stages of the model
include: Vigilance; Disruption, enduring to survive; Enduring to live, striving to
regain self; Suffering, striving to restore self; Leaming to live with the altered self
(Morse, 1997). Morse describes stage five as the major task, that of learning to live
with the altered self, learning to accept the consequences of their experience and
accepting that life will not be the same again. She describes the experience of
learning to revalue life, to appreciate different things, to establish different goals and
to reprioritise aspects of life.
This fifth stage described by Morse encapsulates the expenence of the
women with FM who participated in the focus groups. They were learning to live
with the altered self.

Bladder Symptoms
Previous studies by Clauw and colleagues ( 1997a), White and colleagues
( 1999a) and Pairi ( 1994) have shown the prevalence of genitourinary symptoms in
patients with FM. This current study is the first research on bladder irritability
symptomatology in Australian women with FM. The effects of the bladder symptoms
were very significant for the women participating in the focus groups. FM impinged
on every aspect of these women's lives . The further impact of the urogenital
symptoms of FM on their lives was enormous, further restricting their freedom of
movement and available choices. The dual impact of non-bladder and bladder
symptoms combined to increase the challenges for these women to find the most
manageable way through each day.
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All of the women in the focus groups experienced a range of sensory urinary
symptoms. Following the interview guide items of the I CSI/I CPI index, the women
were asked about the urinary symptoms of urgency, frequency, nocturia and pain or
burning in the bladder and how problematic these symptoms were. Further
discussion was elicited by following the questions of the Kings Health
Questionnaire. This questionnaire allowed the women to expand on to the effect that
their bladder dysfunction had on their daily roles, physical activities, social lives,
personal relationships, emotional health, and sleep and energy capacity. Their
accounts are described below.

The Impact of Urinary Frequency
Some of the women from the focus groups were not aware that their urinary
symptoms could be part of the condition of FM. Day time urinary frequency is
described as the complaint by the patient who considers that she voids too often
during the day (Abrams et al., 2002a). Urinary frequency was a significant symptom
for the women in the focus groups. Urinary frequency ranged from 'less than one in
five times' to 'almost always'. The impact of their urinary frequency ranged from 'a
very small problem ' to 'a big problem'. Some of the women were very conservative
in their description of how problematic urinary frequency was for them. One woman
voided from 15 to 25 times a day and described it as a nuisance. Another described
her frequency as part of her life and she dealt with it. She visited the toilet so often
during the day that it had 'become her day'. She chose to forget about it and to 'get
on with her life'.
Well, I mean you have really got to time your outings and ifI do go out it
is only for a short time. Just before I came here I had to go and pick up
some macca and I had to go to the toilet. I left, and it was only a five
minute drive but as soon as I got there I had to go again and when I
finished and got my things I had to go again and now I am here. I haven 't
been yet but I have crossed my legs at the moment (Focus group 1, T)
Unknowingly some of the women were increasing the irritability of their
bladders by decreasing their fluid intake, feeling that if they drank less they would
void less often. For some women this was a way of saving time. One of the
participants drank a maximum of 400mls per day. All the women knew where the
nearest toilet was situated. They spoke of knowing 'all the toilets in the city'. The
- 153 -

women spoke of their fear of aggravating their bladder problems and their anxiety at
managing everyday and family activities in relation to their bladders.
It is difficult because if you can 't find a toilet if you are out. . . Jf it is a
problem finding the toilet when you are out then it is a matter of how
often you are out. Ifyou are out all day and every day, then it is a major
problem. Or someone else who is at home all day with access to the
toilet, it is not a problem. (Focus group 2, A)
Existing urinary frequency can be aggravated by a 'just-in-case' behaviour
where women will void just in case they may not be able to find a toilet when they
next need to void. This self-induced frequency compounds and aggravates the
existing problem. Textbook descriptions of this self-induced frequency were given
by most of the women. One woman described how she voided before leaving home
to do the shopping at a centre ten minutes from her home. On arriving at the
shopping centre, her first stop was the toilet. Another spoke of her pre-bedtime
voiding pattern . Every night she voided four times within the 20 minutes before
getting into bed, then another three voids while reading in bed for an hour and then
waking every two hours to void during the night.
But when I am awake that feeling is there I 00% of the time. I also have
found that I go to the toilet more than I ever have before. And I am
already thinking ahead, before I leave home I will go. When I left home
tonight I went, and I arrived in the building and I went because I just
know that if I don 't go at regular intervals I am going to need to excuse
myself (Focus group 2, Al)
The urinary frequency impacted on the women's ability to travel short and
long distances by car or by plane. Some of the women would rather stay at home
than cope with the inconvenience and embarrassment resulting from their urinary
frequency and urgency.
The same with travel. .. ! have a daughter living in a remote area. We go
about one and a half hours inland and it always has to be that I am
always saying to my husband, 'How many kilometres to the next stop '
and saying all the time that we are going to have to stop. If I can 't make
it !just have to stop and open the car door and go by the side of the road.
I ask him to tell me ifa car is coming because I can 't see and quickly pull
my pants down and go to the toilet and pull up. !find it quite upsetting... !
didn 't go up there the last time she asked me. (Focus group 1, E)
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Urinary frequency for the majority of women caused a disruption in their
lives. It impacted on their family lives, their working lives and their social lives. One
woman spoke of having to resign from her professional position as a counsellor
because she was unable to spend an uninterrupted hour with her clients because of
her urinary frequency. Another spoke of her love of the theatre, but the demands of
her bladder dictated where she sat in the theatre and dictated its own interval. The
activity created by the women regularly going to and from the toilet during the two
hour focus group was evidence of the demands made on them by their bladders. The
frustration of the bladder dictating to these women what they did and where they
went was summed up by (T) in her comment 'We never go anywhere'. However, the
resilience and humour of these women, despite their disability, were notable.
People do comment though. People say to me, 'But you have just been,
why do you want to go to the toilet again when you have just been ? ' /just
say, ' Well I have got to go! What do you want? Do you want me to wee
on the carpet or are you going to let me go? ' I mean /just make a joke of
it. There is no other answer because when you have got to go, you have
got to go, but it can be offputting to people you don 't know because you
have gone to seek the toilet again. But that has been the way it has
been... and then you get someone who stops you on the way to the toilet. I
just have to say that I will come back to you, just give me a moment.
(Focus group 3, A)
Using the ICSI/ICPI questionnaire, the women in the focus groups were
asked how many times during the last month had they had to urinate less than two
hours after they had finished urinating. Figure 6 displays the proportion of women
with varying urinary frequencies. They were also asked how much of a problem
frequent urination was for them during the past month. Figure 7 displays this impact
of urinary frequency on the women in the focus groups.
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ICS I Urinary Frequency
n = 10
< than 1 time in 5
1 .00

< than half the time

Almost Alway s

2.00

4.00

About half the time

> than half the time

2.00

1 .00

Figure 6: Proportion of Women in the Focus Groups with Varying Urinary Frequency

IC P I Uri nary Frequency
n = 10
N o problem

Big problem
1 .00

1 .00

Very small problem
1 .00

Medium problem
4.00

Small problem
3.00

Figure 7: Impact of Urinary Frequency on Women in the Focus Groups
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The Impact of Urinary Urgency
Urinary urgency is described as the complaint of a sudden compelling desire
to pass urine that is difficult to defer (Abrams et al., 2002a). This was a significant
symptom experienced by women in the focus groups. The unpredictability of the
urge to urinate was a fear that encouraged self-induced frequency, an increase in
urinary frequency because of 'voiding-just-in-case' behaviour. The majority of
women in the group experienced this urgency/frequency combination. Just listening
to the pouring of the drinking water from the jug to the glass during the group
discussion was enough to prompt the desire to void in some women.
The women expressed fear of being 'caught out' in many situations. They
described embarrassing episodes of urgency in the gym, at the office river cruise
Christmas party, travelling on aeroplanes, during their daily walking regime, and the
urgency of the 'key-in-the-door' situation when arriving at home. One woman had
her personal key to the staff toilets to enable her to 'make it'. As with urinary
frequency, some kept their fluids restricted because of the unpredictability of, and the
anxiety associated with, the urinary urgency.
It is just the urgency. It just catches me out. At work some of the people
must think I am nuts because suddenly I will get up and go to the loo. You
are going to the bathroom and that is it. You can't concentrate on
anything else suddenly, just suddenly. They must think I am odd! (Focus
group 3, S)
Some of the women experienced a constant sensation of needing to void.
Some described this as a burning sensation even when on voiding they only 'passed a
few drops'. One woman described this urgency as being more apparent and difficult
to control when her other FM symptoms were heightened.
This urinary urgency placed another demand on these women whose capacity
to manage yet another symptom was already extended beyond normal limits. The
fear of their urinary urgency extending to urge incontinence increased the stress on
the women.
When I have the urge to go, I get really stressed. When I am out and I am
in the car and I have to go home, it is like you just want to put the
accelerator right down and go through all the traffic lights because it is
really painful. I find that when you hold on, I find you are using all the
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muscles in your legs and your back. You are doing everything to hold on
and it is very painful. I don 't leak, but Ifind that I use every muscle in my
body and once I have gone, I am pretty wiped out. (Focus group 1 ,V)

One of the important treatment regimes for people with FM is to maintain
some form of exercise to increase endorphin levels, to maintain levels of aerobic
fitness and to maintain muscle integrity. This was hampered for some by their
urinary urgency. Walking was often restricted to parks and areas where public toilets
were available. Some experienced the need to stop and stand still and wait during
their walk to manage the urgency. Swimming is encouraged as an appropriate form
of exercise for people with FM because of the minimal weight-bearing impact when
exercising in water. For some of the women, their urgency was aggravated in these
situations because they experienced the need to void as soon as they entered the
water.
The frustration of repeat visits to their general medical practitioners for urine
cultures to check for urinary tract infections added to their list of medical
maintenance. The women felt that, because they were experiencing acute symptoms
of urinary urgency, frequency and discomfort, they therefore must have a urinary
tract infection.
I thought I must have had a bladder infection so I will go to my doctor.
He did two or three urine samples and came back with nothing,
completely clear. The problem just seemed to be getting worse and worse
and worse. I just felt I needed to go 100% of the time, all the time,
continuous. I could go to the toilet, go and sit in my seat and then feel as
though I needed to go straight back again. (Focus group 2, J)

The women were asked to respond to the ICSI/ICPI question on urinary
urgency: How often during the last month had they felt the strong urge to urinate
with little or no warning? Figure 8 displays the proportion of women with varying
urinary urgency. They were also asked how much needing to urinate without warning
over the past month had been a problem for them. Figure 9 depicts the response to
this question.
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ICSI Urinary Urgency
n = 10
Almost always
1.00

< than 1 time in 5
3.00

> than half the time
2.00

About half the time
1.00

< than half the time
3.00

Figure 8: Proportion of Women in the Focus Groups with Varying Urinary Urgency

ICPI Urinary Urgency
n = 10
Big problem

No problem
2.00

2.00

Medium problem
1.00

Very small problem
2.00

Small problem
3.00

Figure 9: Impact of Urinary Urgency on Women in the Focus Groups

The Impact ofNocturia
Nocturia refers to a person's need to wake at night one or more times to void
(Abrams et al., 2002a). Hetta (1999) comments that the importance of sleep can be
gauged by considering the consequences of insufficient sleep. Sleep deprivation has
a deleterious effect on frontal lobe functioning, impacting on concentration and
intellectual skills (Hetta, 1999). Hetta lists the effects of sleep deprivation as fatigue
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difficulties, reduction in creativity, mood alterations, muscle stiffness and an
increased risk of infections. Nocturia has a profound effect on a person's mental and
physical health. Jennum (2002) describes nocturia as an annoying and potentially
damaging symptom because it fragments sleep and may therefore result in adverse
consequences.
For women with FM, nocturia 1s more difficult to define. Coyne and
colleagues (2003) state that nocturia is not a benign symptom. This was certainly
evident from the participants in the focus groups. What factors cause these women to
get up at night to void more than the acceptable once per night after they have gone
to sleep? Is it the insomnia that is such a significant feature of FM that causes the
women to void many times during the night because they are awake for long
periods? Is it the musculoskeletal pain that wakes these women from sleep and, when
awake, they feel the need to go to the toilet? Is it the irritability of the bladder that
wakes women from sleep and results in nocturia? Or is it the anxiety about the
possibility that they may not sleep again that night that impacts on bladder
behaviour? The women in the focus groups who voided more than once during the
night were unsure of the reason they were up going to the toilet at night. Excerpts
from the focus groups demonstrate these issues.
But the worse thing is having the burning sensation and getting up so
many times at night. I feel as though I have got to go and when I go at
night time I get up many many times. (Focus group 1, F)
In winter, if the pain wakes me up I can't sleep because of the pain and
the combination of going to the toilet and the winter, I wake up more.
The pain is all over muscle pain .../ am just a wreck. In summer the pain
is not as bad. In summer it is the urge to go to the toilet that wakens me.
(Focus group 3, A)

If my sleep is not deep then it just niggles and niggles and niggles.

You
have just got to get up and go or else you won't go back to sleep. But I
think it might be the sleep in the first place. I don't know. (Focus group 3,
S)
Whatever the reason, the end result was disturbed sleep with increased

fatigue and increased pain the following day. Some of the women felt their nocturia
was a small problem because, although it was annoying, they could 'handle' it. For
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one woman, it was a small problem because she did not know what sleep meant. She
was grateful if she had three hours maximum sleep during a night. Others felt that
their bladder disturbed them because they were light sleepers. This deprivation of
restorative sleep in FM patients has a major impact on their sense of well being and
management of their symptoms.
I wake up every two hours. IfI have four hours of continuous sleep, I am
happy... Do !feel worn out and tired? Fancy asking me this? I couldn 't
say anything about if my bladder affects my sleep because I am awake
anyway. I definitely feel worn out and tired all the time. (Focus group 1,
T)
Tricyclic medications in doses lower than those used to treat depression are
often prescribed for women with FM to provide the benefits of reducing
sleeplessness and for pain management. The tricyclic medication can increase the
amount of delta wave sleep, improve the availability of serotonin to nerve cells and
enhance the effects of endorphins that can decrease pain (Wallace & Wallace, 1999).
The anticholinergic effects of the tricyclics also result in relaxation of the bladder,
decreasing the intensity of bladder contractions and deceasing frequency by delaying
the desire to urinate (Hanno, 1994a)
Four of the ten women in the focus groups were taking tricyclic medication
primarily for the relief of FM symptoms rather than for the bladder effects.
Medications for the treatment of the variety of symptoms of FM can impact
positively on the quality and amount of sleep with a resultant positive impact on the
bladder. These medications would probably be impacting positively on their bladder
irritability without the women necessarily being aware of this secondary effect. One
woman was medicated with ditropan, an anti-cholinergic drug used for urinary
frequency, urgency and incontinence.
I went to see my doctor about my sleep to get some tablets because I used
to be exactly like that until Ifound a GP who had chronic fatigue. That
was the first thing he said to me, ' We will get your sleep sorted out first
and then we will worry about everything afterwards '. It made such a
difference to my life, a huge difference. That was the big turning point for
me. (Focus group 3, A)
The women were asked to respond to the ICSI/ICPI question on nocturia :
How often during the last month had they most typically got up at night to urinate?
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Figure 10 displays the proportion of women with varying nocturia episodes. They
were also asked how much had getting up at night to urinate over the past month
been a problem for them. Figure 11 shows this impact of nocturia on the women in
the focus groups.

ICSI Nocturia
n = 10
4 Times
1.00

3 Times
1.00

2 Times

Once

2.00

6.00

Figure 10: Proportion of Women in the Focus Groups with Nocturia

ICPI Nocturia
n = 10
Medium problem
2.00

Big problem
1.00

No problem
1.00

Very small problem
6.00

Figure 11: The Impact of Nocturia on Women in the Focus Groups
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The Impact of Bladder Pain, Burning, Discomfort or Pressure
For the women in the focus groups, pain and discom fort in the bladder often
accompanied urinary urgency. This was described as a sharp pain or the burning
sensation 'that is always there'. For some women the bladder discomfort was worse
when their FM was ' flaring'. Pain from their musculoskeletal system seemed to be
reflected in their bladder symptoms. Some of the women described their bladder pain
as a cramping in the bladder itself.
All the gynaecologists kept telling me was to do more pelvic floor
exercises. Th ey said I was very weak in the area. The more pelvic floor
exercises I did, the more I got bladder cramps. The bladder cramps
became worse and I got chronic pain in that bladder area. It felt like a
ball moving inside me. The urges became greater to go to the toilet and
so forth. And they kept saying do more pelvic floor exercises, just keep
going, keep going and I just became so debilitated. It was like giving
childbirth again. The pain was so chronic in that area. (Focus group l ,V)
Pain was sometimes evident when the bladder was emptying or at the end of
a void. It was described as 'a pain that shoots up the bladder'. Some of the
participants described their bladder symptoms as a discomfort or pressure rather than
pain or burning. Some commented that their abdomens felt swollen.
For me the problem is not so much the burning or pain, but the
discomfort and the pressure. (Focus group 1 , F)
For others it was the burning sensation that accompanied u rinary urgency.
The women were often checked and rechecked for urinary tract infection for the
burning symptoms, but no abnormalities were detected. Not only did the descriptions
of the type of pain vary, but also the intensity of the bladder/pelvic pain differed with
each participant.
With pain, I suppose it depends on your personality. I mean it is quite
significant, but to me, it is a small problem because on the scale of things
(Focus group 2, All)
Yes, in the lower part of the abdomen just above this bone. Yes, it is a
feeling of um... at the beginning I thought it was inflammation so I got
checked and there was no infl.ammation, especially not being active
sexually. I have been checked through and through and there was no
inflammation. And it is getting worse. (Focus group 2, An)
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For some wom en, the bladder pain was just part of the whole spectrum of
body pain, just another sore part of the body. It was part of the larger problem and
was not singled out from the rest of the body pain.
The women were asked to respond to t he ICSI/IC PI question on bladder pain,
if, during the past month, t hey had experienced pain or burning in the bladder. Fi gure
12 depicts the proportion of women with varying bladder pain experiences. They
were also asked how much had burning, pain, discomfort or pressure in their bladder
been a problem for them over the past month. Figure 1 3 shows this impact of bladder
pain on the women in the focus groups.

ICS I Bladder Pain or Burni ng
n = 10
U s ually

Not at all

1 .00

1 . 00

Fairly often
1 .00

Almost alway s
2.00

A few times
5.00

Figure 12: Proportion of Women in the Focus Groups with Bladder
Pain/Burning/Pressure/Discomfort
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IC P I B ladder Burni ng , Pai n, Discomfort or P ressure
n = 10
Big problem
4.00

Very small problem
4.00

Small problem
2.00

Figure 13: Impact of Bladder Pain/Burning/Pressure/Discomfort on Women in the Focus
Groups

Stress Urinary Incontinence and Urge Urinary Incontinence
Stress urinary incontinence is the complaint of involuntary leakage on effort
or exertion or on sneezing or coughing (Abrams et al., 2002a). Urge unnary
incontinence is the complaint of involuntary leakage accompanied by, or
immediately preceded by, urgency (Abrams et al., 2002a). Although the literature
shows that urinary incontinence is not a major symptom for women diagnosed with
FM who experience bladder irritability, it is of interest to note the incidence of
incontinence within the focus groups.
Four of the ten women did not experience any stress urinary incontinence.
Three women experienced a little, two women experienced it moderately and one
woman experienced a lot. Three of the ten women did not experience any urge
urinary incontinence. Three women experienced it a little and four women
experienced it moderately. Data on the incidence of both stress and urge urinary
incontinence will be recorded from Phase II of this study.
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Vulvodynia

An unexpected cause of pain for the women in the focus group was the pain
associated with vulvodynia-like symptoms. The International Society for the Study
of Vulvovaginal Disease (National Vulvodynia Association, 2002b) defines
vulvodynia as chronic vulvar discomfort or pain, especially that characterised by
complaints of burning, stinging irritation or rawness of the female genitalia.
Julian (1997) recommends that vulvodynia needs to be managed as a pain
syndrome rather than as a pain secondary to an underlying disease or as a problem
with an obvious cure. Silver and Wallace (2002) describe vulvodynia as an
associated symptom of FM. Reed, Haefner, Punch, Roth Gorenflo and Gillespie
(2000) comment on the controversy in regard to the nature and etiology of
vulvodynia. They note the absence of abnormal dermatological physical findings, the
lack of infectious and allergy or oncologic aetiology in the genital region. Their
research findings determined that a primary psychological cause of vulvodynia was
not supported.
Within the focus groups, four of the ten participants experienced significant
vulvodynia symptoms.
My problems came more from the vulvodynia than the bladder. Real
burning pain of the vulva and I went from gynaecologist to gynaecologist
trying to find out what the problem was and they did swab upon swab
upon swab and found nothing ... They did biopsies of different areas. They
did it from the vulva, right up in the cervix and they always found chronic
inflammation, but no pathogens present. (Focus group 1, V)

The symptoms described included dyspareunia, burning pain of the vulva,
skin soreness, chaffing and irritation of the skin in the vulva! area. There were few
interventions offered that gave symptom relief.
Well, when I have intercourse is my main issue. It hurts during
intercourse and after intercourse although I am not so bad now, but I
used to puff up like a balloon and have to go and get iceblocks and pat
myself. (Focus groupl, E)

The women spoke of changes of sexual behaviour because of their pain and a
fear of increasing their pain. The dyspareunia combined with the urinary urgency that
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some of the women experienced with sexual intercourse affected their sexual
activity. One women described having sexual intercourse as 'something you paid for'
with pain over the next two or three days together with the added concern of
infections. Some chose to not be sexually active because 'between that and being
squeezed and touched being so painful I thought I don 't need this, leave me alone'
(Focus group 2, An). Another young woman spoke of her avoidance of a physical
relationship when she had other FM symptoms as well as vulvod ynia symptoms. She
commented that because she knows what it would feel like, it is not something she
would like to feel.
What happens with us is that I have only been remarried for three years
and my husband felt he was the cause of it so he was sort of reluctant to
initiate and then I would think 'what is wrong with me ' so we had some
trouble initially. We went and had a bit of a talk with the doctor and she
said, 'It is not you, it is her make up ' and that was embarrassing and
having to go to the toilet often (Focus group 1, E)
For the women who lived with partners, the centrality of their relationship
was very important. They were very aware of the need to consciously include their
husbands in aspects of their lives where and when energy allowed.
The vulvod ynia symptoms hampered their FM walking regime because of the
severe chaffing of the skin of the vulva and on the inside of their thighs. They wore
loose-fitting under garments or 'boxer' shorts to minimise the friction on the
perineum.
When it is really bad when I used to get that burning, even the edges of
my underwear would drive me crazy. I would want to pull at my pants
and relieve it. So that was really bad. (Focus group 1,E)
Vulvod ynia symptoms increased the demand on these women, not only by
having to endure more symptoms, but also having to seek out relief and treatment
strategies. This extra symptomatology increased the demand on their time and
energies. Some of the women consulted with different health professionals in their
attempt to find answers for and relief from the vulvod ynia type symptoms. A sexual
health practitioner who suggested that their symptoms might be part of a more
enveloping s yndrome first suggested a diagnosis of FM to two of the women. The
women had not connected their musculoskeletal symptomatology with the
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vulvodynia symptoms. Further consultations with rheumatologists confirmed a
dia gnosis of FM. Women did not think of their symptoms as being potentially
related. As well, some self-consciousness about their vulvodynia symptoms may
have limited their disclosure of the problem, as was expressed by the following
participant.
To me it stopped me going back to work so it has had a real impact for
me. Ifind it hard to talk about. Even in this group it has been difficult. It
is not easy. (Focus group 1, V)
Because of the vulvodynia-like symptoms experienced by the women with
FM in these focus groups, the Vulval Symptom Assessment (VSAS) (Appendix K)
was developed to collect data about this symptom in Phase II of this study. The
VSAS was developed as a two-part questionnaire to assess the incidence of
vulvodynia symptoms and the impact of these symptoms on women with FM.

The Impact of Urogenital Symptoms
The responses of the women in relation to their urogenital symptoms
reflected an guish, humour, frustration, embarrassment, resi gnation, determination
and acceptance. The impact of FM (Fi gure 5) was dramatically increased when
urogenital symptoms were present (Fi gure 14). These urogenital symptoms
encroached on the already restricted dimensions of their lives. One would expect
that, for many, this increased burden of sensitisation of the urogenital system would
be the final insult and result in self -absorption and self-pity.
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Figure 14: The Increased Tethering Effect and Impact of Non-Bladder and Urogenital
Symptoms on Women with FM, Depicting Illness in the Foreground

The urogenital symptoms encroached on an already restricted space in the
women's lives, increasing the demands on their patience, their capacity to experience
life and their significant relationships. This increased burden of sensitisation of the
urogenital system stretched the capacity of these women to re-evaluate their life
styles, to appreciate different things, to establish different goals and to reprioritise
aspects oflife as described by Morse (1997) in learning to live with their altered self.
The unpredictability ofbladder symptoms, combined with the randomness of
other FM symptoms, challenged the women daily in most of their roles. Their daily
roles had to be constantly reassessed and adapted to accommodate their bladder
symptomatology. One woman adapted to her severe urinary urgency and frequency
by 'working around the toilet' and, because there were two toilets in her house, she
could work at either end of the house! Another spoke of her learning to adapt to and
cope with her bladder symptoms and only then would she feel confident enough to
seek work outside of the home again. Others spoke of their symptoms with
acceptance and humour. One woman spoke of being able to turn on the lights of the
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city with the pressure that came from her bladder and, because of her
frequency/urgency, she was able to find a toilet by smell. Overall, the frustration of
always having to make allowances for their urogenital symptoms accentuated the
tethering effect of the already existing physical, emotional, social and psychological
impact of FM on their lives. The increased impingement on the self by the urogenital
symptomatology is diagrammatically represented in Figure 14.

Chronicity of Symptoms of FM
FM is not a life-threatening disease, but it is a quality of life threatening
disease. Data obtained from the three focus groups revealed the impact of the
chronicity of the symptoms and its impact on their quality of life. The
unpredictability and chronicity of the multitude of symptoms from FM constantly
challenged these women and their families. These women's experiences of living
with the chronicity of FM were multifaceted and enduring.
Paterson (2001) presents a shifting model of chronic illness, The Shifting
Perspectives Model of Chronic Illness. This model was derived from a metasynthesis
of qualitative research reported from the experiences of people with chronic illness.
The model suggests that living with a chronic illness is an ongoing and continually
shifting process where an illness-in-the-foreground or a wellness-in-the-foreground
perspective has specific functions in a person's world. Paterson (2001) describes the
illness-in-the-foreground perspective as a focus on the sickness, suffering, loss or
burden associated with living with chronic illness. She describes the wellness-in-the
foreground perspective as viewing the chronic illness as an opportunity for
meaningful change in relationships, a re-visioning of what is possible and normal.
These perspectives of chronic illness are not static.
This model of chronic illness framed many of the dynamics experienced by
the ten women in the focus groups. The women reflected this shifting perspectives
model of chronic illness. The pre-diagnostic phase and the immediate post-diagnostic
phase could be described as the illness-in-the-foreground perspective. Pre-diagnosis
the women knew they had a health problem, they sought numerous medical opinions,
but remained frustrated and in pain during this long phase without any diagnosis or
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resolution. On diagnosis, one woman spoke of being overwhelmed ' knowing there
was something new wrong with you' . Another woman spoke ofbeing wary and upset
when diagnosed. For some of the women, the diagnosis of FM was a relief, a
validation of their experiences of a multitude of symptoms experienced over many
years. One woman developed an instant wellness-in-the-foreground perspective,
seeking management strategies for her FM on the day ofdiagnosis.
I know that when I was diagnosed, on the way home my husband said to
me, 'The specialist said you should not work. So it would be better ifyou
didn 't '. And I said, 'Heyl Do you want it to control me or for me to
control it ' and that was the mind set that I took. I think the diagnosis was
such a huge relief It put it into some sort ofperspective. But ifyou said
to me on any given day, 'Are you without pain? ' Well the answer is no,
never but some days it is not even a conscious thought and then you have
other days where you just drag yourself through the day. So I think, I
really think that your mental attitude to it (Focus group 2, All)

A few women in the focus groups had stayed within the illness-in-the
foreground perspective where they focused on the illness, the pain, the loss and the
strain of living with a chronic illness. The diagnosis of FM for them was a negative
and destructive event resulting in absorption with their disabilities. This illness-in
the-foreground perspective (presented in Figure 14) shows the impact of FM
nonbladder, bladder and urogenital symptoms.
However, the majority of women in the focus groups were challenged by
their diagnosis and embraced a more wellness-in-the-foreground perspective in
coping with FM (Figure 15). Paterson (2001) describes this appraisal oftheir chronic
illness as an opportunity for change and for the woman to develop harmony between
her self-identity and the identity shaped by the illness. The majority ofthe women in
the focus groups portrayed this in a seeking, self-educating and inquiring mode.
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Figure 15: The Increased Tethering Effect and Impact of Non-Bladder and Urogenital
Symptoms in FM, Depicting Wellness in the Foreground

The emphasis on FM in the group discussions did frame and highlight the
reality of their condition at that time. For some, the emotions of maintaining such an
organised regime to maintain a 'normal' life surfaced via anger, fear, tears and
absolute fatigue. Paterson (2001 ) recognises this as a maj or paradox of living in the
wellness-in-the-foreground perspective. She reminds us that, through this wellness
in-the-foreground perspective, chronic illness is in the background but the
management of the illness is always in the foreground. The focus group discussions
and sharing of FM experiences and information brought the reality of living with FM
and its chronicity momentarily to the foreground for all of the participants.
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Conclusion
The findings from the focus groups of Phase I of this study have confirmed
that the key urinary symptoms and their impact for women diagnosed with FM who
experience bladder irritability are compatible with, and inclusive in, the ICSVICPI.
These sensory symptoms included urinary frequency, urinary urgency, nocturia and
bladder pain, burning, discomfort or pressure. This qualitative study has been
valuable in confirming these sensory symptoms of FM and directing the choice and
formation of questionnaires for data collection for Phase II of this research on FM
and bladder irritability. New relevant variables for the data collecting questionnaires
were identified as a result of the qualitative methodology of this first phase.
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'estimates of reliability based on the average correlation among items within a test'
(p. 251). A criterion of at least 0.70 was pre-set as the acceptable level for internal
consistency reliability (Nunnally & Bernstein, 1994). Internal consistency reliability
also involved assessment of item-to-total correlations with an expected value of
between 0.40 and 0.70 (Carmines & Zeller, 1979).

The Symptom Index
The Symptom Index (ICSI) achieved an internal consistency estimate, as
measured by Cronbach' s alpha coefficient, of 0.60. Item means ranged from 1.26
(s.d. = 1.1) to 3.26 (s.d. = 1.3). The possible range of scores was O to 5. The item
means, standard deviations and possible item scores for each item are shown in Table
3 (n = 90).
Table 3: The Symptom Index: Item Mean, Standard Deviation and Possible Score Ranges

Item Mean

s.d.

Possible Score
Ranges

1. Urinary Urgency

2.59

1.44

0-5

2. Urinary Frequency

3.26

1.34

0-5

3. Nocturia

2.58

1.32

0-5

4. Bladder Pain

1.26

1.10

0-4

Item

The overall mean score for the Symptom Index was 9.68 (s.d. = 3.52). The
possible range was O to 19. Item-to-total correlations ranged from 0.26 to 0.54. The
two items referring to nocturia and pain achieved lower item-to-total correlations,
contributing to the slightly lower Cronbach's alpha coefficient for this symptom
index.
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impact scores of urgency, frequency, nocturia and bladder pain. The overall mean
score for the combined Symptom and Problem Index was 19.01 (s.d. = 6.40). The
possible range was Oto 35. Item-to-total correlations ranged from 0.37 to 0.66. This
is within the acceptable range of 0.30 to 0.70 as specified by Carmines and Zeller
(1979).

Factor Analysis
For further validation of the ICSI/ICPI instrument within this FM population,
a factor analysis was undertaken to assess the internal structure of the scale. The
structure of the eight-item ICSI/ICPI scale was examined using Principal Component
Factor Analysis with Varimax Rotation. Pallant (2001) suggests that the larger the
sample size for factor analysis, the better. Nunnally and Bernstein (1994) recommend
ten cases for each item. Therefore, 90 cases were sufficient to assess the eight-item
scale. Pallant (2001) also recommends that, for a factor analysis, at least 50% of the
inter-item correlations should be greater than 0.30. The data met these criteria with
20 of the 28 inter-item correlations being above 0.30. Results of the Principal
Component Analysis revealed two components with eigenvalues greater than 1.00
(3.520 and 1.505). These two components explained a total of 62.82% of the
variance. The screeplot showed a distinct curve drop after the second component.
These two components were retained for further analysis.
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Table 5: Item and Factor Loadings> 0.40 and Explained Variance for Two Components Based
upon PCA Varimax Rotation.

Items

Factor Loading

Factor Loading

Component 1

Component2

ICPI Bladder burning, pain,
discomfort or pressure

.803

ICSI Bladder pain or burning

.782

ICSI Urinary urgency

.685

ICPI Urinary urgency

.684

ICPI Urinary frequency

.599

.507

ICSI Nocturia

.865

ICPI Nocturia

.802

ICSI Urinary frequency

.417

.648

% of Variance explained

34.32%

28.5%

The rotated solution revealed a pattern of interpretable loadings. According to
Kim and Mueller (1978), a factor loading should be greater than 0.40, and the
differences between factor loadings should be greater than 0.15 to be interpretable.
The symptoms of, and problems associated with, bladder pain, burning and
urinary urgency loaded on Component 1. The symptoms and problems of nocturia all
loaded on to Component 2. The symptom of urinary frequency also loaded on to
Component 2. The problem of urinary frequency loaded on both components with
the difference between the factor loadings being less than 0.15. This item was judged
to be more interpretable as a Component 2 item.
This pattern of loading of urinary symptoms and impact within the FM
population clearly displays two separate components of symptom and problem
combinations as distinct from the original ICSI/ICPI developed for the interstitial
cystitis population. These two components form the two subscales of the resultant
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study was to validate the ICSI/ICPI within the FM population, data was collected
using this Interstitial Cystitis instrument. The data collected was in response to these
ICSI/ICPI questions. The analysis of the data has produced a more specific
configuration of the eight questions of the original ICSI/ICPI index for the FM
population. Although the sensory urinary symptoms and impact are similar for both
the interstitial cystitis and FM populations, the ICSI/ICPI and the Fibromyalgia
Bladder Index represent each population more specifically.
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refers to the direction of the relationship and not the strength. Pallant (2001) cites
Cohen in suggesting the following guidelines in interpreting values of the strength of
the correlation between O and 1: r = 0.10 to 0.29 small; r = 0.30 to 0.49 medium; r =
0.50 to 0.10 large.
As shown in Table 10, there was a significant positive correlation between
the total Fibromyalgia Bladder Index with the total Kings Health Questionnaire.
Individual correlations between the Fibromyalgia Index and the individual Kings
Health Questionnaire's domains ranged from 0.351 to 0.615. There was a significant
positive correlation between both of the individual subscales of the Fibromyalgia
Bladder Index with the Kings Health Questionnaire and the Fibromyalgia Impact
Questionnaire. The correlation between the Urgency and Pain Subscale and the
Kings Health Questionnaire was not as high because the latter is designed more
specifically for incontinence rather than for the sensory bladder symptoms of pain
and urinary urgency. Individual correlations ranged from 0.136 (Kings Health
Questionnaire sleep and energy domain with the Urgency and Pain Subscale) to
0.663 (Kings Health Questionnaire bladder effects on life with the Frequency and
Nocturia Subscale).
Significant positive correlations were also evident between the Fibromyalgia
Bladder Index and the Fibromyalgia Impact Questionnaire (Table 10). There was
also a significant correlation between both of the individual subscales of the
Fibromyalgia Bladder Index and the Fibromyalgia Impact Questionnaire. Individual
correlations ranged from 0.198 (Fibromyalgia Impact Questionnaire question asking,
In the past week, how tense, nervous or anxious have you been? with the Frequency
and Nocturia Subscale) to 0.433 (Fibromyalgia Impact Questionnaire total score with
the total Fibromyalgia Index). Significant correlations were evident between the
Fibromyalgia Impact Questionnaire and all nine domains of the Kings Health
Questionnaire (r=0.352 to 0.589, p=0.002 to 0.000). These findings provide evidence
for the concurrent validity of the new instrument, the Fibromyalgia Bladder Index,
and confirm that it is not redundant in relation to the Kings Health Questionnaire.
In summary, this assessment has provided evidence that the Bladder Urgency
and Pain and the Bladder Frequency and Nocturia subscales yield reliable and valid
estimates for assessing the symptoms and impact of bladder symptoms for women
- 192 -

with FM. The index, consisting of two subscales, has demonstrated internal
consistency reliability, acceptable test-retest reliability and evidence of concurrent
validity.

Descriptive Statistics of the Sample Population

The following tables summarise the level of distress exhibited by this sample
population as measured by the new Fibromyalgia Bladder Index, the Kings Health
Questionnaire, the Fibromyalgia Impact Questionnaire, the SF-36 and the Vulval
Symptoms Assessment Scale.
Fibromyalgia Bladder Index
The Fibromyalgia Bladder Index comprises the Bladder Urgency and Pain
Subscale and the Bladder Frequency and Nocturia Subscale. In order to develop
meaningful total scores for these subscales, the items in the Fibromyalgia Bladder
Index were weighted because some of the items of the questionnaire were scored out
of four while others were scored out of five. Weighting was undertaken by
multiplying the five-answer questions by four, and the four-answer questions by five
to give an equal score out of 20 for each question. With four questions on each of the
two subscales, the highest possible score on each subscale is 80 (4 x 20) and 160 (8 x
20) on the combination of both subscales. Table 11 shows the frequencies of the two
individual and combined subscales of the Fibromyalgia Bladder Index.
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including FM. Table 17 compares the descriptive statistics for each SF-36 scale for
the following four studies: this current Australian FM study; Schlenk and colleagues'
(1998) FM participants in the chronic disorder population study (USA); the female
population norms for the SF-36 of Australia (Australian Bureau of Statistics, 1995);
and the female population norms for the SF-36 of the United States of America
(Ware et al., 2002).
It is of interest to note that the findings for the current Australian study on
FM and bladder irritability reveal a poorer state of health as shown by the SF-36
descriptors than in the other three studies. The item means for all eight SF-36
domains were lowest in the Australian FM population. The specific impact of the
urinary symptomatology measured in this current study may be greater because of
the verification of urological symptoms in this population. The small FM sample
used in the FM USA study and their less rigorous approach to the confirmation of
bladder symptomatology may also account for the lower level of quality-of-life
distress in the Australian population.
Table 17: Current FM Study Descriptors for the SF-36, Australian Female Population SF-36
Norms, United States of America Female Population SF-36 Norms, Descriptors for the
SF-36 FM Participants in Chronic Disorder Population Study (USA). Descriptive
Statistics: Sample Size, Item Mean, Standard Deviation and Possible Score Ranges

Domains
Physical F unctioning
(Q 3 a-j)

Role: Physical (Q 4 a-d)

Population

n

Item
Mean

s.d.

Possible
Score
Ranges

Current FM Study

88

45.40

24.05

0- 100

FM Study (USA)

18

61.67

24.01

0-100

81.1

24.3

0- 100

Australian Norms

97

USA Norms

1412

81.47

24.60

0- 100

Current FM Study

88

12.22

25.42

1-100

FM Study (USA)

18

38.89

37.60

1- 100

Australian Norms

9736

78.8

36

1-100

USA Norms

1412

77.77

36.2

1- 100
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The Vulval Symptom Assessment Scale
The Vulval Symptom Assessment Scale (VSAS) (Appendix K) was
developed specifically for this study following the findings from the Phase I focus
groups. Four of the ten women in the focus groups experienced moderate to severe
vulvodynia-like symptoms of dyspareunia, vulval pain, irritation, burning and
rawness. As there is no validated data-collecting tool for these symptoms within the
FM population, the VSAS was developed as an initial screening tool to gauge if
vulval symptoms were a significant problem in this population of women. The VSAS
consists of five questions on vulval symptoms and four questions on the impact of
these symptoms on quality of life. Possible score ranges are from O to 3 with the
higher score indicating a greater symptomatology and impact. The findings are
detailed in the following Table 18
Table 18: The Vulval Symptom Assessment Scale. Descriptive Statistics: Sample Size, Item
Mean, Standard Deviation and Possible Score Ranges

n

Item
Mean

s.d.

Possible
Score Ranges

• Burning

90

.72

.87

0-3

• Stinging

90

.63

.87

0-3

• Irritation

90

.92

.88

0-3

• Rawness

89

.67

.89

0-3

• Pain

89

.82

.90

0-3

• Daily activities

89

.49

.71

• Physical
activities

0-3

87

.46

.73

0-3

• Social activities

87

.31

.62

0-3

• Sexual activities

73

.71

.92

0-3

Domain
SYMPTOM

IMPACT
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Figure 19: Visual Summary of the Distribution of Vulval Symptoms
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Figure 20: Visual Summary of the Distribution ofVulval Symptom Impact

The relative sizes of the means and the standard deviations reflect the skewed
distribution followed by the VSAS items, with most subjects taking relatively low
values (0 or 1) on individual items and a smaller number taking appreciably higher
values (2, 3 or 4). Figure 19 and Figure 20 display the participants' scores on
vulvodynia-like symptoms and symptom impact respectively.
Factor analysis was undertaken to assess the internal structure of the scale.
The structure of the Vulval Symptom Assessment Scale (VSAS) was examined using
Principal Component Factor Analysis with V arimax Rotation. Results of the
Principal Component Analysis (Table 19) revealed two components with eigenvalues
greater than 1.00 (5.937 and 1.089). These two components explained a total of
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Figure 21: Plot of Participants' Scores on Both VSAS Factors

A plot of the subject scores on the two VSAS factors presents an integrated
picture of the distribution of the subjects in the context of the levels of their vulva!
symptoms and vulva! problems, and confirms the skewed patterns noted at the
individual VSAS item levels. For both vulva! symptoms and vulva! problems, the
majority of subjects clusters at relatively low levels with a smaller number exhibiting
dramatically higher symptom and vulva! problem experiences. Factor scores are
scored so that the mean level takes the value zero. The higher the score, the higher
the levels of symptoms or symptom impact/problem the patient experiences. A score
of+3 on the problem factor is someone who is experiencing a lot of problems while
a score of -1 on the problem factor is someone who is experiencing very few
problems.
To confirm that the items measured by the VSAS constituted a separate
construct and were not included in the FBI, correlations amongst the Fibromyalgia
Bladder Index subscales and the Vulval Symptom and Vulval Impact Scales were
analysed. Only one of the correlations was significant. The correlation between the
Fibromyalgia Bladder Index Subscale of Urgency and Pain and the Vulval Impact
score was significant, although relatively modest in magnitude (r = 0.331, p = 0
.005). None of the other correlations was significant. This suggests that the separate
assessment of vulval symptoms and their impact is important and distinct, and
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therefore it cannot be assumed that these vulval symptoms are encapsulated within
the Fibromyalgia Bladder Index.

Predictive Ability of Urinary Symptoms and Problems on the Fibromyalgia
Bladder Index
Hassard (1991) explains regression analysis as an elegant and informative
way of testing the possible existence of, and describing a relationship between, a
dependent variable and one or more explanatory or independent variables. For this
study, it provides a technique for examining the possibility of the women's
demographic and health profile characteristics having an influence on their
Fibromyalgia Bladder Index scores and providing some insight into the possible
predictive values of these independent variables. The aim of the multiple regression
here is to determine which of the independent variables have a genuine relationship
with either of the subscales of the Fibromyalgia Bladder Index and to determine the
strength and nature of the relationship (Hassard, 1991).
Is it possible that some of the independent variables can predict the women in
this study who scored highly on the Urgency and Pain Subscale and the Frequency
and Nocturia Subscale? How well can these variables predict a particular outcome
and which variables in the set of variables is the best predictor of the outcome
(Pallant, 2001)? What variables are the predictors of pain/urgency and
frequency/nocturia in this FM population?
Variables from the Fibromyalgia Impact Questionnaire, the Kings Health
Questionnaire, The SF-36 Health Survey, the Vulval Symptom Assessment Scale,
the participants' age and the number of years since self-diagnosis of FM from the
demographic questionnaire were all entered into a forward stepwise multiple
regression as independent variables. Tables 20 and 21 show the results of this
analysis for the Pain and Urgency Subscale while Tables 22 and 23 show the results
from the analysis for the Frequency and Nocturia Subscale.
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Table 20: Regression Analysis: Pain and Urgency Subscale. Variables Entered

Step

Variables Entered

1.

Kings Health Questionnaire. Total Score for Emotions:

2.

SF-36 Questionnaire. Total Score for General Health Questions:

Table 21: Regression Analysis: Pain and Urgency Subscale. Model Summary

R

R Square

F

df.

p

1.

.466a

.217

24.384

1,88

p= 0.000

2.

.525b

.276

16.570

2,87

p= 0.000

Step

a.

Predictors: Kings Health Questionnaire. Total Score of Emotions

b.

Predictors: Kings Health Questionnaire Total Score of Emotions, SF-36 Questionnaire general
health questions 1 + 1 l a+ I lb+ 1 l c+ 1 l d

The Kings Health Questionnaire score from the emotions domain enters on
the first step and explains 21% of the variance in the Urgency and Pain Subscale.
The Total Score for this emotions domain is a composite of the three individual
questions: 'Does your bladder problem make you feel depressed?'; 'Does your
bladder problem make you feel anxious or nervous?'; and 'Does your bladder
problem make you feel bad about yourself?'
The MOS SF-36 Health Survey general health questions enters on the second
step in a negative relationship with the outcome and explains an additional 5.9% of
the variance, for a total of 27.6% of the variance in the Urgency and Pain Subscale
explained. The total score for the MOS SF-36 general health questions is a composite
of the individual questions: 'In general, would you say your health is excellent, very
good, good, fair, or poor?'; 'I seem to get sick a little easier than other people:
definitely true, mostly true, don't know, mostly false, definitely false?'; 'I am as
healthy as anyone I know: definitely true, mostly true, don't know, mostly false,
definitely false?'; 'I expect my health to get worse: definitely true, mostly true, don't
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know, mostly false, definitely false?'; 'My health is excellent: definitely true, mostly
true, don't know, mostly false, definitely false?'
Both predictors in this model achieved statistical significance (p = 0.000).
Once these predictors had been entered into the model, no other explanatory
variables achieved statistical significance.
In summary, the Kings Health Questionnaire emotional domain (Do bladder
problems make one feel depressed, nervous, anxious or bad about oneself?) is highly
predictive of a woman's score on the Pain and Urgency Subscale. The greater the
feelings of depression, anxiety and lack of self worth, the higher the subscale score.
The MOS SF-36 Health Survey general health questions score is also highly
predictive of the score on the Pain and Urgency Subscale, with a low MOS SF-36
general health questions score being predictive of a high Pain and Urgency score.
The poorer the subjects' perceptions of their current health status, and the more
negative their perceptions of their future health prospects, the higher their Pain and
Urgency score is likely to be.
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problem affect your physical activities (eg going for a walk, run, sport, gym etc)?'
and 'Does your bladder problem affect your ability to travel?' All three predictors in
this model achieved statistical significance (p = 0.000). No other explanatory
variables achieved statistical significance.
In summary, the Kings Health Questionnaire question (How much do you
think your bladder problem affects your life?) is highly predictive of a woman's
score on the Frequency and Nocturia Subscale, with the larger the effect on one's
life, the higher one's score on the Frequency and Nocturia Subscale. The impact of
the bladder on sleep and tiredness, as measured by the Kings Health Questionnaire
sleep/energy score, is also highly predictive of a woman's score on this second
subscale, with the greater the sleep effects and fatigue, the greater the score on
frequency and nocturia. In addition, the more extensive the physical limitations from
her bladder problems, the higher a woman's score on the Frequency and Nocturia
Subscale is likely to be.
In order to clarify the relationship between the predictors (and, more
specifically, the individual questions on which these composite predictor scores were
based) and the Bladder Pain and Urgency Subscale, the 25% of the sample reporting
the highest subscale scores and the 25% of the sample reporting the lowest subscale
scores were identified. The top quartile reported Pain and Urgency scores of 52 or
greater (out of a possible range of 0-80), while the bottom quartile reported Pain and
Urgency scores of 23 or less.
Table 24 shows the predictor variable characteristics of the 25 subjects
reporting Pain and Urgency scores> 51. Note that a high score on the Kings Health
Questionnaire (KHQ): Emotions (Items 1-3) indicates a greater impact on emotional
health while, for the MOS SF-36 General Health Survey Questions (Items 4-8), a
high score indicates better health perceptions.
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Table 24: Impact of the Highest 25% of Scores (score> 51) on the Predictors of the Bladder
Urgency and Pain Subscale. Item Mean, Median, Standard Deviation and Possible
Score Ranges

n
Valid

n
Missing

Item
Mean

Median

s.d.

Possible
Score
Ranges

Does your bladder problem
make you feel depressed?
(KHQ)

25

0

2.36

2.00

.95

1-4

Does your bladder problem
make you feel anxious or
nervous? (KHQ)

25

0

2.56

2.00

.87

1-4

Does your bladder problem
make you feel bad about
yourself? (KHQ)

25

0

2.20

2.00

1.12

1-4

In general would you say
your health is excellent,
very good, good, fair, or
poor? (SF-36)

25

0

2.12

2.00

.87

1- 5

How true or false is this
statement for you? I seem
to get sick a little easier
than other people. (SF-36)

25

0

2.40

2.00

1.35

1-5

How true or false is this
statement for you? I am as
healthy as anyone I know.
(SF-36)

25

0

2.24

2.00

1.20

1-5

How true or false is this
statement for you? I expect
my health to get worse.
(SF-36)

25

0

2.56

3.00

.92

1-5

How true or false is this
statement for you? My
health is excellent. (SF36)

25

0

1.88

2.00

.97

1- 5

Item
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In summary, the Kings Health Questionnaire emotional domain questions on
the bladder problem making one feel depressed, nervous, anxious or bad about
oneself predicts a high score on the Pain and Urgency Subscale. The differences of
the item means of the three emotional domain questions indicate the different levels
of impact for the highest 25% (Table 24) and the lowest 25% (Table 25) of the scores
of the women: the higher the score, the greater the impact. For the MOS SF-36
Health Survey general health questions, a higher score indicates a better health state.
This is reflected in the item means of these five items. A low score on the SF-36
general health questions predicts a high score on the Pain and Urgency Subscale. The
differences of the item means of the five general health questions of the SF-36
indicate the different levels of impact for the highest 25% (Table 24) and the lowest
25% (Table 25).
In order to also clarify the relationship between the predictors (and, more
specifically, the individual questions on which these composite predictor scores were
based) and the Frequency and Nocturia subscale, the 25% of the sample reporting the
highest subscale scores and the 25% of the sample reporting the lowest subscale
scores were also identified. The top quartile reported Frequency and Nocturia scores
of >57 (out of a possible range of 0-80) while the bottom quartile reported Frequency
and Nocturia scores of< 36.
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CHAPTER 7

DISCUSSION: PHASE II

Introduction

Within the area of instrument development, Waltz, Strickland and Lenz
(1991) suggest that it is possible to identify an already existing instrument that is
acceptable. They state that such an existing instrument may need to be modified and
imply that modifying an existing instrument is usually more efficient than developing
a new instrument. Such modifications do result in a new instrument and therefore the
psychometric properties of the new instrument must be re-evaluated. This was the
situation for this current study.
Phase II of this study involved the testing of the ICSI/ICPI instrument for
reliability and validation within the female FM population. Prior to this current
study, there was no valid and reliable measure for gauging sensory urinary symptoms
within the female FM population. This is the first study to modify and validate such
an instrument for women with FM. The aim of Phase II of this study was to validate
an existing instrument for FM patients that had been developed and validated for
urinary symptoms and impact within the interstitial cystitis population. This
ICSI/ICPI was identified as appropriate for the FM population for a number of
reasons, firstly, because of the genitourinary symptoms of women with FM and
secondly because of the similarity of these symptoms to those experienced by
women with interstitial cystitis. Rationale for the development of this instrument was
also based on Clauw and colleagues' (1997a) work that suggests the possible
involvement of the central nervous system mechanisms that contribute to the
pathogenesis of FM may be operative in IC.
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This current research has revealed two separate components of urinary
symptom and urinary problem combinations within the FM population that are
distinct from the original ICSI/ICPI developed for the interstitial cystitis population.
These two separate components form the two subscales of the newly developed
Fibromyalgia Bladder Index.

The Fibromyalgia Bladder Index
Munro, Visintainer and Page (1986) describe factor analysis as a tool that
enables the study of variables in groupings that are not obvious, a method of
reducing data so it can be easily described and used as an aid in instrument
development. They describe factor analysis as the most important statistical tool for
validating the structure of new instruments
Factor analysis was undertaken to assess the internal structure of the
ICSI/ICPI using Principal Component Factor Analysis with Varimax Rotation. The
factor analysis resulted in two components that formed the two subscales of the
newly developed Fibromyalgia Bladder Index. The difference between the symptom
and impact combinations of the ICSI/ICPI index and the Fibromyalgia Bladder Index
are very relevant to the Fibromyalgia population.
Whereas the ICSI/ICPI consisted of two subscales, one of the symptom index
and one of the problem index, results from this study suggest that the items are better
grouped for the Fibromyalgia Bladder Index subscales as a combination of both
symptoms and problems. This instrument therefore more appropriately measures a
different grouping of bladder symptoms and symptom impact from the ICSI/ICPI for
the FM population. Psychometric testing of this structure confirms that this is the
most valid and reliable measurement framework for the FM population.

Bladder Urgency and Pain Subscale
The first subscale of the Fibromyalgia Bladder Index is the Bladder Urgency
and Pain Subscale that consists of the symptoms of bladder urgency and bladder pain
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or burning, and the problems that bladder urgency and bladder pam, burning,
discomfort or pressure present. Urgency is the complaint of a sudden compelling
desire to pass urine that is difficult to defer and the increased bladder sensation is like
an early and persistent desire to void (Abrams et al., 2002a). For women with urinary
urgency, the urge to void is often compounded by the discomfort and pain resulting
from these inappropriate and urgent detrusor contractions. Bladder pain is felt
suprapubically or retropubically, usually increasing with bladder filling, and may
persist after voiding (Abrams et al. , 2002a). The anxiety and fear of urge
incontinence further compounds the impact of urinary urgency and pain.

Bladder Frequency and Nocturia Subscale
The second subscale of the Fibromyalgia Bladder Index is the Bladder
Frequency and Nocturia Subscale. Bladder frequency during the day is the complaint
by the patient who considers that she voids too often (Abrams et al. , 2002a). It can be
aggravated by urinary urgency and can result in a decrease in bladder capacity. This
can exacerbate nocturia, when the woman wakes at night one or more times to void
(Abrams et al., 2002a). For women with FM and nocturia, it is difficult to
differentiate between the impact of FM on their bladder and the impact of their
bladder on FM. One study of nocturia in community-dwelling women in the United
Kingdom (Middlelkoop et al. , 1996) has shown the overall prevalence of nocturia in
women over 19 years to be 18% and that 63% of these women experienced the
nocturia as bothersome. Of the women with FM in this current study, nocturia (2 or
>2 micturitions per night) was experienced by 77% of the participants. Of the women
who experienced nocturia, 55% reported that this symptom was a medium or big
problem for them.
Insomnia, often described as the deprivation of restorative sleep, is a major
problem for FM sufferers. How much of an impact does the insomnia have on the
urinary frequency? Is it a behavioural response of 'if I go to the toilet again I may be
able to go to sleep?' or is it the effect of FM irritability of the bladder that results in
the increased voiding? As one participant mentioned, 'My frequency does not stop
just because the sun sets!' Whatever the answer, frequency and nocturia are
intrinsically linked.
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The Fibromyalgia Bladder Index therefore measures the two most relevant
groupings of variables that impact on women with FM who experience bladder
irritability. This condition-specific instrument is more specific and precise than the
ICSI/ICPI for the FM population. As indicated above, it specifically reflects the
reality of symptoms and symptom impact of bladder irritability for women with FM.

Reliability and Validity of the Fibromyalgia Bladder Index
Following the development of the Fibromyalgia Bladder Index, the
psychometric properties of this new instrument were evaluated. Central to all
measurement is a determination of the reliability of the measurement method.
Portney and Watkins (1993) describe reliability as the extent that a measurement is
consistent and free from error and describe a reliable instrument as one that performs
with predictable consistency under set conditions. These authors also state that
reliability is fundamental to clinical research because without it therapists cannot
have confidence in collected data or draw rational conclusions from it.
The two indicators used to ensure reliability for the Fibromyalgia Bladder
Index were internal consistency reliability measured by Cronbach's alpha coefficient,
and test-retest reliability. The interpretation of reliability coefficients depends on
their proximity to the value of 1. Portney and Watkins (1993) state that a coefficient
below 0.50 represents poor reliability, coefficients from 0.50 to 0.75 a moderate
reliability and values above 0. 75 are indicative of good reliability. On this
interpretation, the Fibromyalgia Bladder Index Bladder Urgency and Pain Subscale
achieved good reliability with an internal consistency estimate as measured by
Cronbach's alpha coefficient of 0. 76. The second subscale, the Bladder Frequency
and Nocturia Subscale also achieved good reliability with an internal consistency
estimate as measured by Cronbach's coefficient of 0. 76.
Test-retest reliability assessment establishes that an instrument is capable of
measuring a variable with consistency (L. Portney & Watkins, 2000). The intraclass
correlation coefficient was used in this study to analyse test-retest reliability.
Administering the index to the same study sample at two intervals, two weeks apart,
and then correlating the scores from both administrations of the same test completed
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this assessment. Although it was the ICSI/ICPI that was administered, the items of
both subscales are exactly the same as those of the Fibromyalgia Bladder Index. The
test-retest of the combined subscales of the Fibromyalgia Bladder Index showed a
high correlation of 0.85, indicating a reliable scale. The test-retest correlations for the
subscales of 0.84 for the Urgency and Pain Subscale and 0. 79 for the Frequency and
Nocturia subscales confirmed that the individual subscales are also highly reliable.
Following the reliability testing of the Fibromyalgia Bladder Index, it was
important to test its validity by examining the simple correlations between it and
other similar instruments. Criterion-related validity was tested as concurrent validity
by measuring the correlation of the Fibromyalgia Bladder Index with established
validated measures. The Fibromyalgia Bladder Index was compared with the 'gold
standard' urinary Kings Health Questionnaire and the Fibromyalgia Impact
Questionnaire. Eighty-three women completed all three questionnaires. The
concurrent validity of the Fibromyalgia Bladder Index was confirmed against both of
these validated questionnaires with significant positive correlations.

Participants' Characteristics
The descriptive statistics of this study were used to summarise the stories of
bladder irritability of these women diagnosed with FM. Approximately 80% of the
women were between the ages of 30 and 60 years. Littlejohn (1996) states that FM
can occur at any age, being frequent in adolescent females, reaching its main
prevalence in the 30- to 40-year age group, but also common in the elderly. At the
age extremes of this study population, approximately 5% of the participants were
aged between 24 and 30 years, while approximately 14% of the women were aged
between 61 and 65 years.
The majority of participants (62.2%) were either married or in a relationship
and all but 15% of the participants had children. The demographic information
revealed that approximately 50% of participants were well educated, with tertiary
qualifications. Many referred to themselves as 'high achievers' in their chosen
careers. However, only 21. 1% were currently working in their professional capacity.
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The main health concerns of the participants reflected the known impact of
FM on other organ systems of the body. Participants' main health concerns involved
symptoms from the musculoskeletal system (47.8%), the neurological system
(33. 3%), and the digestive system (33.3%). Many of these symptoms were managed
pharmacologically, with 65% of participants taking medication for central nervous
system impact (mainly tricyclics and selective serotonin reuptake inhibitors for pain
and sleep enhancement), 40% for musculoskeletal dysfunction, 22% for other pain
medication and 17.8% for gastrointestinal dysfunction.
Approximately 35% of the participants were using some form of hormone
replacement therapy. This may have been an artefact of the age range of the
participants because approximately 90% of the participants were over the age of 40.
Further studies could consider the possible implications and symptom differences
between women who were and those who were not taking hormone replacement.
Surgical histories showed a significant number of the participants had
undergone a hysterectomy (47.8%), other gynaecological surgery (41. 1%) and
gastrointestinal surgery (32.2%). In relation to urological symptomatology, it is
interesting to note that the high hysterectomy and other reproductive organ surgery
rate may be suggestive of gynaecological surgery increasing sensitisation within the
pelvic region. Does the increased rate of pelvic surgery indicate a predisposition or
vulnerability by these women to increased visceral nociception and/or pelvic
symptomatology, or is the surgical intervention itself part of the etiology and an
aggravating factor of continuing symptomatology? Further studies considering the
pre-surgical histories of the women could give some indication.
The high hysterectomy and other reproductive organ surgery rate and the high
education level within this sample may possibly represent a selection bias. However,
a comparison of this study's data with published results with similar populations
using the FIQ, KHQ and SF-36 indicate that, for these well-validated indicators, the
results are similar.
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Impact of Bladder Irritability and Fibromyalgia on Participants

Responses from the Kings Health Questionnaire indicated that many of the
women in this FM population reported that their health was fair, and that their
bladder problem affected their life in a small to moderate way. The higher score on
the Kings Health Questionnaire indicated a greater impairment of quality of life. The
six domains of the questionnaire referred to the effects of their bladder on aspects of
their lives. Responses to questions about their role and physical limitations resulting
from bladder concerns ranged mainly from not at all to slightly. It is important to
note that the majority of people diagnosed with FM have many and varied symptoms
that impact on their activities of daily living, bladder symptoms being only one of
these (Littlejohn, 1996). Few women experienced social or personal relationship
limitations because of their bladder. The majority of women responded that their
bladder problem affected their sleep and they were worn out and tired. Sleep
disturbance affects 75% of people with FM (Merskey & Bogduk, 1994), resulting in
unrefreshed sleep and tiredness on waking. This again raises the question as to
whether it is this FM sleep dysfunction, the nocturia or a combination of both that is
having the greatest impact on the energy and fatigue levels of women with FM and
bladder symptomatology.
The Fibromyalgia Impact Questionnaire data also elucidated the experience
of the women with FM and bladder irritability. For many women with bladder
irritability who do not have FM, the impact on their quality of life has been well
documented. Pinnock and Marshall (1997) have shown that the impact of lower
urinary tract symptoms on quality of life in an Australian community is a major
reason for people seeking medical help. Data from this current study on FM and the
irritable bladder reveals the added burden and subsequent stress placed on these
women who cope with the other multi-factorial symptomatology of FM as well as
bladder symptoms. A high score on the FIQ reflected a greater impact on the health
status of the woman.
Physical impairment on the FIQ was minimal for this population. This was
because the FIQ assesses more the activities of daily living rather than activities such
as running or lifting heavy objects as assessed in the SF-36 Questionnaire.
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Depression and anxiety were the next lowest scores in this population. Although the
FIQ is not a validated measure for depression, the questions of how tense or nervous
they felt or how depressed or blue they were did indicate the participants' personal
sense of mental well-being at the time. These findings are of interest against the
backdrop of recent findings by Giesecke and colleagues (2003) whose data supported
the clinical notion that there are distinct subgroups of patients with FM. Three FM
groups were described by the authors as patients who experience extreme tenderness
with no associated psychological or cognitive aspect, an intermediate group who
exhibit moderate tenderness and experience normal mood, and the third group in
whom mood and cognitive aspects can be instrumental and influential in symptom
reporting. In this current study, pain, stiffness and fatigue combined with 'waking
very tired and non-rested in the mornings' placed an almost suffocating burden on
the women. The mean total FIQ score for this study was similar to other studies
revealing the impact of FM (Table 14).
The MOS SF-36 Health Survey data measured the participants' personal
perceptions of eight health domains that impacted on their quality of life. Higher
scores on the SF-36 reflect a minimal impact on health status while low scores
signify a greater level of impact. Results on the mental health indicators of the SF-36
were consistent with results from the FIQ. Mental health status of the participants
was in the moderate range with a mean score of 57.38 within a possible score range
of 1-100. These findings are in contrast to previous reports of depression and
inability to cope with life stressors in FM suffers. Although the SF-36 is not a
validated measure for depression, it describes whether the people were nervous,
whether they were so down in the dumps that nothing could cheer them up, whether
they felt calm or peaceful and whether they felt down, or if they were happy people.
The FIQ and the SF-36 are not diagnostic tools for depression, but rather screening
tools that indicate potential levels of psychological distress. Low scoring for role
limitations due to emotional problems impacted on the amount of time the women
spent at work and other regular daily activities, on the amount they accomplished
during work or daily activities, and on how carefully they did these activities. Low
scoring on the bodily pain and vitality domains reflected the levels of pain and the
chronicity of symptoms typical of FM.
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Responses to the SF-36 indicated that the greatest negative impact from FM
was in the physical role domain where the participants had to cut down on time at
work, accomplished less, and were limited in their work and activities because of
their physical health. These effects of physical health on role performance together
with vitality and bodily pain were rated as having the most negative impact.
This was confirmed in the comparisons with Australian and United States of
America population norms for the SF-36. The comparisons of the means of the SF36 domains from this study with that of the Australian population female norms and
the United States of America female norms (Table 17) truly reflects the enormous
impact on the quality of life for the Australian women with FM. The scores of the
women in this study were significantly lower in all SF-36 domains than those of the
Australian and United States SF-36 normative data for females.

The Vulval Symptom Assessment Scale
The Vulval Symptoms Assessment Scale (VSAS) developed specifically for
this study has shown that vulvodynia-type symptoms of vulval irritation, vulva! pain,
vulval burning, vulval rawness and vulval stinging are a reality for many women
with FM who experience bladder irritability. The symptoms and symptom impact
experienced ranged from a little to a lot, with 50% (45) of the women experiencing
some vulval burning, 43% (39) with some vulval stinging, 65% (59) with some
vulval irritation, 46% (41) with some vulval rawness and 57% (51) with some vulval
pain. These vulval symptoms affected 37% (34) of the women in their daily
activities, 33% (29) in their physical activities, 24% (21) in their social life and 46%
(34) in their sexual activities. The inclusion of the VSAS in this study has revealed
some significant vulval symptoms.
The VSAS was developed in response to the significant impact that vulval
symptoms had on four of the ten women in the Phase I focus groups of this study.
The focus groups were held to ensure all relevant information would be considered in
the development of, or validation of, an existing instrument for bladder sensitivity
issues within the FM population. The qualitative approach of the focus group has
contributed to the quantitative findings of this Phase II of the study by identifying the
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need for data collection on vulva} symptoms and their impact within this population.
The findings from the VSAS in Phase II of the study confirmed the presence of
vulva} symptoms and their associated impact within this FM population.
Factor analysis was undertaken to assess the structure of the VSAS scale. The
analysis displayed two factors, the vulva} symptom factor and the vulva} impact
factor. These were correlated with the two subscales of the Fibromyalgia Bladder
Index (FBI). The findings displayed the VSAS as a separate construct, not included
in the FBI. Only one significant and relatively modest correlation was found. This
suggests that the separate assessment of vulva} symptoms and their impact on women
with FM is important in urogenital appraisals for these women. The VSAS data
collection results have also highlighted that the impact of vulva} symptoms
contributes to the distress of women already coping with FM and bladder irritability.
The vulva} factor scores illustrate that distinctive subgroups of vulva}
symptom experiences and vulva} impact/problem experiences are present in this
study group. Further examination of the nature of these distinct experiences could
form the basis for further research, perhaps through analysis by cluster and
discriminant analysis techniques. In particular, the apparent presence of a subgroup
of women who experience high levels of vulval problems while experiencing
relatively low levels of vulval symptoms raises questions about the nature of the
differences between these women and the subgroup of women who, while
experiencing similar levels of vulva} symptoms, experience much lower levels of
vulval problems.
Perhaps the difference between vulvodynia and dyspareunia as described
below by Graziottin (2004) accounts for this as the VSAS data collection instrument
for vulva} symptoms and problems did not distinguish between vulvodynia and
dyspareunia. A recent presentation by Graziottin (2004) describes the results of a
critical review of the literature on sexual pain disorders and vulvodynia. He describes
vulvodynia as a pain disorder which may be a predisposing factor to dyspareunia
while dyspareunia is described as a sexual pain disorder. Graziottin describes the two
conditions as etiologically different and suggests that, although they do interact and
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overlap, the conditions should be kept separate from the diagnostic and treatment
perspectives.
Mcinnes (2003) reminds us that sex is an important contributor to the quality
of life for many patients with chronic illness and their partners. She emphasises that
the effects of chronic illness on sexuality are multi-factorial and that they impact on
all phases of the sexual response. She describes sex for someone whose life is
restricted by chronic disease as a powerful source of comfort, pleasure and intimacy
where a satisfying sex life can allow one to feel normal when so much else in life has
changed.
Graziottin and colleagues (2004) have also shown that the overactive bladder
symptoms of urgency, frequency and nocturia have a significant impact on quality of
life and sexual activity and can affect sexual identity, sexual function and sexual
relationships. The authors acknowledge that the combination of silence where the
patient is too embarrassed to disclose symptoms and the physician is sometimes too
busy to ask often results in the under diagnosis and under treatment of these urinary
symptoms. According to the epidemiologic survey by Laumann and colleagues
(1999), the presence of urinary tract symptoms appears to impact on sexual function.
The analysis of sexual dysfunctions by risk factors in women shows that urinary tract
symptoms have a risk ratio of 4. 02 (2. 75-5. 89) of being associated with arousal
disorders and a risk ratio of 7. 61 ( 4. 06-14.26) of being associated with sexual pain
disorders. Because of the strong association between sexual dysfunction and quality
of life, Laumann and colleagues (1999) recommend that sexual dysfunction be
recognised as a significant public health concern.
Wesselmann (2004) confirms that vulvodynia has detrimental effects on the
sexual life of women and their sexual partners. She notes that some patients with
vulvodynia also describe additional pain syndromes, including gastrointestinal,
pelvic and chronic somatic pain, have been confirmed by epidemiological studies,
suggesting generalised alterations in pain modulation mechanisms in women with
vulvodynia. A study by Foster (2004) on the effects of capsaicin injections in normal
and vulvodynia-afflicted women has shown the pain response of the vulvodynia
group of women extended far beyond the anatomic location of the primary injection
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site and they experienced greater spontaneous pam and allodynia. The author
suggests this as possibly indicative of a central sensitisation state, as cutaneous
response to capsaicin has been proposed as an assessment tool for central
sensitisation.
Further research in this area could focus on the development and validation of
a vulval symptom and impact instrument, measuring the impact that these vulval
symptoms have on sexual response, sexual satisfaction, sexual health and sexual
activities for women in this population. Glazer ( 1999) comments on the lack of an
interdisciplinary approach to the management of vulvovaginal pain disorders. He
lists the overlapping specialities treating these conditions as pain management,
gynaecology, dermatology, urology, gastroenterology, rheumatology, pathology,
neurophysiology and sex therapy. The development of a validated vulval symptom
assessment scale as an outcome measure specific to the FM population may promote
a more focused treatment regime.
The data from this study combined with many individual vocal stories from
the ninety women participants. Together they revealed a constellation of feelings of
helplessness in understanding and managing their varied pelvic symptoms, distress at
the impact of their symptoms and frustration at not finding 'bladder and/or pelvic
pain and discomfort solutions'.

Is there a Clinical Definition for Bladder Irritability in Women with
Fibromyalgia?

The development of the Fibromyalgia Bladder Index as a validated
instrument for measuring sensory symptom and impact within the FM population is a
start to the understanding and the documentation of the urinary issues experienced by
these women. Although this research commenced with the intention of validating the
ICSI/ICPI within the FM population, a more condition-specific instrument for the
FM population has been developed. This research specifies two distinct areas of
symptom/impact in the two subscales, one of urinary urgency and pain, the Urgency
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and Pain Subscale, and the other of urinary frequency and nocturia, the Frequency
and Nocturia Subscale.
These two subscales identifying these distinct components have clinical
implications. The question arises as to whether the Bladder Urgency and Pain
Subscale reflects the disorder of pain amplification due to the increased sensitivity of
the pain system for women with FM. Is this a chain phenomenon of sensory pain
and/or increased bladder sensation resulting in increased urgency, resulting in
increased frequency? Does the Bladder Frequency and Nocturia Subscale indicate
increased bladder irritability resulting in increased frequency and smaller bladder
capacity? Or are we looking at sleep deprivation where night becomes day in
urological terms, resulting in night time frequency rather than nocturia? These
questions are difficult to answer because of the multiple symptomatology, the
enigm atic nature of the function and innervation of the bladder wall, and the severe
implications of a lack of sleep within this FM population. Jackson (1999) confirms
that nocturia is a highly bothersome symptom with a multi-factorial aetiology and
recommends further research into the understanding of the aetiology of nocturia.
Within this area of bladder irritability, research is continuing in identifying
and

validating

classification

criteria

for

the

diagnosis

of

certain

urological/neurological conditions. This was demonstrated at the International
Consultation on Interstitial Cystitis where clinicians and researchers are combining
knowledge and experience to specify a definition and diagnostic protocol for
interstitial cystitis (Bade, Ishizuka, & Yoshida, 2003). Bade and colleagues comment
on the strict definition of IC that has developed into a universal diagnostic instrument
for IC research. They feel that, for clinical practice, the criteria are too strict, which
can result in the under-diagnosis of IC. They refer to the clinical definition of IC as
the combination of urgency, frequency and bladder or pelvic pain in the absence of
other pathology. The urological term, overactive bladder (OAB), also refers to the
symptom complex of frequency, urgency and nocturia with or without urge urinary
incontinence (Bade et al. , 2003). Currently there are no classification criteria
available to differentiate between OAB and IC. However patients with OAB by
definition do not have pain, whereas this is an integral and problematic part of the IC
syndrome (p 221 lines 6-7). To add to this uncertainty, what is the clinical definition
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of bladder irritability in FM? Are women with FM presenting with urinary urgency,
bladder pain, frequency and nocturia being diagnosed and treated for recurrent
urinary tract infections, overactive bladder or IC?
The circumstances facing professionals working in the area of interstitial
cystitis either as clinicians or researchers is similar to that of those working in the
area of FM. There is confusion regarding the clinical diagnostic criteria because of
the historically strict criteria for the research diagnosis of the conditions. Perhaps
FM, like IC, is under-diagnosed? Sensory symptoms of IC and those of women with
FM and irritable bladders are very similar. Although nocturia seems to be more
prevalent within the FM population, the effect of insomnia on night time frequency
must be taken into account.
Bade and colleagues (2003) postulate that there is a relationship between IC
and OAB and that this overlap may extend to chronic prostatitis. Clauw and
colleagues (1997a) in their research on FM and IC also postulate that some of the
pain of IC may be caused by centrally mediated nociceptive abnormalities rather than
the peripheral mechanisms involving the bladder. Sant and Theoharides (1999a)
report that, although the pathophysiology of IC is not completely understood, altered
epithelial permeability, mast cell activation and sensory nerve upregulation play
pivotal roles. Van De Merwe, Yamada and Sakamoto (2003) at the International
Conference on Interstitial Cystitis in Kyoto 2003 recognised that IC was often
associated with other diseases such as FM.
Kahn, Tatro, Parsons, and Willems (2004) in their study on the incidence of
IC in patients with vulvodynia have shown a significant majority of patients with
vulvodynia have a positive potassium sensitivity test which indicates that their pain
may have a bladder component such as interstitial cystitis. The authors recommend
that IC be considered in the differential diagnosis of patients with vulvodynia and
encourage further research into the relationship between these two diseases.
At the 3rd International Consensus on Incontinence in Monaco in 2004, a
committee was formed to provide a consensus on painful bladder syndrome. This is
the first time since the International Consensus on Incontinence was formed under
the auspices of the World Health Organization in 1998 that painful bladder syndrome
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has been specifically addressed. Following an extensive literature review, a
diagnostic and treatment algorithm (Appendix B) was formulated and presented. The
algorithm provides a more liberal definition of painful bladder syndrome/interstitial
cystitis compared with the previous NIDDK criteria (Rosamilia, 2004). The initial
history and symptom assessment includes bladder pain with or without the sensation
of urinary urgency, urinary frequency and nocturia.
The development of the Fibromyalgia Bladder Index will be beneficial in
monitoring the clinical status of FM patients who experience bladder irritability
symptoms. The index is not a diagnostic instrument developed to help formulate a
diagnosis, but rather it has been developed as an adjunct to clinical assessment and
possibly as an outcome measure for intervention therapies for the patient with FM.

Strengths of the Study

Recently the National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS) of the National Institutes of Health (NIH) in the United States of
America conducted a 'Fibromyalgia Program Assessment' to provide expert
recommendations for FM research portfolios (NIAMS, 2003). Approximately forty
currently funded researchers, scientists, representatives of patient advocacy groups
and NIH staff attended. One of the listed main challenges in conducting FM research
was identified as confusion or inconsistency regarding appropriate outcome
measures. The development of the condition-specific questionnaire, the Fibromyalgia
Bladder Index, is a beginning in meeting this need for validated and reliable outcome
measurements.
This research is the first of its kind in Australia. The relationship between FM
and IC was first researched in the United States of America when Clauw and
colleagues (1997a) found many current symptoms were similar for the FM and IC
populations. This Australian research has added to this knowledge by developing a
urinary outcome measure validated for the FM female population who experience
bladder sensitivity. The methodology of the research is sound and confirms the
theoretical framework that guided this investigation.
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For the patient with FM and bladder irritability symptoms, this research will
increase the medical and public awareness of the urogenital implications associated
with FM. The significant consultation in the FM area as seen in the Canadian
consensus document on FM (Jain et al., 2004) and the development of a painful
bladder syndrome committee at the recent International Consensus on Incontinence
(Rosamilia, 2004) gives a strong indication of the direction of future research and
continuing consultation in these two areas.

Limitations of the Study

The sample was not randomly selected because of the difficulty of recruiting
sufficient women for the study. It would have been preferable to also have a control
group of FM women who did not experience sensory bladder symptoms. This would
have enabled a greater focus on the impact of sensory urinary symptoms on the
quality of life for women already impacted on by the non-urinary symptoms of FM.
This study did not compare the differences in urological symptoms between
the groups of women who were of different educational levels, women of different
menopausal status, women on different hormone replacement therapy protocols or
between women who had and who had not had gynaecological/pelvic surgery. These
group variables should be included in further analysis.
Subsequent studies with other populations and samples are required to further
explicate the predictive capabilities of the Fibromyalgia Bladder Index and calculate
appropriate cut off scores that may be useful in making interpretations.
However, given the scope of this two-phased study and the time limits
associated with this doctoral research, the findings emerging from this work make a
substantive contribution. Further testing in the context of post-doctoral studies should
involve testing of a larger sample, including a control group, now that a tool has been
developed and tested and the merits of pursuing this line of inquiry have been
demonstrated.
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CHAPTERS

RECOMMENDATIONS AND CONCLUSIONS

Introduction

The Fibromyalgia Bladder Index assesses the important domains of urinary
urgency, urinary frequency, nocturia and bladder pain and discomfort in the female
FM population. This new instrument, the Fibromyalgia Bladder Index, has
demonstrated respectable psychometric properties that indicate that it is a specific
and potentially helpful additional outcome measure for research and clinical use in
the Fibromyalgia population. The use of the Fibromyalgia Bladder Index by
clinicians when assessing women with FM and bladder irritability may help to
identify women who suffer significantly from these bladder symptoms and/or
problems and assist in quantifying these symptoms. This index may therefore have a
place in rheumatology and urology clinics to assess the urinary symptoms and their
impact on women with FM and expedite treatment regimes.
Radley and Jones (2004) comment that within the area of urogynaecology
and pelvic floor medicine, clinician-administered instruments have been shown to
lack sufficient reliability and objectivity and more accurate measures of health
related quality of life are achieved through the use of self-completed questionnaires.
These self-administered health status measures/instruments provide information
about patients' observations of their own health and can be used for both clinical and
research purposes. In the development of such instruments, Radley and Jones (2004)
describe questionnaire validation as an extended process that includes not only the
psychometric testing of the instrument, but also an evaluation of its performance in
practice.
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To date, there has been little in the medical literature to increase practitioners'
awareness of the severity and impact of FM irritable bladder symptoms on women.
Therefore, the Fibromyalgia Bladder Index may add to the assessment tools available
for such a thorough assessment of FM symptomatology. Yunus (2002a) emphasises
the necessity of a thorough medical and psychological evaluation in helping to
achieve a proper diagnosis, assess severity, recognise both aggravating and relieving
features of FM symptoms and recognise associated conditions.

Recommendations
This research was initiated because of my association with and clinical
knowledge of symptomatology of patients who had disabling urological symptoms in
conjunction with their FM. The purpose of this study was to investigate the impact
and measurement of these bladder irritability symptoms in Australian women who
had been diagnosed with FM and to quantify these symptoms through the
development of an appropriate outcome measure/instrument. This has been achieved
with the validation of the Fibromyalgia Bladder Index within the FM population of
women who experience sensory bladder symptoms. The theoretical framework
formulated at the commencement of this study has provided direction for this study
by providing a guide for examining variables and their relationships. The theory was
based on the relevant literature, previous research findings and current research.
This study has contributed to the knowledge of bladder irritability symptoms
and the impact of these symptoms on the quality of life of these women. Together,
these outcomes form a sound foundation for the following six areas of
recommendation: further refining of the Fibromyalgia Bladder Index; utilisation of
the index in FM assessments; development of FM educational, support and self help
programs; pelvic health and pelvic fitness awareness; intervention studies, and the
development of a vulvodynia index.

Further Refining of the Fibromyalgia Bladder Index
The development and validation of the Fibromyalgia Bladder Index may act
as a catalyst for further research into this area of FM and bladder irritability. A
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continuation of this research is recommended to develop a scored index with specific
cut-offs to help interpret severity of symptoms on the Fibromyalgia Bladder Index.
The use of valid and reliable assessment measures ensures consistency in
measuring the progress of a patient from pre- and post-intervention assessments and
encourages the development of evidence-based practice (O'Connell et al., 2002).
Therefore, a third phase to this study on FM and bladder irritability is recommended.
This phase would be of a pre-test/post-test study design to assess any changes
resulting from intervention to assess the sensitivity of the Fibromyalgia Bladder
Index to detect any resultant changes and responses. Such an intervention could
include bladder health educational programs that cover bladder education, good
bladder habits, bladder training and pelvic floor muscle education and training. These
programs could be conducted by physiotherapy and nurse continence advisors.

Use of the Fibromyalgia Bladder Index in FM Assessments
The primary aim of treatment in chronic, incurable conditions is to enable the
patient to live an occupied and productive life and, therefore, palliation of symptoms
should be the primary goal of care (Bennett, 2002e ). As quality of life is severely
impaired with FM patients, Bennett recommends the use of questionnaires that
provide details on quality of life as providing the best assessment of change in a
patient's overall state of health.
Radley and Jones (2004) extend this notion further by suggesting the routine
implementation of these types of instruments in urogynaecology clinical practice.
However, these authors recognise that the application of individual condition
specific instruments in clinical practice is limited by the narrow specification of each
questionnaire. Therefore, this would necessitate the use of many individual
questionnaires to adequately address most areas of pelvic floor symptomatology.
Radley and Jones are aware of the increased time burden that paper-based
instruments would create for study participants, health care providers and practice
managers. They suggest that this is the reason that condition-specific questionnaires
are not used in mainstream clinical practice.
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With these limits in mind, they recommend the implementation of computer
interviewing as one option for managing challenges of busy clinics. Radley and
Jones (2004) cite studies by Velikova, Wright and Smith on automated collection of
quality-of-life data, comparing paper and computer touch screen questionnaires.
Studies by Kleinman, Leidy, Crawley, Bonomi and Schoenfeld (2001) have shown
that the reliability and validity of electronic questionnaires are compatible with paper
questionnaires. Buxton, White and Osoba (1998) have shown the quality of
electronic questionnaire-acquired data to be high, with good test-retest reliability.
This computerised technology may offer a realistic method for the collection and
monitoring of clinical data. An electronic pelvic floor symptoms assessment (e-PAQ)
has already been developed and enables participants to provide comprehensive
assessment of symptoms, data entry and immediate data analysis (Radley & Jones,
2004). The e-PAQ is currently being evaluated within the continence area. Radley
and Jones state that this electronic assessment, the e-PAQ, was developed within the
area of urogynaecology because of the need to comprehensively evaluate symptoms
in the related areas of bowel, bladder, vaginal and sexual function.
The development of a single electronic instrument such as the e-PAQ that
combines paper-based questionnaires into a single instrument that is acceptable to
patients, while maintaining data integrity and minimising respondent burden, is an
attractive proposition for the assessment of patients with FM. Following a diagnosis
of FM, a combination of valid and reliable indexes relevant to the patient' s specific
symptoms could be completed and kept on record, following the initial consultation,
to provide baseline data for continuing assessment and management. With the future
introduction of computerised questionnaires with immediate data entry and analysis,
the use of multiple condition- specific questionnaires for conditions such as FM is
feasible.
For women with urological symptoms of FM, the Fibromyalgia Bladder
Index could be included as one of these specific measures as part of an FM primary
assessment and/or pre-intervention questionnaire. The Fibromyalgia Bladder Index
will monitor the symptoms and impact of sensory bladder symptoms via the Urgency
and Pain Subscale and the Frequency and Nocturia Subscale, presenting clear
indications of bladder symptoms and impact at different time intervals.
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An Australian study assessed the use of quantitative clinical measurements
being used by rheumatologists in the longitudinal follow up in outpatient practice of
patients with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and FM
(Bellamy et al., 1999). Rheumatologists agreed that outcome measures for use in
clinical practice should include simplicity, brevity, ease of scoring, reliability and
validity, and sensitivity to change. Following the completion of studies on the
sensitivity of the index to monitor change, the Fibromyalgia Bladder Index, a simple
eight-item validated reliable outcome measurement tool for women with FM and
bladder irritability will meet the above criteria.

Education
This study has identified a need for increased education of health care
professionals with respect to urinary symptomatology within this population.
Professional education for health professionals would include information for
primary

care

medical

general

practitioners,

rheumatologists,

urologists,

physiotherapists and continence advisors on the sensory urinary symptoms and
impact experienced by women with FM. Education on the multifaceted
symptomatology of FM would include information on the urogenital symptoms.
Goh, Samanta, Cavendish and Heney (2004) emphasise the need to recognise
and prioritise the teaching of rheumatology in the undergraduate curriculum and to
develop a core curriculum that is acceptable worldwide. One of their
recommendations is the assessment of rheumatological conditions by the use of
reliable and validated tests. The authors also recommend the acquisition of skills for
appropriate attitude development in managing patients with chronic conditions (Goh
et al., 2004).
The study has also identified a need within the female FM population for
increased awareness of urogenital symptomatology. The development of self
help/support groups within local communities for patients with FM with a focus on
patient education and support is also recommended. The development of an
Australian FM information pamphlet for patients is an essential part of this patient
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education and could be distributed via health professionals at times of clinical
consultation.
The literature also documents the positive effects of exercise on pain, self
efficacy, sleep, fatigue and quality of life in the FM population. There is a need for
further research in this area, with an emphasis on the pelvic health and pelvic fitness
of women with FM. Education on good bladder habits, bladder training and exercises
and awareness of the pelvic floor and abdominal musculature specific to pelvic
awareness and stability should form part of exercise programs for FM. The
Fibromyalgia Bladder Index will increase the awareness of the specific symptoms
and impact of sensory bladder symptoms within the female FM population and
perhaps open the doors to a more inclusive treatment protocol for the re-education
and maintenance of pelvic fitness in these women.

Intervention Studies Specifically for Urological Symptoms/Impact of FM
This study has identified women with FM who experience sensory bladder
symptoms that have a significant impact on their quality of life, adding to their
existing FM burden. Further research may quantify with objective testing more
specifics regarding bladder function in these women with FM. Urodynamic cross
sectional profiles encompassing measurement of bladder capacity, sensory urgency
and bladder instability, together with cystoscopy and histology of bladder biopsies in
patients with FM who also have bladder symptomatology would provide more
information on these irritable bladders prior to intervention therapy.
Evidence-based guidelines for the optimal treatment of FM have recently
been developed (Goldenberg, Burckhardt, & Crofford, 2004). These guidelines
resulted from a search of all human trials of FM (randomised controlled trials and
meta-analyses of randomised trials) using the Cochrane Collaboration Reviews and
extensive medical data bases. The final guidelines suggest that, notwithstanding the
chronicity

and

complexity

of FM,

there

are

non-pharmacological

and

pharmacological interventions that do have clinical benefit. Based on current
evidence, these authors recommend a program that emphasises education, some
medications, exercise, and cognitive therapy (Goldenberg et al. , 2004). To date, there
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have been no specific treatment programs encompassing the evidence-based
guidelines for optimal treatment as suggested by Goldenberg and colleagues (2004)
for this area of urogenital symptoms in women with FM.
The theoretical framework for this study described the central nervous system
hyperexcitability being responsible for the resultant spectrum of conditions in FM
(Clauw, 1 995a). As mentioned by Clauw, the clinical spectrum of FM, encompassing
neurogenic

inflammation,

increased

peripheral

and

visceral

nociception,

neuroendocrine disturbances and autonomic nervous system dysfunction, can result
with symptoms being evident in any of the effector arms of the central nervous
system. This study has focused on the urogenital symptomatology. A randomised
controlled intervention study on specific assessments and treatment protocols for
urogenital symptoms for women in this population is indicated.
Further research in the area of FM and bladder irritability should be
undertaken. The lower levels of quality of life in the Australian FM sample reported
in this study, compared with those of the USA chronic disorder population study as
illustrated by the SF-36 measurement of general health status raises questions about
the rationale for these differences. One interpretation for these differences may be
that this current Australian study captures the urinary distress more completely
because all participants met the study inclusion criteria of having at least two sensory
urinary symptoms. The data reported in the United States study did not involve
recruitment of women specifically with bladder symptoms. Therefore the
combination of FM and urinary symptoms may account for the poorer quality of life
scores obtained in this Australian study. A larger randomised, controlled study of the
FM population in Australia would provide more evidence of the specific impact of
urinary and non-urinary symptomatology in this population.

Development and Psychometric Testing of a Vulva/ Symptom/Impact Index
This current research within the FM population of women with urinary
symptoms has shown the presence and impact of vulvodynia-like symptoms.
Vulvodynia is described as an under-diagnosed, and difficult to treat gynaecological
disorder (Masheb, Lozano, Richman, Minkin, & Kerns, 2004). Their recent research
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on subtypes of vulvodynia showing the absence of differences between subtypes on
standardised measures of pain, sexual function, psychological function and quality of
life suggests little clinical significance of these subtypes and buttresses the theory
that vulvodynia represents a continuum of chronic vulvar pain.
There is a need to reach a consensus for the diagnostic criteria for vulvodynia
(Masheb et al., 2004). Gibbons (2004) speculates that the lack of an accurate
diagnosis or access to contemporary therapy for chronic vulvar pain is partly caused
by the current confusion in classification and the multitude of treatments advocated.
Although further research and consultations into the area of vulvodynia and
dyspareunia and the accurate classification of these conditions should be prioritised,
the development and testing of a specific instrument for vulval symptoms and impact
within this FM population and within the non-FM population who experience vulval
symptoms could provide further insight into this chronic pain condition.

Conclusion
The boundaries of evidence-based medicine on FM and other central
sensitivity

syndromes

are

expanded

by

Yunus

(2004)

to

include

the

phenomenological aspects of mind, perceptions, feelings and suffering. Yunus refers
to Cassel's definition of suffering as that which can be defined as the state of severe
distress associated with events that threaten the intactness of a person. For patients
with a chronic disease, this intactness can be threatened or lost as a result of the
anguish, misery, loss of control and sense of hopelessness and helplessness resulting
from the chronicity (Yunus, 2004). He describes suffering as a phenomenological
condition, as an entity that goes beyond structural pathology.
One of the difficulties for women with a diagnosis of FM is the lack of
objective pathology and diagnostic markers. As a result, it is possible for the health
professional to underestimate the impact of the disease and therefore the suffering
that these patients experience. For the FM patient, the added impact of urological
symptoms may increase morbidity and, therefore, suffering may be intensified. Masi,
White and Pilcher (2002) suggest that a person-centred approach can assist in the
subgroupings of patients for greater specificity in care programs and in improved
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clinical investigations. The authors define a person-centred approach as an attention
to maj or biopsychosocial issues of individuals. They suggest that this person
centered approach can enhance the patient/doctor relationship and assist in
prioritising the patient's goals in treatment plans (Masi et al., 2002).
For the health professional, specific FM indexes could elucidate some of the
very specific symptoms pertinent to this population that impact on quality of life for
FM patients. Use of such specific indexes is recommended as a clinical tool to
possibly enhance this person-centred approach. This possibility could be
demonstrated in the clinical setting where specificity of information from the
Fibromyalgia Bladder Index could encourage collaborative management of the
patient between rheumatology and urology disciplines, with increased positive
outcomes for the patient.
With this person-centred approach in mind, it is worthwhile to conclude by
placing the results of this study in the context of the personal burdens experienced by
women living with a chronic illness such as FM who manage both non-bladder and
bladder FM symptoms. The concluding quotation reminds us of the relevance of this
work.
"Having a chronic illness or living with chronic pain changes not only how
you do things but who you are. In the face of extraordinary physical challenges,
some have an easier time than others honing in on the strength and hearty wisdom
necessary to reinvent a different life and new vision for the future. Inevitably, a
former self, as well as a previous way of being in the world, fall away and give rise
to a new way offunctioning and embracing life " (Sveilich, 2005).
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Appendix B: Draft algorithm for the treatment of painful bladder syndrome (including IC)
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Appendix C: Interview guide - Phase 1
I am interested to know what bladder symptoms you are experiencing and how these
symptoms affect your daily life. We will be discussing your experience of
these symptoms in relation to a specific questionnaire that has been
developed to measure the severity of the symptoms and how much of a
problem they are for you.
1.

During the past month how often have you felt the strong need to urinate with little,
or no warning?

2.

How would you specifically describe how often you get this strong urge?

3.

During the past month, have you had to urinate less than 2 hours after you finished
urinating?

4.

How would you specifically describe how often you had to urinate less than 2 hours
after you finished urinating?

5.

During the last month, how often did you most typically get up at night to urinate?

6.

During the past month, have you experienced pain or burning in your bladder?

7.

How would you specifically describe how often you have experienced this?

8.

Do you experience pain or burning in any other part of your pelvis other than your
bladder?

9.

During the past month, has frequent urination during the day been a problem for
you?

10.

Describe how much of a problem this has been.

11.

During the past month, has getting up at night to urinate been a problem for you?

12.

Describe how much of a problem this has been.

13.

During the past month has the need to urinate with little warning been a problem?

14.

Describe how much of a problem this has been.

15.

During the past month, has burning, pain, discomfort or pressure in your bladder
been a problem?

16.

Describe how much of a problem this has been.

17.

Are there any other bladder problems or issues that affect you that we have not
discussed?
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If you wish to be involved in the second phase of this research, please advise
me at the end of the focus group discussion.
If you have any queries you can contact me by telephone on Tel
during office hours or by email at ..........

My supervisor at Edith Cowan

University Professor Linda Kristjanson can also be contacted on . . . ...... . if you
require any further information.
Thank you so much for participating in this study.
Kaye Brand
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Appendix M: Recruiting Notices for Rheumatology Consulting
Rooms

FIBROMYALGIA
IS IT AFFECTING YOUR BLADDER?
Currently there is research being conducted at Edith Cowan
University in Perth on Fibromyalgia and its effect on the bladder.
The researcher, Kaye Brand is a Physiotherapist who has a particular
interest in Fibromyalgia and has for many years worked as a
Physiotherapist continence adviser treating women with bladder problems.
Fibromyalgia is a syndrome that can affect many different areas of the body.
For some women with Fibromyalgia, their bladders can become more sensitive than
normal and this can create discomfort and sometimes cause a change in their bladder
patterns.
Kaye is interested in hearing from women who have been diagnosed with
Fibromyalgia, who have bladder irritability problems and who may be interested in
taking part in this research.
You can help! If you do have bladder symptoms associated with your
Fibromyalgia, please consider participating in this research.

Each piece of

information contributes to our understanding about this condition.
To find out further details about the research, please contact (before July 30t11)
Kaye Brand, Edith Cowan University
Telephone
Email:

- 294·31-08)
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Appendix N: Media Release for Study Recruitment
PRESS / MEDIA RELEASE
August 2002
RESEARCH ON FIBROMYALGIA AND THE BLADDER

Researchers at Edith Cowan University (ECU) are seeking women aged 1865 years who have been diagnosed with the condition Fibromyalgia to volunteer as
participants for a research project.
This research project will be exploring issues of bladder symptoms in women
with the condition of Fibromyalgia and the impact that these symptoms have on the
quality of life of these women.
Kaye Brand, a Edith Cowan researcher, says that Fibromyalgia is estimated to
affect between 2 to 4% of the population, and is the most commonly diagnosed
rheumatological disorder after osteoarthritis. The symptoms of Fibromyalgia can be
severely debilitating and are characterised by chronic and widespread pain and
stiffness throughout the body, sometimes accompanied by fatigue, poor sleep, and
other associated symptoms.
One of the associated symptoms of Fibromyalgia is bladder irritability. These
bladder symptoms include urinary frequency (going to the toilet very often), urinary
urgency (an urgent need to 'go'), bladder pain or pressure or a feeling of bladder
fullness.
The symptoms of a chronic illness like Fibromyalgia can radically disrupt a
woman's life activities and identity. This research will determine the increased
impact these urinary symptoms have on the quality of life of a woman already coping
with other symptoms of Fibromyalgia.
One outcome of the research is to produce an assessment format to be used
by health professionals that will enable accurate assessment of the symptoms and
impact of these urinary symptoms within the female Fibromyalgia population.
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